

PCT

Exp Mail EV335610972US
USAN 10/816,459
WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68		A1	(11) International Publication Number: WO 99/36575
			(43) International Publication Date: 22 July 1999 (22.07.99)
(21) International Application Number: PCT/US99/01037		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 15 January 1999 (15.01.99)			
(30) Priority Data: 09/007,905 15 January 1998 (15.01.98) US			
(71) Applicant: VALIGENE CORPORATION [US/US]; Suite 2300, 70 East 55th Street, New York, NY 10022 (US).			
(72) Inventors: IRIS, Francois, J., M.; 3, rue du Bouquet, F-92370 Chaville (FR). POURNY, Jean-Louis; 150, rue Perronet, F-92200 Neuilly (FR).			
(74) Agents: ANTILER, Adriane, M. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).			
		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: MULTIPLEX VGID

(57) Abstract

The present invention relates generally to the field of genomics. More particularly, the present invention relates to a method for gene identification beginning with user-selected input phenotypes. The method is referred to generally as the ValiGeneSM Gene Identification method, or the VGIDSM method. When more than two source populations of nucleic acids are simultaneously compared, the method may be referred to as multiplex VGIDSM. The method employs nucleic acid mismatch binding protein chromatography to effect a molecular comparison of one phenotype with others. Genes are identified as having a specified function, or as causing or contributing to the cause or pathogenesis of a specified disease, or as associated with a specific phenotype, by virtue of their selection by the method. Identified genes may be used in development of reagents, drugs and/or combination thereof useful in clinical or other settings for prognosis, diagnosis and/or treatment of diseases, disorders and/or conditions. The method is equally suited for gene identification for agricultural, bio-engineering, medical, veterinary, and many other applications.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MULTIPLEX VGID

This application is a continuation-in-part of U.S. Patent Application Serial No. 09/007,905 (Attorney Docket No. 9408-003) entitled "METHOD FOR IDENTIFYING GENES UNDERLYING
5 DEFINED PHENOTYPES" filed January 15, 1998, which is incorporated herein by reference in its entirety.

1. FIELD OF THE INVENTION

The present invention relates generally to the field of genomics. More particularly, the present invention relates
10 to a method for gene identification beginning with user-selected input phenotypes. The method is referred to generally as the ValiGeneSM Gene Identification method, or the VGIDSM method. The method employs nucleic acid mismatch binding protein chromatography to effect a molecular comparison of one phenotype with others. Genes are
15 identified as having a specified function, or as causing or contributing to the cause or pathogenesis of a specified disease, or as associated with a specific phenotype, by virtue of their selection by the method. Identified genes may be used in development of reagents, drugs and/or combinations thereof useful in clinical or other settings for
20 prognosis, diagnosis and/or treatment of diseases, disorders and/or conditions. The method is equally suited for gene identification for agricultural, bio-engineering, medical, veterinary, and many other applications. When more than two source populations of nucleic acids are simultaneously compared, the method may be referred to as multiplex VGIDSM.

25

2. BACKGROUND OF THE INVENTION

Identification of a particular genotype responsible for a given phenotype is an essential goal underlying gene-based medicine because it affords a rational departure point for the development of successful strategies for disease
30 management, therapy and even cure. While, by one recent estimate, only two percent (2%) of the human genome has yet been sequenced, perhaps more than 50% of expressed human

genes are at least partially represented in existing databases (Duboule, D., October 24, 1997, Editorial: The Evolution Of Genomics, *Science* 278, 555). It is therefore quite clear that understanding functional interactions among the products of expressed genes represents the next great
5 challenge in medicine and biology. This pursuit has been referred to as "functional genomics," although this term is perhaps too broad to have a clear meaning (Heiter, P. and Boguski, M., October 24, 1997, Functional Genomics: It's All How You Read It, *Science* 278, 601-602). Nevertheless, it is the prevailing view that functional genomics generally
10 describes " . . . a transition or expansion from the mapping and sequencing of genomes . . . to an emphasis on genome function." (*Id.*). Further, this new emphasis will require " . . . creative thinking in developing innovative technologies that make use of the vast resource of structural genomics information." Perhaps the best definition of functional
15 genomics is " . . . the development and application of global (genome-wide or system-wide) experimental approaches to assess gene function by making use of the information provided by structural genomics." (*Id.*, emphasis added).

One of the major advantages of the present invention is the circumvention of large-scale sequencing in determining
20 functional relationships among genes. The VGIDSM method of the present invention is a straightforward yet very powerful genetic comparison or subtraction technique. Functional information is obtained from global (*i.e.* genome-wide) expressed gene comparison of two or more user-defined phenotypes using mismatch binding protein chromatography.
25 With the VGIDSM method, disease genes may be identified over a time period of weeks, unlike the years required to succeed using positional cloning.

2.1. CHARACTERISTICS OF DISEASE AND OTHER PHENOTYPES

Genetic diseases and other genetically-determined phenotypes, irrespective of mode of inheritance, can be due to single or multiple lesions (i.e. mutations) affecting one
5 gene or more than one gene simultaneously. Genetic heterogeneity (i.e. a difference in DNA sequence), by definition, characterizes all diseases which have a genetic component. Genetic diseases can be further categorized among four broad genotypic groups, as described below.

A mono-allelic disease is characterized as having a
10 mutation in a single allele of a single gene. This disease group is the simplest in terms of genetic analysis since mono-allelic diseases arise, by definition, from a unique lesion affecting a single gene. Mono-allelic diseases have also been described as displaying "molecular monomorphism," which is another way of saying that a single molecular defect
15 in a single gene accounts for the disease phenotype. Since such genetic lesions are unique, they are invariably "causative" of the disease in question. For a mono-allelic disease, only a few affected individuals need to undergo genetic analysis to attribute a given mutation to a disease phenotype. That is, large familial studies are not required
20 to identify the disease-causing gene. Only a few examples of such diseases are known. One example is sickle cell anemia, which is due to a single base substitution (i.e. A -> T) in the gene encoding hemoglobin. This base substitution changes the respective codon from GAG to GTG, ultimately resulting in a glutamate-to-valine amino acid substitution at position six
25 of the hemoglobin β chain molecule and the characteristic, devastating sickle-shaped erythrocyte.

A polyallelic disease is characterized as having several different mutations arising independently in a single gene. Here, each independent mutation event gives rise to a different disease allele. A significant proportion of all
30 genetic disease is thought to result in this way. Because such *de novo* mutations are so frequent, polyallelism is a

very common characteristic of genetic disease. Duchenne's muscular dystrophy (DMD), Becker's myopathy, and cystic fibrosis (CF) are well-known examples of polyallelic diseases (see e.g. McKusick, Mendelian Inheritance in Man, Catalog of Autosomal Dominant, Autosomal Recessive, and X-Linked Phenotypes, 10th Edition, 1992, The Johns Hopkins University Press, Baltimore, Maryland). Polyallelism may arise in at least two ways. First, each new case of a disease may arise from an independent mutation event in the target gene. For example, in DMD, at least 30% of cases present novel mutations in the dystrophin gene which differ from all previously-characterized mutations. Second, selective fixation of different founder-effect mutations contributes to the occurrence of polyallelism. One example of this is the β -thalassemias in which the world population of affected individuals presents remarkably high polyallelism, but local populations are characterized by limited allelic heterogeneity.

Non-allelic genetic disease is characterized as having more than one candidate gene. Here, a genetic disease which is clinically well-defined may be due to a lesion (mutation) of any one gene among several candidate genes. For example, imperfect osteogenesis is caused by lesion of any one of five distinct type 1 collagen genes. However, the identification of candidate genes for a non-allelic genetic disease is made more difficult when the several candidate genes, unlike the collagen genes, are not related in sequence. For example, pituitary dwarfism is physiologically due to hyperfunction of the anterior pituitary gland. In a minority of pituitary dwarfism cases, the causative lesion has been traced to the gene complex elaborating growth hormone (Kaplan and Delpech, 1993, in Molecular Biology and Medicine, 2nd ed., Médecine-Sciences Flammarion, Paris, Chap. 12, pp. 307-308). In the vast majority of cases, however, these genes are perfectly normal and the causative disease loci are not even linked to the growth hormone complex (as demonstrated by polymorphism linkage studies, *Id.*). Therefore, other

unidentified genes comprising alleles not related to growth hormone account for the majority of pituitary dwarfism cases. Such non-allelic diseases clearly require more than just linkage analysis to identify all of the involved genes. The VGIDSM method of the present invention provides a rapid,
5 rational way of approaching this problem.

A polygenic disease is characterized as having several abnormal genes acting concurrently to produce a pathologic phenotype. This group includes many genetic diseases often described as "multifactorial disorders." Examples include diabetes mellitus, hypertension, atherosclerosis, autoimmune
10 disorders, and many others. For the majority of polygenic diseases, the metabolic complexities are so great that a rational basis on which candidate genes could be identified may not have existed before the invention set forth herein. In the few instances where a candidate gene has been suggested, this knowledge has still proven largely inadequate
15 to identify susceptible individuals, or to explain pathogenesis.

The last two groups of genetic disorders described above (i.e. non-allelism and polygenism) represent the greatest challenge currently facing human and veterinary medicine. Because of an absence of sufficient biochemical and
20 physiological data, credible candidate genes have largely gone unidentified. This absence of credible candidate genes has, in turn, ruled out the possibility of identifying susceptible individuals and attempting preventive intervention before symptoms appear. The invention set forth herein provides one way to overcome these limitations by
25 identifying credible candidate genes.

2.2. GENE IDENTIFICATION BY POSITIONAL CLONING

There are several known methods available to identify candidate disease genes, and to further select genes among identified candidates, which are systematically associated
30 with a given pathology. These include various methods for differential expression analysis (e.g. differential display,

serial analysis of gene expression or SAGE), and positional cloning methods. In the positional cloning approach, the initial steps are quite similar or identical; most often, it is only the final steps that differ (see e.g. Rommens et al., 1989, Science 245, 1059-1065; Duyk et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87, 8995-8999). The major drawbacks of positional cloning methods generally include: (a) the slow pace of discovery, often requiring several years for success; (b) the high complexity of the techniques involved, requiring highly-trained individuals who must pay painstaking attention to detail to get satisfactory results; (c) the labor-intensive nature of the techniques, often requiring enormous amounts of sequencing; and (d) the extreme expense associated with any slow, complex, labor-intensive effort. Positional cloning can be considered as four discrete steps which are well-known in the art. Each of these steps is briefly described below.

15

2.2.1. LINKAGE MAPPING

The first step in using positional cloning for disease gene identification consists of a search for genetic linkage between a locus implicated in pathogenesis and a number of genotypic polymorphic markers. This step requires segregation analysis in affected families. Linkage mapping takes advantage of the fact that the closer two genetic loci are to each other, the smaller the chances of an independent recombination event in separating them. Therefore, the aim is to find a specific fragment of genomic DNA bordered by two known markers systematically present in all affected members of a family, but rarely present in the unaffected members. If such a genomic fragment can be identified, the pathogenic locus will be found located between the markers.

Linkage mapping presents difficulties that vary according to the mode of inheritance of a disease. In an ideal linkage map, all bearers of an abnormal gene will be identified. In the case of an autosomal dominant disease, this is only theoretically possible if: (a) all bearers show

the diseased phenotype (i.e. penetrance is complete); and (b) disease manifestation is precocious. In the case of autosomal recessive disorders, it is only possible to detect the homozygotes (all affected) and the obligate heterozygotes (the parents). It is therefore essential to have access to
5 families where there are at least two living, homozygous affected siblings when mapping an autosomal recessive disorder.

In a few lucky cases of linkage map construction and analysis, specific chromosomes can be easily ruled out as carrying the diseased gene of interest. In these rare
10 instances, the gene search quickly becomes more focused. For example, DMD is a recessive disorder which is very rare in females. As a result, the search for the DMD gene could safely be limited to the X chromosome. However, in the majority of cases, such a simplified approach is not at all available. A case in point is CF, where it took five years
15 of intensive effort just to identify the chromosome associated with the disease.

2.2.2. CHROMOSOMAL LOCALIZATION

The genomic fragment identified in the preceding step is often very large (i.e. several million bases) and entirely
20 unknown in terms of the number and identity of genes it encodes. Therefore, it is often essential to localize the genomic fragment to a specific chromosome in order to take advantage of other known markers which may not yet be associated with the fragment. Chromosomal localization may be carried out by utilization of polymorphic markers (e.g.
25 microsatellites) identified on genomic DNA or large genomic fragments cloned into yeast artificial chromosomes (YACs) that have been assigned to specific human chromosomes. Chromosomal localization may also be effected by fluorescently labeling a large (e.g. 100 kilobase) identified genomic fragment for hybridization and karyotype analysis
30 (Dauwerse et al., 1992, Hum. Mol. Genet. 1, 593-598).

2.2.3. FURTHER REFINEMENT

Once the identified genomic fragment has been localized to a specific chromosome, the largest possible number of polymorphic markers is used to bracket the smallest possible region (i.e. locus) encoding the gene of interest. This step
5 can yield genomic fragments that are still very large, i.e. one-half to one million bases long. Since the average length of a gene is on the order of seventy thousand bases, such a region is very likely to encode many different genes. Furthermore, this approach does not allow one to distinguish between monogenic and polygenic disorders. If an apparent
10 lack of genetic heterogeneity cannot be clinically determined, then the actual degree of heterogeneity must be assessed by systematic comparison of different families. In this very-frequent case, the results from each family must be analyzed separately to determine whether they are consistent with a "single locus" hypothesis. This is a complex problem
15 since genetic heterogeneity may be clinically undetectable (e.g. pituitary dwarfism, see above). Alternatively, apparent clinical heterogeneity may lead to the erroneous conclusion that different genes are involved when, in fact, different allelic forms of the same gene are involved (e.g. DMD and Becker's myopathy, see above).

20

2.2.4. FROM LOCUS TO GENE

Having defined a genetic locus for a disease-associated gene using the above methods, there is much work left to be done before the gene itself is ultimately identified. The identification problem encompasses two major difficulties.
25 First, it is necessary to generate new markers for further map refinement. The new markers must be located as close as possible to, and ultimately in, the gene concerned. Second, it is necessary to demonstrate that the identified gene is actually responsible for the disease. These two tasks require the utilization, in parallel, of a wide variety of
30 methods. Two of the most commonly followed approaches are briefly described below.

Exon trapping involves the cloning of short fragments generated from an entire identified locus into retroviral vectors which have been engineered to reveal the presence of exons (*i.e.* coding sequences) within a short fragment. Any positive clones (*i.e.* clones containing an exon) function as
5 new markers and must next be sequenced and mapped back to the locus in order to define the relative position of each. The exon trapping approach is enormously labor-intensive in that it requires massive amounts of DNA sequencing and produces a substantial number of false positives and false negatives. Of course, the exon map generated includes exons from any
10 gene within the locus and is not specific to exons from the disease gene of interest. Accordingly, further work is required.

Complementary DNA (cDNA) subtraction assays utilize cDNA libraries constructed from cells of an affected individual and from cells of a healthy individual. The procedure has
15 two successive phases. In phase one, the cDNA inserts from the healthy individual are immobilized on a membrane and used to trap (subtract) the homologous cDNA inserts present in the affected individual's library. In phase two, the procedure is inverted: *i.e.* the cDNA inserts from the library of the affected individual are immobilized and used to subtract
20 homologous inserts from the healthy cDNA library. Therefore, these two phases yield cDNA fragments that are entirely unique to the affected or to the healthy individual, respectively. Any fragment homologous (similar but not identical) to a sequence present in the immobilized library remains trapped. Accordingly, this approach often results in
25 a complete loss of the gene of interest.

Clones obtained by the exon trapping or cDNA subtraction approaches are then used for direct hybridization to:
(a) yeast artificial chromosome overlapping segments (YAC contigs) covering the locus of interest; (b) mRNA preparations obtained from affected and healthy individuals;
30 and/or (c) enriched genomic libraries obtained from the same

affected and healthy individuals. Any positive hybridization signals are then further analyzed by sequencing.

At the last step in positional cloning, i.e. gene identification, one is often confronted with results that cannot precisely pinpoint the relevant gene. In this
5 instance, the only approach remaining is to entirely sequence and analyze the smallest genomic region of the defined locus, which may still range from 300 to 700 kilobases. The problematic nature of positional cloning for disease gene identification is further highlighted below in noting a few of the realities associated with the approach.

10 Positional cloning projects are so labor intensive that they have been undertaken, in most instances, only by large consortia of international research groups comprising at least three laboratories per consortium. Each laboratory of such a consortium, in turn, is typically composed of five or more researchers devoting essentially all of their time and
15 effort to the project. For example, identification of the CF gene took a total of eight years, finding the gene for polycystic kidney disease type 1 (PKD1) took six years, and finding the ataxia-telangiectasia gene took over five years. Many other examples could be recited, and many positional cloning efforts have yet to identify the target gene.
20 Notably, these are all *monogeneic* diseases, i.e. only one gene is responsible for the disease and it is the same gene in all cases of the disease.

The difficulties are amplified in the context of polygenic or multifactorial disorders. Here, very little progress has been made in gene identification. For example,
25 after over fifteen years of intensive searching by a considerable number of research teams, the genetic causes of diabetes mellitus (type I and type II) remain largely unknown. The same can be said for chronic renal failure (CRF), multiple sclerosis (MS), atherosclerosis, and many others. This list names only a few of the most prevalent
30 polygenic or multifactorial disorders.

One of the major reasons for this state of affairs is that, in the absence of any information allowing the testing of likely candidate genes, it is necessary to first map the loci associated with the disorder to specific chromosomal regions before having a chance of isolating the genes
5 concerned by positional cloning (see above). Of course, it would be considerably simpler to forego mapping entirely and work from mRNA transcripts of genes expressed in affected tissues. However, this approach has proven virtually impossible using past methods. This is due, at least in part, to the fact that tissues and cells express a great many
10 genes. Furthermore, genes associated with pathologies are often expressed at very low levels. Therefore, the few relevant disease mRNA transcripts may be lost among an enormous number of other transcripts. Still further adding to the identification problem, the disease transcripts may differ widely among affected individuals. These intrinsic
15 shortcomings of past positional and subtraction methodologies are such that very small quantities of mRNA cannot be used.

The VGIDSM method for gene identification set forth herein provides a simple solution to this enormous problem. It allows one to identify phenotype-associated genes, in monogenic as well as polygenic contexts, in a matter of weeks
20 rather than years and at greatly reduced expense.

2.3. MISMATCH REPAIR

DNA mismatch repair genes comprise one of several mechanisms by which high fidelity DNA replication is maintained in cells under physiologic conditions. Many
25 investigators over the years have manipulated one or more of these genes to achieve various ends. First described in bacteria, the mismatch repair system comes into play when the product of the *MutS* gene recognizes and binds to a mispaired base pair (see Cox, E.C., 1997, *MutS*, Proofreading And Cancer, *Genetics* 146, 443-446). *MutS* works in concert with
30 the products of the *MutH* and *MutL* genes; these three proteins together form the so-called *MutHLS* mismatch repair system. A

recent review has provided a detailed description of this system in eukaryotes (see Kolodner, R., 1996, Biochemistry And Genetics Of Eukaryotic Mismatch Repair, *Genes Dev.* 10, 1433-1442).

Hereditary nonpolyposis colon cancer (HNPCC) arises from
5 mutations in the *hMSH2* gene, the human homolog of the bacterial *MutS* gene, as shown by two laboratories in 1993 (see Fishel, R. et al., 1993, The Human Mutator Gene Homolog *MSH2* And Its Association With Hereditary Nonpolyposis Colon Cancer, *Cell* 75, 1027-1038; Leach, F.S. et al., 1993, Mutations Of A *MutS* Homolog In Hereditary Nonpolyposis
10 Colorectal Cancer, *Cell* 75, 1215-1225). The human *MSH2* protein also functions via binding to DNA mismatches (Fishel, R. et al., 1994, Binding Of Mismatched Microsatellite DNA Sequences By The Human *MSH2* Protein, *Science* 266, 1403-1405; Fishel, R. et al., 1994, Purified Human *MSH2* Protein Binds To DNA Containing Mismatched Nucleotides, *Cancer Res.* 54, 5539-
15 5542). Another human homolog of bacterial *MutS* has recently been linked to cancer susceptibility (Edelman, W. et al., November 14, 1997, Mutation In The Mismatch Repair Gene *Msh6* Causes Cancer Susceptibility, *Cell* 91, 467-477).

Traditionally, manipulation of the mismatch repair system has been employed in a variety of ways. For example,
20 a method for *in vitro* recombination of mismatches has been described which takes advantage of *MutS*-deficient *E. coli* (Resnick, M.A. and Radman, M., August 2, 1994, System For Isolating And Producing New Genes, Gene Products And DNA Sequences, U.S. Patent No. 5,334,522). Others have described using the *MutS* protein to detect DNA mismatches *in vitro* with
25 antibodies (Wagner, R.E., Jr. and Radman, M., April 2, 1997, Method For Detection Of Mutations, European Patent EP 0 596 028 B1). Still others have used the inability of the system to repair loops of five nucleotides or greater *in vivo* to design a system capable of detecting a single mismatch in a DNA fragment as large as 10 kilobases (see Faham, M. and Cox,
30 D.R., 1997, A Novel *in vivo* Method To Detect DNA Sequence Variation, *Genome Research* 5, 474-482).

3. SUMMARY OF THE INVENTION

This invention provides a method for identifying a gene or allele, or several genes or alleles, underlying a phenotype-of-interest. In this regard, genes or alleles are identified as having a specified function, or as causing or
5 contributing to the cause or pathogenesis of a specified disease, or as associated with a specific phenotype, by virtue of their selection by the method.

This invention is based, at least in part, on the recognition that comparison of a population of nucleic acid molecules with one or more other populations of nucleic acid
10 molecules, so as to isolate genes underlying specific phenotypic traits, is greatly facilitated by first taking steps to insure *internal homogenization* of one or more of the populations to be compared before performing the *external comparison* of two or more populations. In this regard, internal homogenization is effected by a first round of
15 hybridization and sorting of matched from mismatched DNA duplexes. Similarly, external comparison is effected by a second round of hybridization and sorting of matched from mismatched DNA duplexes, as described in detail hereinbelow.

This invention provides a method for identifying one or more genes underlying a defined phenotype comprising the
20 following steps in the order stated: (a) removing mismatched duplex nucleic acid molecules formed from hybridization within each of two source populations of nucleic acids; and (b) retaining mismatched duplex nucleic acid molecules formed from hybridization between the two source populations, the retained molecules in step (b) comprising the one or more
25 genes underlying the defined phenotype.

Further, this invention provides a method for identifying one or more genes underlying a defined phenotype comprising the following steps in the order stated: (a) removing mismatched duplex nucleic acid molecules formed from hybridization within a first source population of nucleic
30 acids; and (b) retaining mismatched duplex nucleic acid

molecules formed from hybridization between the first source population and a second source population of nucleic acids, the retained molecules in step (b) comprising the one or more genes underlying the defined phenotype.

Nucleic acid sample populations may be derived from many
5 different sources. In one embodiment, the first and second source populations each are nucleic acid populations derived from at least two individuals having consanguinity. In another embodiment, the first and second source populations each are nucleic acid populations derived from more than two individuals having consanguinity. In one embodiment, the
10 first and second source populations each are nucleic acid populations derived from two to six individuals having consanguinity. In another embodiment, the first and second source populations each are nucleic acid populations derived from three individuals having consanguinity. In still another embodiment, each source population is a cell line.

15 Further, nucleic acid sample populations may be manipulated in various ways so as to facilitate gene identification. In one embodiment, the source populations are normalized cDNA libraries to facilitate identification of rare transcripts. In another embodiment, the source populations are linearized cDNA libraries to facilitate
20 hybridization. In still another embodiment, the source populations are normalized and linearized.

Still further, nucleic acid sample populations may be manipulated in various ways so as to facilitate removal of undesired cDNAs. In one embodiment, the two source populations are of DNA, the DNA of a source population is
25 labeled, and the hybridization in step (b) is carried out using an excess of labeled DNA. In another embodiment, the excess of labeled DNA is a three-fold excess.

Genes underlying virtually any defined phenotype may be identified using the method of the invention. In a preferred embodiment, the defined phenotype is selected from the group
30 consisting of a plant resistance phenotype, a microorganism resistance phenotype, cancer, osteoporosis, obesity, type II

diabetes, and a prion-related disease. Additional examples of preferred defined phenotypes follow immediately below.

Defined plant phenotypes include but are not limited to resistance to herbicides, resistance to insect predators, resistance to fungal infections, increased yields, resistance
5 to frost, resistance to dehydration, enhanced stem strength, and many others.

Defined microorganism phenotypes include but are not limited to susceptibility or resistance to antibiotics, detoxification of liquids, soils, solids, and/or gases contaminated by pollutants or toxic compounds (e.g. dioxin,
10 nitrous oxides, carbon monoxide, sulfur dioxide, free radicals, and so on).

Defined animal and/or veterinary phenotypes include but are not limited to resistance to neurological disorders such as prion-related diseases, infectious disorders (e.g. porcine plague), foot-and-mouth disease, and many others.

15 Defined human phenotypes include but are not limited to susceptibility to cancer, autoimmune diseases, neurological disorders, metabolic disorders (e.g. diabetes, obesity), systemic diseases (e.g. osteoporosis), and many others.

This invention provides a method for identifying one or more genes underlying a defined phenotype displayed by a cell
20 or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a second cDNA library is derived. The method comprises the steps of (a) hybridizing insert DNA from the first cDNA library with itself, (b) hybridizing insert DNA from the second cDNA library with itself, (c) contacting the DNA hybridized in
25 step (a) with a first immobilized mismatch binding protein, (d) contacting the DNA hybridized in step (b) with a second immobilized mismatch binding protein, (e) separating unbound DNA from bound DNA contacted in step (c), (f) separating unbound DNA from bound DNA contacted in step (d), (g) labeling unbound DNA separated in step (f) with a label
30 capable of binding a partner molecule or agent immobilized on a substrate, (h) hybridizing labeled DNA with unbound DNA

separated in step (e), (i) contacting DNA hybridized in step (h) with a third immobilized mismatch binding protein, (j) separating unbound DNA from bound DNA contacted in step (i), (k) contacting unbound DNA separated in step (j) with the partner molecule or agent immobilized on the substrate
5 capable of binding the label, and (l) separating unbound DNA from bound DNA contacted in step (k), which unbound DNA separated in step (l) encodes one or more identified genes underlying the defined phenotype.

Further, this invention provides a method for identifying one or more genes underlying a defined phenotype
10 from organisms having consanguinity. The method comprises the steps of (a) hybridizing insert DNA from a first collection of cDNA libraries derived from organisms having the defined phenotype with itself, (b) contacting DNA hybridized in step (a) with a first immobilized mismatch binding protein, (c) separating unbound DNA from bound DNA
15 contacted in step (b), (d) labeling unbound DNA separated in step (c) with a label capable of binding a partner molecule or agent immobilized on a substrate, (e) hybridizing DNA labeled in step (d) with insert DNA from a second collection of cDNA libraries derived from organisms not having the defined phenotype, (f) contacting DNA hybridized in step (e)
20 with a second immobilized mismatch binding protein, (g) separating unbound DNA from bound DNA contacted in step (f), (h) contacting unbound DNA separated in step (g) with the partner molecule or agent immobilized on the substrate capable of binding the label, and (i) separating unbound DNA from bound DNA contacted in step (h), which unbound DNA
25 separated in step (i) encodes identified genes underlying the defined phenotype. This paragraph sets forth a preferred embodiment in which the DNA labeled in step (d) corresponds to undesired material labeled for removal.

Still further, this invention provides a method for identifying one or more alleles underlying a defined
30 phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or

individual from which a second cDNA library is derived. The method comprises the steps of (a) hybridizing insert DNA from the first cDNA library with itself, (b) hybridizing insert DNA from the second cDNA library with itself, (c) contacting the DNA hybridized in step (a) with a first immobilized
5 mismatch binding protein, (d) contacting the DNA hybridized in step (b) with a second immobilized mismatch binding protein, (e) separating unbound DNA from bound DNA contacted in step (c), (f) separating unbound DNA from bound DNA contacted in step (d), (g) labeling unbound DNA separated in step (f) with a label capable of binding a partner molecule
10 or agent immobilized on a substrate, (h) hybridizing DNA labeled in step (g) with unbound DNA separated in step (e), (i) contacting DNA hybridized in step (h) with a third immobilized mismatch binding protein, (j) separating unbound DNA from bound DNA contacted in step (i), (k) releasing bound DNA separated in step (j) from the third immobilized mismatch
15 binding protein, (l) contacting DNA released in step (k) with the partner molecule or agent immobilized on the substrate capable of binding the label, (m) denaturing DNA contacted in step (l), and (n) separating unbound DNA from bound DNA denatured in step (m), which unbound DNA separated in step (n) encodes one or more identified alleles underlying the
20 defined phenotype.

Yet still further, this invention provides a method for identifying one or more alleles underlying a defined phenotype from organisms having consanguinity. The method comprises the steps of (a) hybridizing insert DNA from a first collection of cDNA libraries derived from organisms
25 having the defined phenotype with itself, (b) contacting DNA hybridized in step (a) with a first immobilized mismatch binding protein, (c) separating unbound DNA from bound DNA contacted in step (b), (d) labeling unbound DNA separated in step (c) with a label capable of binding a partner molecule or agent immobilized on a substrate, (e) hybridizing DNA
30 labeled in step (d) with insert DNA from a second collection of cDNA libraries derived from organisms not having the

- defined phenotype, (f) contacting DNA hybridized in step (e) with a second immobilized mismatch binding protein, (g) separating unbound DNA from bound DNA contacted in step (f), (h) releasing bound DNA separated in step (g) from the second immobilized mismatch binding protein, (i) contacting DNA
- 5 released in step (h) with the partner molecule or agent immobilized on the substrate capable of binding the label, (j) denaturing DNA contacted in step (i), and (k) separating bound DNA from unbound DNA denatured in step (j), which bound DNA separated in step (k) encodes one or more identified alleles underlying the defined phenotype.
- 10 The cDNA library collections will vary according to the specific attributes of the sample source. In one embodiment, the first and second cDNA library collections each are nucleic acid populations derived from at least two individuals having consanguinity. In another embodiment, the first and second cDNA library collections each are nucleic
- 15 acid populations derived from more than two individuals having consanguinity. In one embodiment, the first and second cDNA library collections each are nucleic acid populations derived from two to six individuals having consanguinity. In another embodiment, the first and second cDNA library collections each are nucleic acid populations
- 20 derived from three individuals having consanguinity.
- A nucleic acid sample population may be left unlabeled or labeled with a unique label in various ways. In one embodiment, labeling is effected by polymerase chain reaction using a 5'-biotinylated primer. In another embodiment, labeling is effected by polymerase chain reaction using a 5'-
- 25 peptide-labeled primer. In a preferred embodiment, labeling using a 5'-biotinylated primer is performed when using one unlabeled sample population and one labeled sample population. In another preferred embodiment, labeling using a 5'-peptide-labeled primer is performed when multiplexing, i.e. when using three or more nucleic acid sample
- 30 populations.

A labeled nucleic acid sample population may be sorted in various ways. In one embodiment, the substrate for binding the biotin label is streptavidin. In another embodiment, the substrate for binding the peptide label is an antibody. In still another embodiment, the antibody is an
5 anti-peptide antibody. In yet still another embodiment, the anti-peptide antibody is monoclonal.

A variety of wild-type and recombinant, engineered mismatch binding proteins may be used to effect sorting (i.e. binding and release) of DNA duplexes containing mismatches. In one embodiment, the mismatch binding protein is *E. coli*
10 MutS. In another embodiment, the mismatch binding protein is hMSH2. In still another embodiment, the mismatch binding protein is an hMSH2-hMSH6 protein complex.

This invention provides a method for identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but
15 not displayed by a cell or individual from which a second cDNA library is derived. The method comprises the steps of (a) amplifying insert DNA from the first cDNA library by polymerase chain reaction, (b) amplifying insert DNA from the second cDNA library by polymerase chain reaction, (c) hybridizing DNA amplified in step (a) with itself, (d)
20 hybridizing DNA amplified in step (b) with itself, (e) contacting DNA hybridized in step (c) with a first immobilized MutS, (f) contacting DNA hybridized in step (d) with a second immobilized MutS, (g) separating unbound DNA from bound DNA contacted in step (e), (h) separating unbound DNA from bound DNA contacted in step (f), (i) amplifying
25 unbound DNA separated in step (g) by polymerase chain reaction using unlabeled primers, (j) amplifying and labeling unbound DNA separated in step (h) by polymerase chain reaction using 5'-biotinylated primers, (k) hybridizing DNA amplified and labeled in step (j) with DNA amplified in step (i), (l) contacting DNA hybridized in step (k) with a third
30 immobilized MutS, (m) separating unbound DNA from bound DNA contacted in step (l), (n) contacting unbound DNA separated

in step (m) with immobilized streptavidin, and (o) separating unbound DNA from bound DNA contacted in step (n), which unbound DNA separated in step (o) encodes one or more identified genes underlying the defined phenotype.

Further, this invention provides a method for
5 identifying one or more genes underlying a disease phenotype from healthy and affected individuals having consanguinity. The method comprises the steps of (a) amplifying insert DNA from a first collection of cDNA libraries derived from affected individuals by polymerase chain reaction, (b) hybridizing DNA amplified in step (a) with itself, (c)
10 contacting DNA hybridized in step (b) with a first immobilized MutS, (d) separating unbound DNA from bound DNA contacted in step (c), (e) amplifying and labeling unbound DNA separated in step (d) by polymerase chain reaction using 5'-biotinylated primers, (f) amplifying insert DNA from a second collection of cDNA libraries derived from healthy
15 individuals by polymerase chain reaction, (g) hybridizing DNA amplified and labeled in step (e) with DNA amplified in step (f), (h) contacting DNA hybridized in step (g) with a second immobilized MutS, (i) separating unbound DNA from bound DNA contacted in step (h), (j) contacting unbound DNA separated in step (i) with immobilized streptavidin, and (k) separating
20 unbound DNA from bound DNA contacted in step (j), which unbound DNA separated in step (k) encodes one or more identified genes underlying the disease phenotype.

Still further, this invention provides a method for identifying one or more alleles underlying a defined phenotype displayed by a cell or individual from which a
25 first cDNA library is derived, but not displayed by a cell or individual from which a second cDNA library is derived. The method comprises the steps of (a) amplifying insert DNA from the first cDNA library by polymerase chain reaction, (b) amplifying insert DNA from the second cDNA library by polymerase chain reaction, (c) hybridizing DNA amplified in
30 step (a) with itself, (d) hybridizing DNA amplified in step (b) with itself, (e) contacting DNA hybridized in step (c)

with a first immobilized MutS, (f) contacting DNA hybridized in step (d) with a second immobilized MutS, (g) separating unbound DNA from bound DNA contacted in step (e), (h) separating unbound DNA from bound DNA contacted in step (f), (i) amplifying unbound DNA separated in step (g) by
5 polymerase chain reaction using unlabeled primers, (j) amplifying and labeling unbound DNA separated in step (h) by polymerase chain reaction using 5'-biotinylated primers, (k) hybridizing DNA amplified and labeled in step (j) with DNA amplified in step (i), (l) contacting DNA hybridized in step (k) with a third immobilized MutS, (m) separating unbound DNA
10 from bound DNA contacted in step (l), (n) releasing bound DNA separated in step (m) from the third immobilized MutS, (o) contacting DNA released in step (n) with immobilized streptavidin, (p) denaturing DNA contacted in step (o), and (q) separating unbound DNA from bound DNA denatured in step (p), which unbound DNA separated in step (q) encodes one or
15 more identified alleles underlying the defined phenotype. In one embodiment, releasing bound DNA from the third immobilized MutS in step (n) is carried out using ATP or proteinase K.

Yet still further, this invention provides a method for identifying one or more affected alleles underlying a disease
20 phenotype from healthy and affected individuals having consanguinity. The method comprises the steps of (a) amplifying insert DNA from a first collection of cDNA libraries derived from affected individuals by polymerase chain reaction, (b) hybridizing DNA amplified in step (a) with itself, (c) contacting DNA hybridized in step (b) with a
25 first immobilized MutS, (d) separating unbound DNA from bound DNA contacted in step (c), (e) amplifying and labeling unbound DNA separated in step (d) by polymerase chain reaction using 5'-biotinylated primers, (f) amplifying insert DNA from a second collection of cDNA libraries derived from healthy individuals by polymerase chain reaction, (g)
30 hybridizing DNA amplified and labeled in step (e) with DNA amplified in step (f), (h) contacting DNA hybridized in step

(g) with a second immobilized MutS, (i) separating unbound DNA from bound DNA contacted in step (h), (j) releasing bound DNA separated in step (i) from the second immobilized MutS, (k) contacting DNA released in step (j) with immobilized streptavidin, (l) denaturing DNA contacted in step (k), and
5 (m) separating bound DNA from unbound DNA denatured in step (l), which bound DNA separated in step (m) encodes one or more identified affected alleles underlying the disease phenotype. In one embodiment, releasing bound DNA from the second immobilized MutS in step (j) is carried out using ATP or proteinase K.

10 Yet still further, this invention provides a method for identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) hybridizing
15 insert DNA from each cDNA library with itself, (b) contacting each separate population of DNA hybridized in step (a) individually with an immobilized mismatch binding protein, (c) separating unbound DNA from bound DNA contacted individually in step (b), (d) labeling each separate population of unbound DNA separated in step (c) with a
20 different label capable of binding a partner molecule immobilized on a substrate, (e) hybridizing DNA separately labeled in step (d), (f) contacting DNA hybridized in step (e) with an immobilized mismatch binding protein, and (g) separating unbound DNA from bound DNA contacted in step (f).

Still further, this invention provides a method for
25 identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) amplifying insert DNA from each cDNA library by polymerase chain
30 reaction, (b) hybridizing each separate population of DNA amplified in step (a) with itself, (c) contacting each

separate population of DNA hybridized in step (b) individually with immobilized MutS, (d) separating unbound DNA from bound DNA contacted in step (c), (e) labeling each separate population of unbound DNA separated in step (d) by polymerase chain reaction using a distinct 5'-peptide-labeled
5 primer capable of binding a partner molecule immobilized on a substrate, (f) hybridizing DNA labeled in step (e), (g) contacting DNA hybridized in step (f) with immobilized MutS, and (h) separating unbound DNA from bound DNA contacted in step (g).

Further, this invention provides a method for
10 identifying one or more alleles underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) hybridizing insert DNA from each cDNA library with itself,
15 (b) contacting each separate population of DNA hybridized in step (a) individually with an immobilized mismatch binding protein, (c) separating unbound DNA from bound DNA contacted in step (b), (d) labeling each separate population of unbound DNA separated in step (c) with a distinct label capable of binding a partner molecule immobilized on a substrate, (e)
20 hybridizing DNA labeled in step (d), (f) contacting DNA hybridized in step (e) with an immobilized mismatch binding protein, and (g) separating unbound DNA from bound DNA contacted in step (f).

Still further, this invention provides a method for identifying one or more alleles underlying a defined
25 phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) amplifying insert DNA from each cDNA library by polymerase chain reaction, (b) hybridizing DNA amplified from each
30 library in step (a) with itself, (c) contacting DNA from each library hybridized in step (b) individually with an

immobilized mismatch binding protein, (d) separating unbound DNA from bound DNA contacted in step (c), (e) amplifying and labeling each separate population of unbound DNA separated in step (d) by polymerase chain reaction using a distinct 5'-peptide-labeled primer, (f) hybridizing DNA amplified and
5 labeled in step (e), (g) contacting DNA hybridized in step (f) with an immobilized mismatch binding protein, (h) separating unbound DNA from bound DNA contacted in step (g), (i) releasing bound DNA separated in step (h), and (j) separating DNA released in step (i) into single strands.

Still further, this invention provides a method for
10 identifying one or more alleles underlying a defined phenotype comprising the following steps in the order stated: (a) removing mismatched duplex nucleic acid molecules formed from hybridization within each of a plurality of source populations of nucleic acids; (b) retaining mismatched duplex nucleic acid molecules formed from hybridization among the
15 plurality of source populations; (c) separating mismatched strands retained in step (b), which separated strands comprise one or more alleles underlying the defined phenotype.

This invention provides a method for identifying one or more genes underlying a defined phenotype. The method
20 comprises the steps of (a) removing mismatched duplex nucleic acid molecules formed from hybridization within each of a plurality of source populations of nucleic acids, and (b) retaining mismatched duplex nucleic acid molecules formed from hybridization among the plurality of source populations, the retained molecules in step (b) comprising the one or more
25 genes underlying the defined phenotype. In one embodiment, the plurality of source populations comprises at least one normalized cDNA library. In another embodiment, the plurality of source populations comprises at least one linearized cDNA library. In yet another embodiment, the plurality of source populations consists of DNA, the DNA of
30 each of the source populations being labeled with a different

label, and the hybridization in step (b) is carried out using an excess of labeled DNA from one or more source populations. In one embodiment, the excess of labeled DNA is a three-fold excess. Yet in another embodiment, each of the source populations is derived from a cell line.

- 5 This invention also provides a method for identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) hybridizing insert DNA from
10 the first cDNA library with itself, (b) hybridizing insert DNA from each library of the plurality of additional cDNA libraries with itself, (c) contacting the DNA hybridized in step (a) with an immobilized mismatch binding protein, (d) contacting each separate population of DNAs hybridized in step (b) individually with an immobilized mismatch binding
15 protein, (e) separating unbound DNA from bound DNA contacted in step (c), (f) separating unbound DNA from bound DNA contacted individually in step (d), (g) labeling each separate population of the unbound DNA separated in step (f) with a distinguishable label capable of binding a partner molecule immobilized on a substrate, (h) hybridizing DNA
20 separately labeled in step (g) with unbound DNA separated in step (e), (i) contacting DNA hybridized in step (h) with an immobilized mismatch binding protein, (j) separating unbound DNA from bound DNA contacted in step (i), (k) contacting unbound DNA separated in step (j) with the partner molecule of each different label, and (l) separating unbound DNA from
25 bound DNA contacted in step (k), which unbound DNA separated in step (l) encodes one or more identified genes underlying the defined phenotype. In one embodiment, one or more of the cDNA libraries is normalized. In another embodiment, one or more of the cDNA libraries is linearized. In yet another embodiment, labeling is carried out by polymerase chain
30 reaction using a 5'-peptide labeled primer. In yet another embodiment, at least one partner molecule immobilized is an

antibody. In still another embodiment, the antibody is an anti-peptide antibody. In yet another embodiment, the hybridization in step (h) is carried out using an excess of labeled DNA. In yet another embodiment, the excess of labeled DNA is a three-fold excess. In yet another
5 embodiment, an immobilized mismatch binding protein is MutS. In one embodiment, the defined phenotype is selected from the group consisting of a plant phenotype, a microorganism phenotype, and a pathologic phenotype. In another embodiment, the defined phenotype is a pathologic phenotype that is selected from the group consisting of
10 cancer, osteoporosis, obesity, type II diabetes, and a prion-related disease.

This invention further provides a method for identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which
15 a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) amplifying insert DNA from the first cDNA library by polymerase chain reaction, (b) amplifying insert DNA from each of the plurality of additional cDNA libraries by polymerase chain reaction, (c) hybridizing DNA amplified in step (a) with itself,
20 (d) hybridizing each separate population of DNA amplified in step (b) with itself, (e) contacting DNA hybridized in step (c) with immobilized MutS, (f) contacting each separate population of DNA hybridized in step (d) individually with immobilized MutS, (g) separating unbound DNA from bound DNA contacted in step (e), (h) separating unbound DNA from bound
25 DNA contacted in step (f), (i) labeling unbound DNA separated in step (g) by polymerase chain reaction using unlabeled primers, (j) labeling each separate population of unbound DNA separated in step (h) by polymerase chain reaction using a primer having a distinguishable 5'-peptide-label capable of binding a partner molecule immobilized on a substrate, (k)
30 hybridizing DNA labeled in step (i) with DNA labeled in step (j), (l) contacting DNA hybridized in step (k) with

immobilized MutS, (m) separating unbound DNA from bound DNA contacted in step (l), (n) contacting unbound DNA separated in step (m) with one or more partner molecules capable of binding the distinguishable 5'-peptide-labeled primers, and (o) separating unbound DNA from bound DNA contacted in step 5 (n), which unbound DNA separated in step (o) encodes one or more identified genes underlying the defined phenotype.

This invention provides a method for identifying one or more alleles underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which 10 a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) hybridizing insert DNA from the first cDNA library with itself, (b) hybridizing insert DNA from each of the plurality of additional cDNA libraries with itself, (c) contacting DNA hybridized in step (a) with an immobilized mismatch binding protein, (d) contacting each 15 separate population of DNA hybridized in step (b) individually with an immobilized mismatch binding protein, (e) separating unbound DNA from bound DNA contacted in step (c), (f) separating unbound DNA from bound DNA contacted in step (d), (g) labeling each separate population of unbound DNA separated in step (f) with a distinguishable label 20 capable of binding a partner molecule immobilized on a substrate, (h) hybridizing DNA labeled in step (g) with unbound DNA separated in step (e), (i) contacting DNA hybridized in step (h) with an immobilized mismatch binding protein, (j) separating unbound DNA from bound DNA contacted in step (i), (k) releasing bound DNA separated in step (j) 25 from the immobilized mismatch binding protein, (l) contacting DNA released in step (k) with one or more partner molecules capable of binding the distinct labels, (m) denaturing DNA contacted in step (l), and (n) separating unbound DNA from bound DNA denatured in step (m), which unbound DNA separated in step (n) encodes one or more identified alleles underlying 30 the defined phenotype. In one embodiment, at least one cDNA library is normalized. In another embodiment, at least one

cDNA library is linearized. In one embodiment, labeling is carried out by polymerase chain reaction using 5'-peptide labeled primers. In another embodiment, at least one immobilized partner molecule is an antibody. In another embodiment, the antibody is an anti-peptide antibody. In
5 another embodiment, the hybridization in step (h) is carried out using an excess of labeled DNA. In another embodiment, the excess of labeled DNA is a three-fold excess. In another embodiment, at least one of the immobilized mismatch binding proteins is MutS.

This invention provides a method for identifying one or
10 more alleles underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) amplifying insert DNA from the first cDNA library by polymerase chain reaction, (b)
15 amplifying insert DNA from each of the plurality of additional cDNA libraries by polymerase chain reaction, (c) hybridizing DNA amplified in step (a) with itself, (d) hybridizing DNA amplified from each library in step (b) with itself, (e) contacting DNA hybridized in step (c) with immobilized MutS, (f) contacting each population of DNA
20 hybridized in step (d) individually with immobilized MutS, (g) separating unbound DNA from bound DNA contacted in step (e), (h) separating unbound DNA from bound DNA contacted in step (f), (i) amplifying unbound DNA separated in step (g) by polymerase chain reaction using unlabeled primers, (j) amplifying and labeling each population of unbound DNA
25 separated in step (h) by polymerase chain reaction using a distinguishable 5'-peptide-labeled primer, (k) hybridizing DNA amplified and labeled in step (j) with DNA amplified in step (i), (l) contacting DNA hybridized in step (k) with immobilized MutS, (m) separating unbound DNA from bound DNA contacted in step (l), (n) releasing bound DNA separated in
30 step (m) from immobilized MutS, (o) contacting DNA released in step (n) with one or more immobilized antibodies specific

for each distinguishable 5'-peptide-labeled primer, (p) denaturing DNA contacted in step (o), and (q) separating unbound DNA from bound DNA denatured in step (p), which unbound DNA separated in step (q) encodes one or more identified alleles underlying the defined phenotype. In one
5 embodiment, releasing bound DNA from immobilized MutS in step (n) is carried out using ATP or proteinase K. In another embodiment, the method further comprises a step of using the one or more genes or alleles identified to carry out a prognosis or a diagnosis. In one embodiment, the one or more genes or alleles identified, or an encoded protein thereof,
10 is a target for drug intervention. In another embodiment, the plurality of source populations is in the range of three to twelve source populations. In yet another embodiment, the plurality of source populations is in the range of three to six source populations. In another embodiment, the plurality of source populations consists of four source populations.

15 This invention provides a method for identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) hybridizing insert DNA from each
20 cDNA library with itself, (b) contacting each separate population of DNA hybridized in step (a) individually with an immobilized mismatch binding protein, (c) separating unbound DNA from bound DNA contacted individually in step (b), (d) labeling each separate population of unbound DNA separated in step (c) with a distinguishable label capable of
25 binding a partner molecule immobilized on a substrate, (e) hybridizing DNA separately labeled in step (d), (f) contacting DNA hybridized in step (e) with an immobilized mismatch binding protein, and (g) separating unbound DNA from bound DNA contacted in step (f).

30 This invention provides a method for identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but

not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) amplifying insert DNA from each cDNA library by polymerase chain reaction, (b) hybridizing each separate population of DNA amplified in step (a) with
5 itself, (c) contacting each separate population of DNA hybridized in step (b) individually with immobilized Muts, (d) separating unbound DNA from bound DNA contacted in step (c), (e) labeling each separate population of unbound DNA separated in step (d) by polymerase chain reaction using a primer having a distinguishable 5'-peptide-label
10 capable of binding a partner molecule immobilized on a substrate, (f) hybridizing DNA labeled in step (e), (g) contacting DNA hybridized in step (f) with immobilized Muts, and (h) separating unbound DNA from bound DNA contacted in step (g).

This invention provides a method for identifying one or
15 more alleles underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived. The method comprises the steps of (a) hybridizing insert DNA from each cDNA library with itself, (b) contacting each separate
20 population of DNA hybridized in step (a) individually with an immobilized mismatch binding protein, (c) separating unbound DNA from bound DNA contacted in step (b), (d) labeling each separate population of unbound DNA separated in step (c) with a distinguishable label capable of binding a partner molecule immobilized on a substrate, (e) hybridizing DNA labeled in
25 step (d), (f) contacting DNA hybridized in step (e) with an immobilized mismatch binding protein, and (g) separating unbound DNA from bound DNA contacted in step (f).

This invention provides a method for identifying one or more alleles underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is
30 derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived. The

method comprises the steps of (a) amplifying insert DNA from each cDNA library by polymerase chain reaction, (b) hybridizing DNA amplified from each library in step (a) with itself, (c) contacting DNA from each library hybridized in step (b) individually with an immobilized mismatch binding
5 protein, (d) separating unbound DNA from bound DNA contacted in step (c), (e) amplifying and labeling each separate population of unbound DNA separated in step (d) by polymerase chain reaction using a distinct 5'-peptide-labeled primer, (f) hybridizing DNA amplified and labeled in step (e), (g) contacting DNA hybridized in step (f) with an immobilized
10 mismatch binding protein, (h) separating unbound DNA from bound DNA contacted in step (g), (i) releasing bound DNA separated in step (h), and (j) separating DNA released in step (i) into single strands.

This invention provides a method for identifying one or more alleles underlying a defined phenotype. The method
15 comprises the steps of (a) removing mismatched duplex nucleic acid molecules formed from hybridization within each of a plurality of source populations of nucleic acids, (b) retaining mismatched duplex nucleic acid molecules formed from hybridization among the plurality of source populations, and (c) separating mismatched strands retained in step (b),
20 which separated strands comprise one or more alleles underlying the defined phenotype.

25

30

4. BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of a VGIDSM approach for phenotype samples obtained from sources without at least one common ancestor (e.g. cell line samples; healthy and
5 diseased nodes within an individual tissue sample). PCR is polymerase chain reaction.

FIG. 2 is a schematic representation of a VGIDSM approach for phenotype samples obtained from sources having at least one common ancestor (e.g. tissue samples from healthy and
10 disease-affected *siblings*).

FIG. 3 is a flow chart representation of the phenotype selection process to be employed prior to using the VGIDSM method of the invention.

15 FIG. 4 is a schematic map of five hDinP clones isolated using the VGIDSM method and cell line samples as input phenotypes. The VGIDSM approach employed is that illustrated in FIG. 1. A lymphoblast cell line was chosen as cell line # 1 because it expresses a specific alteration in a DNA repair pathway (i.e. "with phenotype" in FIG. 1); a hepatocyte cell
20 line was chosen as cell line # 2 (i.e. "without phenotype" in FIG. 1).

FIG. 5A-B shows BLASTX search results and computer analysis for the hDinP clone listed in SEQ ID NO:1 (#1).

25 FIG. 6 shows BLASTX search results and computer analysis for the hDinP clone listed in SEQ ID NO:2 (Tor-M).

FIG. 7A-B shows BLASTX search results and computer analysis for the hDinP clone listed in SEQ ID NO:3 (#3).

30 FIG. 8A-B shows BLASTX search results and computer analysis for the hDinP clone listed in SEQ ID NO:4 (*1).

FIG. 9A-B shows BLASTX search results and computer analysis for the hDinP clone listed in SEQ ID NO:5 (*2).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method, referred to
5 generally as the ValiGeneSM Gene Identification method, or the
VGIDSM method, for identification of a gene or multiple genes
linked to a user-specified phenotype. In this regard, genes
linked to a phenotype include genes which cause the
phenotype-of-interest, genes which merely contribute to a
phenotype which is partly due to genetic factors and partly
10 due to environmental factors, as well as structurally altered
genes arising as an effect of a phenotype. The methodology
comprising VGIDSM can be used to perform a function-based
analysis of the protein-coding genome of any organism
irrespective of biological kingdom. Further, the VGIDSM
method can simultaneously identify multiple alleles of the
15 gene of interest which are associated with multiple
phenotypes, including disease phenotypes. Accordingly,
phenotype-specific diagnostic tools are provided by genes
identified using the VGIDSM method. In particular, such
diagnostic tools may be used as an indication of the presence
of the phenotype-of-interest. Further, phenotype-specific
20 prognostic tools are provided by genes identified using the
VGIDSM method; such prognostic tools may be used to indicate
or predict a disease course and/or outcome for various
disease phenotypes.

The VGIDSM methodology is based on a constant underlying
principle, i.e. the ability to specifically trap and
25 subsequently release mismatched artificial cDNA hybrids
formed by annealing interactions between cDNA's originating
from phenotypically-distinct sources. Thus, the VGIDSM
methodology is a powerful molecular comparison tool which
does not require global sequence information. Instead, a
comparison among phenotypic groups is accomplished using cDNA
30 annealing interactions and subsequent sorting of matched from
mismatched hybrids.

The details of the VGIDSM method vary depending upon the precise "comparison" to be made. This is due to the fact that mRNA transcripts derived from different sources will vary in their "complexity" (i.e. genetic heterogeneity) and therefore should undergo slightly different processing approaches, as described in detail below. In one embodiment, the VGIDSM method is used to isolate transcripts that are identical among phenotypically-distinct groups. In another embodiment, the VGIDSM method is used to isolate transcripts that are different among such groups. The VGIDSM method is broadly applicable for identifying the genes underlying specific functions. Common input phenotypes for use with the VGIDSM method are healthy (normal) and affected (disease) phenotypes. Other common input phenotypes are susceptible and resistant phenotypes (e.g. viruses susceptible and resistant to antiviral agents, microbes susceptible and resistant to antibiotics, plants susceptible and resistant to herbicides, insects susceptible and resistant to insecticides). In this regard, one skilled in the art will recognize that the VGIDSM method may be applied virtually anywhere two or more input phenotypes are identified, regardless of biological kingdom. Guidelines for input phenotype selection are provided in Section 5.4 hereinbelow.

The VGIDSM method utilizes nucleic acids obtained or derived from at least two source groups as starting material. In a preferred embodiment, the nucleic acid is cDNA made from messenger RNA (mRNA), preferably total poly A RNA from the source groups. Small quantities of mRNA are sufficient for using the VGIDSM method. This flexibility in input amount permits a meaningful genetic analysis of rare disease tissue samples, for example. The lower limit amount of source nucleic acid required is the minimal amount sufficient for construction of a cDNA library (i.e. about 1 ng to 1 μ g per source with most cDNA library construction techniques).

At its most basic level, the VGIDSM method may be thought of as an expressed gene subtraction technique. The VGIDSM method is based upon two rounds of highly efficient mismatch

binding protein chromatography for trapping (e.g. by binding to immobilized Muts) of: (a) *internally* heterologous nucleic acids (round one; see upper columns in FIGs. 1 and 2); and (b) *externally* heterologous nucleic acids (round two; see lower columns in FIGs. 1 and 2), as described below. In this regard, internally heterologous nucleic acids refers to heterologous nucleic acids (*i.e.* nucleic acids that do not have identical counterparts) *within* each of two or more source groups, and externally heterologous nucleic acids refers to heterologous nucleic acids *between* the source groups. In the first round, it is generally the *untrapped* material from input phenotypes which is of primary interest (such untrapped material is said to be "homogenized"). By contrast, in the second round, the material of interest is often the *trapped* material. This trapped material must necessarily be an artificially-formed, hybrid duplex of similar, yet non-identical cDNA strands, one strand originating from material left untrapped in the first round subtraction step. For use in the VGIDSM method, nucleic acids are obtained from at least two sources. Best results are obtained where most of the nucleic acids are structurally identical between different sources since this will result in the most effective subtraction in the second round. This situation is most likely to arise where the input source groups are phenotypically identical but for the phenotype-of-interest. Accordingly, the choice of input sources ultimately determines whether the expressed gene-of-interest is identified. Often, the most appropriate samples are obtained from large families containing several affected and unaffected individuals. In the context of positional cloning, the reasons behind this were explained above. In the VGIDSM method, families (particularly families where consanguinity, *i.e.* relationship by a common ancestor, is known to exist) may also provide the most appropriate samples, but for entirely different reasons.

30

Consanguinity gives rise to the direct, non-recombined inheritance of genetic elements which, alone or in association with other factors, can have pathogenic effects. This property of consanguinity can be turned into a considerable advantage in the search for genes directly associated with pathologies. In the presence of consanguinity, it would be expected that all diseased individuals taken from three generations within the same disease-transmitting family (or otherwise inbred) will carry the same disease-causing locus, and hence be identical-by-descent at this locus.

10

5.1. GENETIC HETEROGENEITY

The various cell lines which are available for a given cell type (e.g. hepatocytes) are characterized by functional similarities and differences (i.e. phenotype) as well as by structural genomic similarities and differences (i.e. genotype). In each cell line, the phenotype arises from a unique source, i.e. the expressed genes of that cell line. Samples of a given tissue originating from different individuals are also characterized by phenotype and genotype. However, in tissue samples, the phenotype arises from the aggregate contributions of the expressed genes of several different cell types and these contributions cannot be individually isolated.

20

The consequences of the above for gene identification according to the present invention are two-fold. First, tissues are most useful for isolating genes linked to a broadly-defined phenotype, such as the presence of a disorder affecting individual A but not individual B. Tissue samples are less useful for isolation of unknown genes associated with a narrowly-defined phenotype. Second, cell lines are most useful for isolating genes linked to a very clearly-defined molecular function (e.g. a particular form of DNA repair such as that performed by hDinP; see below). The specific methods described below to isolate unknown genes from tissues and cell lines are therefore different.

25

30

To elaborate further, it is useful to compare function and genetic makeup in tissues and cell lines.

With regard to function, note that all cells of a cell line population are clonal in origin. That is, they not only descend from a single unique cell, they are actual copies of
5 the ancestor cell. All cells of a cell line are therefore functionally identical. By contrast, a tissue sample is composed of many different cell types carrying out different functions, and each given cell type population is made up of groups of functionally similar cells having different lineages.

10 With regard to genetic makeup, different cell lines are of completely different origin. That is, the ancestor cells which gave rise to different cell lines came from different individuals. Cell lines therefore carry entirely different genomes. By contrast, the various cell types comprising a given tissue all share the same genome, irrespective of the
15 functional differences among the cell types within the tissue.

Members of a given cell line population initially present very *high internal consanguinity* and very *high functional identity*. However, due to fast growth rate in artificial conditions, little or no selective pressures and
20 no possibility to eradicate aberrant cells (*i.e.* no immune system), members are free to accumulate mutations and transmit them to their direct progeny (so long as these mutations do not compromise basic metabolism). Therefore, a cell line population potentially carries a wide variety of newly-acquired mutations. This not only reduces the
25 structural genomic homogeneity of the population, but also allows different members of the population to express different forms of a given gene (*i.e.* mutant alleles), as well as genes that are not expressed at all by other members of the cell line population (since a mutation in one gene may affect the expression of other genes). These effects can
30 result in the presence of a wider spectrum of transcripts than might initially be expected from a homogeneous cell

population. Awareness of these effects allows for a measure of control by, e.g., careful attention to growth conditions and cell passage number.

These effects are exacerbated when functionally different cell lines are concurrently utilized. The original
5 allelic forms and distribution of genes in the genome of a first cell line will be different from that found in a second cell line, but neither cell line will be subject to enforced internal genomic homogeneity. Furthermore, since the two cell lines are functionally different, the spectrum of expressed transcripts in one population will be different
10 from that present in the other population.

On the other hand, tissue samples comprising many cell types present *very high internal consanguinity* but *very high functional diversity*. In tissue samples, unlike cell lines, genomic homogeneity is maintained by the immune system of the individual since most aberrant cells are immediately
15 eradicated. This enforcement of genomic homogeneity by the immune system works to reduce the spectrum of transcripts found in tissues. However, the wide variety of cell types within a given tissue generally more than makes up for this effect. For example, different cell types often express different isoforms of a gene family represented by multiple
20 gene copies in the genome (a phenomenon known as differentiation-specific expression). The net result is the presence of an increasing spectrum of different transcripts expressed in tissues as the number of cell types increases. The final expression complexity level is therefore much higher in tissues than in cell lines.
25

5.1.1. GENETIC HETEROGENEITY IN CELL LINES

When starting with cell line samples, the genes-of-interest to be identified may already be well defined in terms of their precise molecular function (for an example, see Section 6 hereinbelow). The sources of genetic
30 heterogeneity in cell lines are quite different than in tissues. First, there is heterogeneity associated with the

genetic differences internal to each cell line. Second, there is heterogeneity associated with the functional characteristics of each cell line. Third, there is heterogeneity associated with the genetic differences between cell lines.

5 It is the solution (i.e. removal) of the internal sources of heterogeneity in the first step of the VGIDSM method together with the complete retention and utilization of the other two sources of heterogeneity in the second step which leads to the direct isolation of the target genes of interest under the VGIDSM approach outlined in FIG. 1. That
10 is, by first retaining only transcripts structurally identical within each cell line, one removes internal heterogeneity. By next removing all transcripts identical between the two cell lines, one is left only with transcripts specific to the key functions associated with the cell line expressing the phenotype-of-interest. The choice of
15 appropriate cell lines is therefore crucial.

The practical aspects of unknown gene isolation from cell line samples are thus entirely defined, as described in detail below in Section 5.2.1. The first step in the approach used for cell lines separately isolates from each cell line nucleic acids (e.g. transcripts) that are
20 structurally identical internally. The second step uses the nucleic acids (e.g. transcripts) from the unspecialized cell line (i.e. "without phenotype" in FIG. 1) to subtract their homologues (i.e. structurally identical externally) from the specialized cell line (i.e. "with phenotype" of interest, see FIG. 1). The second step utilizes MutS, together with
25 another trapping system (e.g. streptavidin-coated beads, see below), to recognize only material originating from the unspecialized cell line (i.e. hybrid as well as native duplexes). The material remaining at the end of the operation corresponds to those few nucleic acids (i.e. transcripts) which are entirely specific (i.e.
30 differentiation-specific) to the specialized cell line.

5.1.2. GENETIC HETEROGENEITY IN TISSUES

When starting with tissue samples, unlike with cell lines, the genes of interest will usually be defined only in terms of their phenotypic effects (i.e. presence or absence of a disease or trait). Furthermore, there is no complete
5 assurance that, in genetically different individuals, the same phenotypic trait does not have entirely different causes. To further complicate matters, the material utilized (e.g. mRNA) according to the second approach of the VGIDSM method comes from a complex source (as explained in detail above) in that: (a) tissue are made of different cell types
10 that cannot be separated; and (b) tissue samples are provided by different individuals.

For tissue samples, three sources of genetic heterogeneity exist to contend with in the isolation of the genes of interest, including disease (affected) genes. First, there is heterogeneity associated with a target tissue
15 comprised of multiple cell types. Second, there is heterogeneity associated with phenotypic differences among normal and affected individuals which do not give rise to disease. Third, there is heterogeneity associated with the genetic differences among normal and affected individuals which gives rise to the disease.

20 It is the solution (i.e. removal) of the first and second sources of heterogeneity which directly leads to isolation of disease genes using the VGIDSM approach outlined in FIG. 2. By selecting as tissue donors several affected and several healthy members of the same genetic group (i.e. consanguineous donors) and then pooling the tissue extracts
25 into only two groups, three things are accomplished. First, genetic differences between affected and unaffected individuals are considerably reduced; second, phenotypic homogeneity among the affected individuals is vastly increased; and third, genetic heterogeneities within each sample group are homogenized.

30 The practical aspects of unknown gene isolation from tissue samples are thus entirely defined, as described in

detail below in Section 5.2.2. The first step utilizes mismatch binding chromatography to isolate transcripts which are structurally identical among affected individuals (i.e. column flow through, see upper column in FIG. 2). These structurally identical transcripts are then used to isolate
5 their structurally different counterparts from the unaffected pool in a second round of mismatch binding chromatography (see lower column in FIG. 2). In this way, none of the transcripts structurally identical between affected and unaffected pools will be trapped by mismatch binding and none of the transcripts structurally different within the
10 unaffected (healthy) pool will be selectively recovered from the material released from binding.

5.2. TWO APPROACHES FOR THE VGIDSM METHOD

The VGIDSM method is designed to identify genes by isolating nucleic acids derived from transcripts that are
15 associated with a given phenotype in the complete absence of pertinent molecular information. In this context, a phenotype corresponds to a detectable biological difference between otherwise-comparable tissues or cell population samples. Biological differences may range from narrow, well-defined metabolic functions (e.g. DNA repair) to broad, less-
20 well-defined clinical observations (e.g. schizophrenia or Alzheimer's disease). As opposed to other expressed transcript isolation methods (e.g. cDNA subtraction technologies), the VGIDSM process does not require subtraction steps based upon known sequences. Moreover, the VGIDSM process does not require any molecular choices to be made by
25 the user. Instead, the VGIDSM user need only select the input phenotypes for comparison.

The operating principle of the VGIDSM process makes use of the fact that any detectable biological difference existing between two or more otherwise-similar samples almost always depends, at least in part, from the presence of
30 concomitant transcriptional differences between these samples. In order to isolate transcripts associated with a

phenotype-of-interest using the VGIDSM method, one does not speculate regarding possible structures that need to be isolated or discarded. Instead, one merely chooses the input phenotypes for use in the VGIDSM comparison assay.

While the VGIDSM method does not allow one to directly
5 identify (i.e. by mismatch binding) promoter-associated mutations contained in non-transcribed portions of genes, any transcripts that are over- or under-expressed as a result of such mutations can be identified (e.g. see the first approach described in Section 5.3.1 and the Example in Section 6 hereinbelow). In summary, the VGIDSM process allows isolation
10 and identification of overexpressed, underexpressed or mutated transcripts that specifically differ between two (or more) transcript source populations.

The VGIDSM method may be applied to any two or more nucleic acid source populations. Nucleic acid source populations used in the VGIDSM method are derived from
15 transcript sources (i.e. messenger RNA from cellular sources) preferably by converting the mRNA to double-stranded cDNA. Transcript sources include, but are not limited to, animals, plants, and microorganisms, including viruses. For example, the VGIDSM method may be applied for the isolation of microbial genes conferring resistance to toxic compounds or
20 metabolites. As another example, the VGIDSM method may be applied to isolate plant genes conferring desirable traits for crop production. For tissues and cell lines, transcript sources may include, but are not limited to: (a) tissue nodes within an individual tissue sample (first approach); (b) cell line samples (first approach); and (c) tissues samples
25 originating from familial clusters having consanguinity (second approach). The first and second VGIDSM approaches that can be most commonly used for these various transcript sources are described in detail below.

5.2.1. FIRST APPROACH: CELL LINES OR SOLE TISSUE SAMPLE

This approach is particularly well suited to the study of genes associated with specific metabolic functions (e.g. in a cell line displaying the phenotype-of-interest) or with
5 disease processes where affected tissue samples are limited and where control tissue from healthy individuals cannot be obtained. This approach also allows comparative study of sporadic versus familial forms of a given pathology.

Three different yet complementary transcript isolations may be performed using the first VGIDSM approach, as follows:
10 (i) isolation of transcripts overexpressed (or unilaterally expressed) in the presence of the phenotype-of-interest; (ii) isolation of transcripts underexpressed (or unilaterally repressed) in the presence of the phenotype-of-interest; and (iii) isolation of transcript variants (i.e. mutants) associated with the phenotype-of-interest.

15 The overall experimental scheme for using the VGIDSM method under the first approach is illustrated in FIG. 1. The first approach identifies a gene or genes underlying a defined phenotype in two steps by, first, removing mismatched duplex nucleic acid molecules formed from hybridization within each of two source populations and, second, retaining
20 mismatched duplex nucleic acid molecules formed from hybridization between the two populations. What follows is a preferred embodiment of the first approach; various modifications that can be made will be apparent to one of skill in the art (e.g. see Section 5.3 hereinbelow).

Selection of input phenotypes is performed by the user,
25 and can be carried out as desired. Nevertheless, preferred guidelines for phenotype selection (choosing transcript sources) are provided hereinbelow in Section 5.4. Following phenotype selection, an independent (i.e. separate) cDNA library is generated for each of two or more transcript sources which differ in the phenotype-of-interest. Cell
30 lines may be used as transcript sources. Alternatively, a single tissue sample from an affected (i.e. disease)

individual may also be used. In the latter instance, different cellular nodes are isolated from within the single tissue sample, each node representing a different pathological stage or phenotypic state.

In one embodiment, samples from transcript sources are
5 processed in pairs, each member of a pair representing a different phenotype. In another embodiment, samples are processed in groups of three or more (a.k.a. multiplex VGIDSM methodology). The two steps of the method can be further subdivided into several parts for clarity of illustration. For example, in the preferred embodiment described below, the
10 first step comprises parts 1-3 and the second step comprises parts 4-6, as follows.

Part 1. Each cDNA library originating from each independent source (e.g. cell line or tissue node) is subjected to a limited PCR
15 amplification (15-20 cycles) in order to linearize the cDNA inserts.

Part 2. The PCR products obtained from each source are independently (i.e. without yet combining materials from different sources) denatured
20 and reannealed.

Following parts 1 and 2, transcripts that present structural differences within each source population will give rise to mismatched heteroduplex molecules. The heterologous transcripts in these heteroduplex molecules
25 arise from random mutations not associated with the phenotype-of-interest. This heteroduplex formation occurs since the random mutations encountered should be common to only a portion of, and not to all, individual cells within each source population.

Part 3. The reannealed PCR products originating from each source are exposed independently to a
30

first round of mismatch column chromatography (see the top two columns in FIG. 1; e.g. columns may be packed with MutS-coated glass beads for "automatic trapping" of the mismatch-containing heteroduplexes).

5

In part 3, mismatched heteroduplexes become trapped in the column. After several cycles of denaturation and random reannealing followed by trapping, the column flow through contains primarily transcripts that are structurally common to all cells within the source. That is, any heterologous
10 transcripts within the source are largely removed from the material being analyzed during part 3 (see upper waste bin in FIG. 1 labeled "removal of heterologous transcripts").

Part 4. The cDNA inserts present in the flow-through obtained from each cell line are independently
15 PCR amplified and labeled.

In part 4, PCR amplification serves two purposes. First, this PCR increases the number of copies of the remaining individual cDNA inserts which originated from each source population. Second, and more importantly, PCR allows
20 independent labeling of inserts originating from each source population. In this way, one is able to selectively remove or retrieve inserts originating from a given source population. For example, FIG. 1 illustrates using two cell lines as source populations, with cell line # 1 displaying the phenotype-of-interest ("with phenotype" in FIG. 1).
25 Here, inserts that will not be part of the final analysis are labeled for removal (i.e. transcripts not associated with the phenomenon of interest; see lower right waste bin "removal of all molecules with DNA strand from cell line # 2"; see also hereinbelow).

The labels used in part 4 are attached to the primers
30 utilized in the relevant PCR reaction. Suitable labels include molecules that can be specifically bound and

subsequently removed from solution together with their attached PCR products. For example, such labels may be: (a) biotin molecules recognized by streptavidin coated onto solid supports; or (b) short peptides recognized by specific monoclonal antibodies attached to solid supports. The solid
5 supports used may be beads, resins, nitrocellulose paper, or others well known to those skilled in the art.

Part 5. The PCR amplified DNA, obtained from independent sources and subjected to parts 1-4, are now combined, denatured and reannealed.
10

Part 6. The reannealed PCR products are then exposed to a second round of mismatch column chromatography (see the lower column in FIG. 1).

15 In the FIG. 1 approach, the material trapped in the lower column is primarily mismatched heteroduplexes composed of one *non-labeled* strand originating from cell line # 1 and one *labeled* strand originating from cell line # 2. This material therefore represents transcripts expressed by both cell lines but carrying cell line-specific mutations, and may
20 either be discarded (see lower right waste bin in FIG. 1) or recovered, cloned, and analyzed. It is to be well noted that if parts 2 and 3 have not first been carried out, any material trapped by the source combination in parts 5 and 6 would not be worth recovering since it would be heavily contaminated by random heterologies present in each source
25 cell line.

Recovery of trapped heteroduplexes from a MutS mismatch binding column can be performed in at least two ways. First, the column may be filled with an ATP-containing buffer. The presence of ATP allows the ATPase activity of MutS to release trapped heteroduplexes. The concentration range of ATP
30 suitable for effecting release is from about 1 mM to about 6 mM ATP; the optimal concentration of ATP for effecting

release is about 3 mM (see e.g. Allen et al., 1997, EMBO J. 16, 4467-4476). Recovery of trapped heteroduplexes using ATP has the added advantage of regenerating the column for subsequent use. Second, recovery may be effected using a protease (with the caveat that certain proteases may not be
5 suitable for use with certain short peptide labels). For example, the column may be treated with a protease-containing buffer (e.g. proteinase K), resulting in the destruction of the MutS protein molecules immobilized in the column and the subsequent release of the trapped heteroduplexes.

Trapped material from the lower column in the example of
10 FIG. 1 is composed of one labeled and one non-labeled strand. This material may be discarded if one is only interested in transcripts from cell line # 1 (see lower right waste bin in FIG. 1). Alternatively, this material may be specifically recovered (e.g. using streptavidin or antibody-coated beads, depending upon the label used at part 4 above), for an
15 examination of the genetic differences in transcripts expressed by both input cell lines. If this specific recovery is desired, the isolated material is PCR amplified over a few cycles for production of clonable fragments having non-labeled 5' ends. It is noteworthy that recovery here preserves the original structures specific to each cell line
20 since, in the PCR reaction, each strand of the original mismatched heteroduplex independently gives rise to a perfectly matched homoduplex. It is also possible to separately clone the transcripts arising from each cell line source. This is accomplished by denaturing the heteroduplexes released from the column and subsequently
25 bound to the label-binder (e.g. streptavidin beads), separating the pellet (containing labeled strands) from the supernatant (containing unlabeled strands), and performing two PCR reactions using material in the pellet and the supernatant as separate templates.

The material untrapped by the lower column in the
30 schematic of FIG. 1 (i.e. column flow-through) potentially contains three types of mismatch-free duplex DNA molecules,

as follows. First, it can contain unlabeled homoduplexes which primarily represent transcripts that are overexpressed or unilaterally expressed by the "non-labeled" cell line (i.e. transcripts that have no, or very few, counterparts in the "labeled" cell line). Second, it can contain
5 homoduplexes labeled on both strands which primarily represent transcripts that are overexpressed or unilaterally expressed by the "labeled" cell line (i.e. transcripts that have no, or very few, counterparts in the "non-labeled" cell line). Third, it can contain hybrid homoduplexes labeled on one strand only which represent transcripts common to both
10 cell lines expressed at comparable levels.

As in the case of the mismatched material, singly-labeled homoduplex hybrids as well as doubly labeled homoduplexes can be specifically removed from solution, leaving behind transcripts originating from the non-labeled cell line that have no counterparts in the labeled cell line.
15 It should be noted that transcripts specific to the labeled cell line (i.e. doubly-labeled homoduplexes) cannot be isolated from transcripts common to both cell lines (i.e. singly-labeled homoduplex hybrids) under the scheme illustrated in FIG. 1. In order to isolate these transcripts, the labeling strategy is reversed and the
20 experiment repeated. Alternatively, a different labeling strategy altogether (i.e. two-label strategy) may be employed in which transcripts originating from cell line #1 are not left unlabeled. Here, the "labelling" step diagrammed in FIG. 1 is performed on both upper column flow throughs, using a distinct label for each column.

25 Thus, in the single experiment outlined above, transcripts specific to one cell line (or tissue node) can be isolated from transcripts that bear cell line-specific (or node-specific) mutations. It is to be further noted that, by using two or more different labeling agents (e.g. biotin and one or more short peptides), the approach can be multiplexed.
30 That is, using multiple labels, several different cell lines or tissue nodes can be analyzed concurrently and the

transcripts specific to each component individually isolated. Multiplexing is limited only by the number of available labels and the user's imagination in choosing input phenotypes.

5

5.2.2. SECOND APPROACH: SAMPLES FROM ORGANISMS HAVING CONSANGUINITY

The second approach for using the VGIDSM method is particularly appropriate for the isolation of founder effect mutations from population samples having consanguinity, i.e. at least one recent common ancestor. What follows are
10 preferred embodiments of the second approach; various modifications that can be made will be apparent to one of skill in the art (e.g. see Section 5.3 hereinbelow). In one preferred embodiment, individuals of a population have a common parent or grandparent. In another embodiment, individuals of a population share a common ancestor within
15 three generations (i.e. great grandparent). In still another embodiment, individuals of a population share a common ancestor within ten generations. Here, obtaining control tissue samples from healthy relatives is an absolute requirement. While the overall procedure, which is illustrated in FIG. 2, is similar to the first approach in
20 that it utilizes mismatch binding, there are important differences under the second approach, as described below.

First, as just mentioned, affected and healthy individuals contributing tissue samples *must* all share at least one recent common ancestor (i.e. consanguineous individuals). Of course, the population labels "affected"
25 (or "diseased") and "healthy" (or "control") are arbitrary in that two input populations differing in a phenotype-of-interest (and not necessarily a disease) are all that is required, so long as all individuals contributing to the input populations have consanguinity.

Second, at least two (2) affected and two (2) healthy
30 relatives should be sampled for optimum results. For best results, samples should be collected from five to six

diseased individuals and an equal number of healthy individuals. Individuals need not all come from the same nuclear family (defined herein as having a common mother or father) and they need not be age-matched.

Third, the cDNA libraries constructed from each tissue
5 sample should be *normalized* in order to reduce the chances of missing rare transcripts. Library normalization techniques include any of those known to one skilled in the art, such as those described in Section 5.3. hereinbelow.

Fourth, a *homogenization* step is performed on the samples obtained from *affected* individuals. Homogenization
10 is carried out as follows: A sample is obtained from each affected individual and is used to construct an independent (i.e. separate) cDNA library; each library is then PCR amplified and the resultant products from all affected individuals are mixed together. Denaturation, reannealing and trapping of mismatched duplexes over an immobilized MutS
15 column is performed (see upper column in FIG. 2). Although this homogenization step will result in a 50% reduction in frequency of heterozygous mutant transcripts in the flow-through material, the step is preferable to insure the isolation of transcripts structurally common to all affected individuals (see upper column flow through in FIG. 2). The
20 material recovered in the upper column flow through is then PCR-labeled as described above.

Fifth, a homogenization step like that performed on affected samples is not applied to healthy (i.e. control) samples. Instead, PCR material obtained from each control cDNA library is mixed together and then directly added to the
25 affected, PCR-labeled products obtained from the upper column flow through illustrated in FIG. 2. This complex mixture is then denatured and randomly reannealed before exposure to the lower MutS column illustrated in FIG. 2. The major reason behind this step is to provide an efficient counterbalance to the effects of consanguinity. The more closely related
30 affected individuals are, the greater the number of structurally identical loci they hold in common. As a

result, the pool of transcripts remaining after the homogenization step may be quite large, but only a few of these are likely to be relevant to the disorder.

Furthermore, familial genetic disorders are often associated with specific mutations that are frequent among affected
5 members of the disease-transmitting family. However, this does not mean that unaffected individuals are mutation-free at the loci concerned. It simply means that unaffected individuals have inherited polymorphisms other than those associated with the disease, and there could be many such silent polymorphisms.

10 The net result of the above considerations is that while affected individuals within a disease-transmitting family are very likely to share the same mutations, healthy members of the family do not necessarily have the same "healthy" alleles. Therefore, in order to identify the mutant loci associated with a familial disorder (together with healthy
15 allelic forms), it is highly advisable to first isolate transcripts structurally common to all affected individuals (i.e. to reduce the complexity by homogenization). At the same time, it is highly advisable to maintain as much diversity as possible within control samples in order to maximize chances of isolating all healthy allelic variants.

20 Accordingly, in approach 2, mismatched heteroduplexes that are trapped by the second column (i.e. lower column in FIG. 2) have potentially two sources: (a) unlabeled heteroduplexes with both strands originating from healthy individuals; and (b) hybrid heteroduplexes labeled on one strand originating from affected individuals and representing
25 transcripts structurally common to all affected individuals which are also present in their healthy relatives with a sequence difference. Thus, any mutant alleles associated with disease, as well as their "healthy" counterparts, will be found in the trapped material. Following release of the trapped material with either ATP or proteinase K (as
30 described above) the labeled strand can be specifically removed from solution.

The flow through material of the second (lower) column in FIG. 2 potentially contains: (a) singly-labeled mismatch-free duplexes representing transcripts structurally common to affected and unaffected relatives; (b) doubly-labeled mismatch-free duplexes representing transcripts structurally
5 common to affected relatives only; and (c) unlabeled mismatch-free duplexes representing transcripts present in unaffected relatives only. These can be specifically recovered by removing from solution all labeled, mismatch-free duplexes using a label binder (e.g. streptavidin-coated beads).

10 It is to be noted that transcripts specific to affected individuals only (i.e. doubly labeled mismatch-free duplexes) cannot be directly recovered from the lower (second) column of FIG. 2 using this approach. To isolate such transcripts, it would be necessary to reverse the labeling strategy and repeat the experiment (i.e. label during the lower left "PCR"
15 diagrammed in FIG. 2). When labeling only healthy individuals, however, mutations associated with disease cannot be isolated from mismatched heteroduplexes trapped in the lower MutS column (singly-labeled mismatched hybrids); further, the vast majority of trapped material will originate from the healthy individuals alone due to the absence of
20 selective recovery of transcripts structurally common to all healthy individuals (i.e. homogenization). Furthermore, a selective recovery step (i.e. a parallel first column) to homogenize the nucleic acid population cannot be carried out on healthy relatives without a serious risk of losing the relevant alleles through the presence of silent polymorphisms
25 which will generate numerous mismatched heteroduplexes at the denaturation-reannealing step and that would remain trapped (upper waste bin of FIG. 2) in the first round of MutS chromatography. Alternatively of course, as described for the first approach in Section 5.3.1. above, more than one label may be used.

30 It should be well noted that the higher the inbreeding levels in the families contributing normal and disease

samples, the fewer the number of mismatched loci ultimately obtained. Although all mismatched loci identified in this way will serve as markers to differentiate healthy from diseased individuals, it should also be noted that silent genetic polymorphisms (i.e. harmless, non-disease-associated changes in DNA) will be identified as well. Accordingly, best results in identifying disease genes will be obtained using highly inbred populations since inbreeding reduces the number of silent genetic polymorphisms between input sources to a minimum.

The genetic loci identified by the above procedure can be used as probes in population studies carried out by the standard immobilized Muts genotyping approach on genomic DNA obtained from affected individuals and healthy individuals (see Wagner et al., 1995, Nucl. Acids Res. 23, 3944-3948). Subsequent statistical analysis, well known to those skilled in the art, will then easily identify the loci and the alleles associated with susceptibility and resistance to the disease.

In summary, the second VGIDSM approach provides numerous advantages in the search for disease-causing genes from consanguineous sample populations. First, the approach turns highly inbred populations into an asset as opposed to a liability. Second, the approach allows rapid gene identification in cases where the lack of physiological and/or biochemical information is such that there is no basis on which possible candidate genes could be proposed. Third, the approach allows rapid identification of genes and all alleles directly and indirectly associated with susceptibility and resistance to a disease. Fourth, the approach can be applied to any consanguineous population, in many contexts, ranging from the search for susceptibility or resistance genes associated with multifactorial diseases, to the search for rare genes conferring desirable monogenic traits.

The number of clones sequenced from the output obtained under either approach to the VGIDSM method is as desired by

the user. Optionally, one or more (e.g. five or six) clones among those initially identified are sequenced to sample the results. Nucleic acid sequences are then computer analyzed for open reading frames, and used to drive a protein database search to determine whether any portions correspond to

5 portions of known proteins. It is preferable to perform such a search by translating the nucleotide sequence into all six possible reading frames (3 in each direction) in order to detect any proteins existing in the database. Of course, the VGIDSM method will also identify genes not yet represented in any database. In this instance, gene function may be

10 inferred from the observed functional differences between the input phenotypes.

5.3. MISCELLANEOUS METHODS USED IN CONJUNCTION WITH THE VGIDSM METHOD

Nucleic acid (e.g. mRNA) extraction and cDNA synthesis

15 are performed using techniques well known to those skilled in the art. For example, Gibco-BRL Trizol kits may be used for mRNA preparation and Promega Universal Riboclone kits may be used for cDNA synthesis, both according to the manufacturers' protocols. The synthesized cDNA may be size-selected by any of the techniques well known to those skilled in the art.

20 For example, agarose gel electrophoresis, sucrose density gradient chromatography, molecular sieve chromatography or high performance liquid chromatography may be used. The cDNA fragments subsequently cloned may range from below 100 bases up to 10 kilobases or more. However, it should be recognized that the optimum size for error-free PCR is about 600 bases.

25 It should further be recognized that the optimum size for error-free reverse transcription is about 400 bases. A suitable viral reverse transcriptase is that obtained from Maloney murine leukemia virus (MMLV). If cDNA is fractionated by agarose gel electrophoresis, it may be recovered from gel slices using a variety of techniques well

30 known in the art. For example, fragments may be collected by overnight diffusion into a small liquid volume, or by using

one of many commercially-available kits, such as Gel-Clean (Promega) or QiaQuick (Qiagen).

There are no special considerations when choosing a vector for cDNA library construction. The VGIDSM method will work independently of the specific library vector employed.

5 Often, the best vector will be the one which the user is most familiar with. Of course, the most important consideration for best results will be to ensure that the libraries constructed represent rare as well as abundant transcripts, e.g. by normalizing the libraries.

Library inserts are PCR amplified using oligonucleotide
10 primers (oligonucleotides) specific to the cloning vector. Labeled oligonucleotides are used as suitable for the particular experimental design being used. For example, in the first VGIDSM approach (see FIG. 1), the oligonucleotides used for the cell line #2 library are labeled with biotin (see Example in Section 6). Any heat stable polymerase may
15 be used, but those with the lowest error rate available are preferred to reduce the number of mismatches created during the PCR. Examples of suitable enzymes are *Taq* DNA polymerase and *Pfu* DNA polymerase. It is important to remember that large numbers of cycles are not required since the goal is simply to produce linearized (and, where needed, labeled)
20 fragments from the library. The PCR products are column purified, heat-denatured, annealed, and cooled to room temperature.

Subtraction of heteroduplex DNA is performed on renatured, cooled PCR products using mismatch-binding chromatography. This may be conveniently performed in a
25 variety of formats including a test tube format, a column format, or any other format selected by the user which permits heteroduplex DNA to bind to immobilized mismatch binding protein. For example, DNA in a reaction buffer (e.g. 350 ng in 100 μ l) may be placed into a vessel (e.g. 0.5 ml Eppendorf tube) containing MutS (e.g. 10 μ g) adsorbed onto
30 glass beads (e.g. 100 μ m diameter, acid washed, from Sigma Chemical Co.). The incubation phase is performed for a time

sufficient to allow mismatch binding to occur (e.g. 15-55 min). The incubation time may vary according to measures taken to increase the contact surface area between the immobilized mismatch binding protein and the reannealed cDNA. Such measures may include slowly rotating the vessel or
5 placing the vessel in a horizontal position. The unbound, reannealed PCR products left free in solution may be recovered as column flow through (in a column format) or as supernatant following centrifugation (in a test tube format).

It is often advantageous to repeat the mismatch binding protein mediated trapping operation using fresh immobilized
10 protein a total of two to four times to insure removal of all mismatched heteroduplexes. The optimum number of repetitions required will depend primarily on the relative amounts of mismatched heteroduplexes to be trapped and the quantity of protein available for trapping in each round.

It will be advantageous, in some instances, to use an
15 excess of DNA from one source over the other when performing a subtraction. For example, prior to performing the second round of trapping using the approach illustrated in FIG. 1, an excess of DNA from the source without the phenotype-of-interest (i.e. cell line # 2) may be used over DNA from the source with the phenotype-of-interest (i.e. cell line # 1) in
20 order to insure the complete removal of all transcripts which are identical between the two sources. In this regard, the source without the phenotype-of-interest may be thought of as a molecular mop for removal of undesired transcripts. The ratio of excess DNA may vary over a wide range, i.e. from 1.01:1.0 to 100:1. It will often range from 1.1:1.0 to 10:1.
25 It will most often range from 1.5:1 to 6:1. A recommended starting ratio is 3:1.

For best results in obtaining cDNAs which represent rare transcripts encoding the phenotype-of-interest, preparation of normalized cDNA libraries from each input mRNA source is performed. A portion of each input library should be
30 preserved in non-normalized form for further analysis, if desired. Normalization techniques known in the art include,

but are not limited to, those described in the following:
Soares and Efstratiadis, June 10, 1997, Normalized cDNA
libraries, U.S. Pat. No. 5,637,685; Sankhavaram et al., March
1991, Construction of a uniform-abundance (normalized) cDNA
library, *Proc. Natl. Acad. Sci. USA* 88, 1943-1947; and Ko,
5 1990, An equalized cDNA library by the reassociation of short
double-stranded cDNAs, *Nucl. Acids Res.* 18, 5709.

Suitable mismatch binding proteins that can be used have
been previously described (see e.g. Wagner, 11 May 1995,
Immobilized mismatch binding protein for detection or
purification of mutations or polymorphisms, International
10 Publication Number WO 95/12689). A preferred mismatch
binding protein is characterized by its ability to bind DNA-
DNA duplexes containing mispaired or unpaired bases (*Id.* at
13). For example, in addition to *E. coli* MutS, the mismatch
binding protein may be human MSH2 (Fishel et al., 1994,
Science 266, 1403-1405; Fishel et al., 1994, *Cancer Res.* 54,
15 5539-5542; Mello et al., 1996, *Chem. Biol.* 3, 579-589), an
hMSH2-hMSH6 protein complex (Acharya et al., 1996, *Proc.*
Natl. Acad. Sci. U.S.A. 93, 13629-13634; Gradia et al., 1997,
Cell 91, 995-1005), or homologues from various other
organisms such as yeast (Miret et al., 1993, *J. Biol. Chem.*
268, 3507-3513).

20 Suitable conditions for annealing (i.e. hybridization)
reactions have been well described, for example, by Sambrook
et al., 1989, in *Molecular Cloning, A Laboratory Manual*, 2d
Edition, Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, New York.

Separation of labeled strands from unlabeled strands or
25 from differently-labeled strands is performed using standard
techniques. For example, biotin-labeled strands bound to
streptavidin-coated beads may be placed into a first
container or vessel for heat denaturation into single
strands. After denaturation, the supernatant is removed from
the first container and transferred to a second container,
30 resulting in separation of labeled strands from unlabeled or
differently-labeled strands. Each set of strands can now be

independently PCR amplified (for a few cycles), cloned and sequenced.

Suitable nucleic acid labels and their partner molecules or agents (*i.e.* binding partners) include, but are not limited to, biotin and streptavidin, and short peptide labels and monoclonal antibodies. These are discussed in Section 5.8 and 5.9 *infra*. Suitable methods of linearizing inserts in a cDNA library include, but are not limited to, PCR and digestion with restriction enzyme(s). Suitable methods of amplifying cDNA include, but are not limited to, PCR and propagation in bacteria.

10

5.3.1. DNA AMPLIFICATION

The polymerase chain reaction (PCR) may be used in connection with the invention to amplify a desired sequence from a source (*e.g.*, a tissue sample, a genomic or cDNA library). Oligonucleotide primers representing known sequences can be used as primers in PCR. PCR is typically carried out by use of a thermal cycler (*e.g.*, from Perkin-Elmer Cetus) and a thermostable polymerase (*e.g.*, Gene Amp™ brand of Taq polymerase). The nucleic acid template to be amplified may include but is not limited to mRNA, cDNA or genomic DNA from any species. The PCR amplification method is well known in the art (see, *e.g.*, U.S. Patent Nos. 4,683,202, 4,683,195 and 4,889,818; Gyllenstein et al., 1988, Proc. Nat'l. Acad. Sci. U.S.A. 85, 7652-7656; Ochman et al., 1988, Genetics 120, 621-623; Loh et al., 1989, Science 243, 217-220).

Any prokaryotic cell, eukaryotic cell, or virus, can serve as the nucleic acid source. For example, nucleic acid sequences may be obtained from the following sources: human, porcine, bovine, feline, avian, equine, canine, insect (*e.g.*, *Drosophila*), invertebrate (*e.g.*, *C. elegans*), plant, etc. The DNA may be obtained by standard procedures known in the art (see, *e.g.*, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover (ed.), 1985, DNA

Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II).

5.3.2. ADJUSTING STRINGENCY

Other methods available for use in connection with the
5 methods of this invention include nucleic acid hybridization under low, moderate, or high stringency conditions (e.g., Northern and Southern blotting). Methods for adjustment of hybridization stringency are well known in the art (see, e.g., Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold
10 Spring Harbor, New York; see, also, Ausubel et al., eds., in the Current Protocols in Molecular Biology series of laboratory technique manuals, 1987-1994 Current Protocols, 1994-1997 John Wiley and Sons, Inc.; see, especially, Dyson, N.J., 1991, Immobilization of nucleic acids and hybridization analysis, In: Essential Molecular Biology: A Practical
15 Approach, Vol. 2, T.A. Brown, ed., pp. 111-156, IRL Press at Oxford University Press, Oxford, U.K.; each of which is incorporated by reference herein in its entirety). Salt concentration, melting temperature, the absence or presence of denaturants, and the type and length of nucleic acid to be hybridized (e.g., DNA, RNA, PNA) are some of the variables
20 considered when adjusting the stringency of a particular hybridization reaction according to methods known in the art.

Conditions of low stringency, by way of example and not limitation, may be as follows (see, also, Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. U.S.A. 78, 6789-6792). Filters containing DNA are pretreated for 6 h at 40°C in a solution
25 containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10⁶ cpm ³²P-labeled probe
30 is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C, and then washed for 1.5 h at 55°C in a

solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and
5 re-exposed to film.

Conditions of high stringency, by way of example and not limitation, may be as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml
10 denatured salmon sperm DNA. Washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography.

5.3.3. OLIGONUCLEOTIDE ANALOGS

15 Oligonucleotides used in conjunction with the invention are often ranging from 10 to about 50 nucleotides in length. In specific aspects, an oligonucleotide is 10 nucleotides, 15 nucleotides, 20 nucleotides or 50 nucleotides in length. An oligonucleotide can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, or single-stranded
20 or double-stranded, or partially double-stranded. An oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, or a combination thereof. An oligonucleotide may include other appending groups, such as biotin, fluorophores, or peptides.

An oligonucleotide may comprise at least one modified
25 base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine,
30 N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine,

3-methylcytosine, 5-methylcytosine, N6-adenine,
7-methylguanine, 5-methylaminomethyluracil,
5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine,
5'-methoxycarboxymethyluracil, 5-methoxyuracil,
2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid
5 (v), pseudouracil, queosine, 2-thiocytosine, 5-methyl-
2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,
uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid
(v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)
uracil, and 2,6-diaminopurine.

An oligonucleotide may comprise at least one modified
10 phosphate backbone selected from the group including but not
limited to a phosphorothioate, a phosphorodithioate, a
phosphoramidothioate, a phosphoramidate, a phosphordiamidate,
a methylphosphonate, an alkyl phosphotriester, and a
formacetal or analog thereof.

An oligonucleotide or derivative thereof used in
15 conjunction with the methods of this invention may be
synthesized using any method known in the art, e.g., by use
of an automated DNA synthesizer (such as are commercially
available from Biosearch, Applied Biosystems, etc.). As
examples, phosphorothioate oligonucleotides may be
synthesized by the method of Stein et al. (Stein et al.,
20 1988, Nucl. Acids Res. 16, 3209), methylphosphonate
oligonucleotides can be prepared by use of controlled pore
glass polymer supports (Sarin et al., 1988, Proc. Natl Acad.
Sci. U.S.A. 85, 7448-7451), etc. An oligonucleotide may be
an α -anomeric oligonucleotide. An α -anomeric oligonucleotide
forms specific double-stranded hybrids with complementary RNA
25 in which, contrary to the usual β -units, the strands run
parallel to each other (see Gautier et al., 1987, Nucl. Acids
Res. 15, 6625-6641).

Oligonucleotides may be synthesized using any method
known in the art (e.g., standard phosphoramidite chemistry on
an Applied Biosystems 392/394 DNA synthesizer). Further,
30 reagents for synthesis may be obtained from any one of many
commercial suppliers.

Spacer phosphoramidite molecules may be used during oligonucleotide synthesis, e.g., to bridge sections of oligonucleotides where base pairing is undesired or to position labels or tags away from an oligonucleotide portion undergoing base pairing. The spacer length can be varied by
5 consecutive additions of spacer phosphoramidites. Spacer phosphoramidite molecules may be used as 5'- or 3'- oligonucleotide modifiers. Such spacers include Spacer Phosphoramidite 9 (i.e., 9-O-Dimethoxytrityl-triethyleneglycol, 1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, and Spacer Phosphoramidite 18 (i.e., 18-O-
10 Dimethoxytrityl-hexaethyleneglycol, 1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite), both available from Glen Research (Sterling, Virginia).

Other spacers are available for use in standard oligonucleotide synthesis. For example, Spacer Phosphoramidite C3 and dSpacer Phosphoramidite can be used to
15 destabilize undesirable self-hybridization events within capture oligonucleotides or to destabilize false hybridization events between incorrectly-matched template/probe complexes. Such spacers, when positioned at the 3' end of an oligonucleotide, will also prevent incorrect extension products from being generated when included in a
20 PCR reaction mixture.

One spacer available from Glen Research, Spacer Phosphoramidite C3 (i.e., 3-O-Dimethoxytrityl-propyl-1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite), can be added to substitute for an unknown base within an oligonucleotide sequence.

25 A branching spacer may be used as one method to increase label incorporation into an oligonucleotide. Such a branching spacer may also be used to increase a detectable signal by hybridization through multiply branched capture probes or PCR primers. Branching spacers are available commercially, e.g., from Glen Research.

30 Biotinylated oligonucleotides are well known in the art. An oligonucleotide may be biotinylated using a biotin-NHS

ester procedure. Alternatively, biotin may be attached during oligonucleotide synthesis using a biotin phosphoramidite (Cocuzza, 1989, Tetrahed. Lett. 30, 6287-6290). One such biotin phosphoramidite available from Glen Research is 1-Dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-
5 propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite. This compound also has a branch point to allow further additions. The branched spacer used in this biotin phosphoramidite has been described by Nelson et al. (Nelson et al., 1992, Nucl. Acids Res. 20, 6253-6259).

Another 5'-biotin phosphoramidite, namely [1-N-(4,4'-
10 Dimethoxytrityl)-biotinyl-6-aminoethyl]-2-cyanoethyl-(N,N-diisopropyl)-phosphoramidite, may be used to biotinylate an oligonucleotide. This compound is sold by Glen Research under license from Zeneca PLC.

Fluorescent dyes may also be incorporated into an oligonucleotide using dye-labeled phosphoramidites. Two such
15 labels are 5'-Hexachloro-Fluorescein Phosphoramidite (HEX), and 5'-Tetrachloro-Fluorescein Phosphoramidite (TET), both available from Glen Research.

5.4. PHENOTYPE SELECTION TO OPTIMIZE THE VGIDSM METHOD

20 Best results are obtained with the VGIDSM method when phenotype selection is first given careful consideration by the practitioner (see FIG. 3). What follows is a preferred, but not limiting, phenotype selection method.

The phenotype selection process generally begins with a literature review. This involves reviewing biological
25 literature, medical literature, chemical literature, published bioassays and clinical data in connection with a phenotype-of-interest and with any phenotypes to be compared with (i.e. subtracted from) the phenotype-of-interest.

In this regard, reference to the most current edition of a catalog of known genetic disease may be made to initiate
30 the literature review. For example, one catalog of human phenotypes is McKusick, Victor A., Mendelian Inheritance in

Man, Catalog of Autosomal Dominant, Autosomal Recessive, and X-Linked Phenotypes (10th Edition, 1992, The Johns Hopkins University Press, Baltimore, Maryland) (hereinafter "MIM™"). MIM™ is also available in a continuously-updated, online version (hereinafter "OMIM™"), which may be accessed at no charge by contacting OMIM™ User Support, Welch Memorial Library, 1830 East Monument Street, Third Floor, Baltimore, Maryland 21205, or via e-mail to omimhelp@welch.jhu.edu. In general, MIM™ and OMIM™ comprise a catalog with one entry per human gene locus, whether or not the gene has been associated with any particular disease. Each entry, usually one or two paragraphs, provides information having the following components (when the information is available): (a) title, including any synonyms in parentheses; (b) a description of the phenotype or gene product; (c) the nature of the basic defect in any associated disorder; (d) a description of diagnosis and management of the disorder, where applicable; (e) genetics, including mapping information; (f) allelic variants; and (g) references. Finding aids in MIM™ include an author index and a title index. The content of OMIM™, in addition to being the most current data available in these catalogs, is fully computer searchable. There were nearly 6,000 entries in the Tenth Edition of MIM™ (1992). Therefore, if one makes the usual assumption that perhaps 100,000 human genes exist, this catalog is only 6% complete. Accordingly, the vast majority of genes identified using the VGID™ method will not be represented. Nevertheless, existing entries may comprise related phenotypes and/or references which provide insight into the genetic nature of the phenotype-of-interest.

Other useful information sources include computer-indexed journal collections such as Medline®. For disease phenotypes, internal medicine handbooks may also be consulted (see Isselbacher et al., eds., Harrison's Principles of Internal Medicine, 13th Edition, McGraw-Hill, Inc., New York). The practitioner skilled in the relevant art generally knows which literature sources to review.

Of course, it is not required that a phenotype be recognized in the literature as having a genetic component in order for the VGIDSM method to identify genes associated with the phenotype. Indeed, it may even be the absence of such a published recognition or understanding which leads the practitioner to ask what genes are identified using the VGIDTM method. In this regard, the practitioner's personal knowledge or belief is an important factor to be considered in phenotype selection. A given phenotype-of-interest can be quite complex and will often be polygenic (see discussion in Section 2.1 hereinabove). In one embodiment, the VGIDSM method may involve one or a combination of the two approaches set forth previously herein. Recall that one approach, schematically set forth in FIG. 1, involves performing the VGIDSM method using phenotypic groups defined by sources not known to share a common ancestor (e.g. most cell line samples). The other approach, schematically set forth in FIG. 2, involves performing the VGIDSM method using phenotypic groups defined by samples obtained from sources known to share at least one common ancestor (i.e. consanguineous sources).

An overview of the phenotype selection process is set forth in FIG. 3. In this figure, PRACTITIONER represents an individual skilled in the relevant biological art (e.g. geneticist, microbiologist, virologist, endocrinologist, plant molecular biologist, pathologist, physiologist, surgeon, postdoctoral fellow, graduate student, research technician); LITERATURE SEARCH represents a review of the relevant literature performed by the practitioner; PERSONAL KNOWLEDGE represents the knowledge, understanding and belief in the relevant biological art provided by the practitioner; and PHENOTYPE SELECTION represents the identification of the appropriate biological samples by the practitioner after having considered the literature search and the practitioner's personal knowledge.

30

5.4.1. TISSUE SAMPLE COLLECTION

Tissue samples are typically collected using methods well known to those of skill in the relevant art. For example, to identify genes involved in colon cancer, the gastroenterologist or endoscopist may collect healthy and diseased biopsy samples using an endoscope. Common sense is
5 the guiding principle here. The VGIDSM method will provide best results where normal and diseased samples are systematically and thoroughly defined using objective criteria.

5.4.2. CELL CULTURE

10 When using the VGIDSM method with cell lines as input phenotypes, utmost care is advised. The specific conditions used for culturing will profoundly influence gene expression in virtually all cell lines. For example, the steroid hormone aldosterone influences the expression of genes important for salt absorption by epithelia, such as the A6
15 cell line derived from *Xenopus laevis*. The concentration of hormones and growth factors may vary over a broad range in media supplements commonly used (e.g. fetal calf serum or newborn calf serum). Therefore, careful attention should be paid to the control of such variables. If problems arise, consideration should be given to the reservation of specific
20 lots for all ingredients used. Further, chemical analyses of specific components may also be required as part of the standardization process. This concern over control of growth conditions is not limited to hormones and growth factors. Gene expression may be influenced by such basic parameters as length of time between passage, incubation temperature, pH,
25 and the like.

Accordingly, gene identification with the VGIDSM method using cell lines as input sources will be optimized and enhanced by careful attention to defining, and maintaining constant, the cell culture conditions associated with the phenotype-of-interest. This is equally true for the
30 phenotype or phenotypes to be compared (i.e. subtracted). The culture of animal cells has been well described by

numerous references in the literature. The literature search conducted in choosing input phenotypes should be focused, in part, on defining the optimum cell culture conditions. For a broad overview of cell culture techniques and other relevant considerations, see Freshney, R.I., 1994, Culture of Animal
5 Cells, A Manual of Basic Technique, 3d Edition, John Wiley & Sons, Inc., New York, New York.

5.5. TROUBLESHOOTING THE VGIDSM METHOD

If a given phenotype-of-interest is initially resistant
10 to the above-described approaches for using the VGIDSM method to identify a gene-of-interest, the following troubleshooting discussion may be helpful. A resistant phenotype-of-interest may be indicated by the identification of no genes, or the identification of too many genes (e.g. over 100), in the appropriate pool under the experimental design chosen.
15 Consider a case where an initial screen does not identify a genetic component associated with a given phenotype-of-interest. In this instance, careful attention should be paid to redefining the nucleic acid populations defined by the input phenotypes. For example, a synergistic effect between one or more genes and an environmental factor may be required
20 for manifestation of the phenotype-of-interest. In this instance, it is desirable to identify and control any environmental factor present. In this way, a weak genetic determinant for a given phenotype-of-interest may be strengthened by careful modification of the criteria for inclusion in a phenotypic group.
25 A variety of biological assays may also be used to further define a phenotypic group. Examples of such assays are set forth in the Section immediately below.

5.6. ASSAYS FOR PHENOTYPE SELECTION

Enzymatic and receptor-based biological assays may be
30 used to further define a phenotype which is initially resistant to gene identification with the VGIDTM method. Such

definition is directed toward exclusion of individuals from a population which may not contribute to the genotype and which, therefore, would be beneficial to exclude from the gene identification assay. The eventual therapeutic use(s) resulting from the gene identification may serve as a guide
5 to selection of relevant biological assays known in the art. For example, the bioassays selected for further definition of the phenotype of schizophrenia might involve a panel of central nervous system receptors implicated in that disease. There are many sources available which describe enzymatic or receptor assays. One example is the *Methods in Enzymology*
10 series published by Academic Press. One skilled in the art would know what assays are most appropriate for defining the input phenotype.

For example, for using the VGID™ method on a neurological disorder with a genetic component, relevant bioassays might include assays for activity of adrenergic
15 receptors, cholinergic receptors, dopamine receptors, GABA receptors, glutamate receptors, monoamine oxidase, nitric oxide synthetase, opiate receptors, or serotonin receptors. For cardiovascular disorders, appropriate assays may include adenosine A₁ receptors, adrenergic receptors (including α_1 , α_2 , β_1), angiotensin I inhibition, platelet aggregation, ion
20 channel blockade (e.g. calcium channels, chloride channels), cardiac arrhythmia measurement, blood pressure, heart rate, contractility or hypoxia. For a metabolic disorder the following bioassays may be used: serum cholesterol, serum HDL, serum HDL/cholesterol ratio, HDL/LDL ratios, serum glucose, kaluresis, saluresis, or urine volume change. For
25 an allergic or inflammation disorder the following bioassays may be used: Arthur's reaction, passive cutaneous anaphylaxis, bradykinin B₂, tracheal contractility, histamine H₁ antagonism, carrageenan affects on macrophage migration, leukotriene D₄ antagonism, neurokinin NK₁ antagonism, or cytokine assays (e.g. the interleukins or macrophage
30 inhibitory proteins). For gastrointestinal disorders the following bioassays may be used: cholecystokinin CCK_A

antagonism, cholinergic antagonism, gastric acidity, or serotonin 5-HT₃ antagonism. The above listings merely provide exemplary assays. One skilled in the art would be able to choose a relevant bioassay or collection of bioassays for use in defining a phenotype.

5

5.7. DISEASES, DISORDERS, AND OTHER PHENOTYPES

The various phenotypes for which genes may be identified using the VGID™ method include, but are not limited to, any of the following disorders, diseases and phenotypes.

Examples of disease states include the following: acquired
10 immunodeficiency syndrome (AIDS), angina, arteriosclerosis, arthritis, asthma, high or low blood pressure, bronchitis, cancer, cholesterol imbalance, cerebral circulatory, clotting disorder, disturbance, cirrhosis, depression, dermatologic disease, diabetes, diarrhea, diuresis, dysmenorrhea, dyspepsia, emphysema, gastrointestinal distress, hemorrhoids,
15 hepatitis, hypertension, hyperprolactinemia, immunomodulation, resistance to bacterial infection, resistance to viral infection, inflammation, insomnia, lactation, lipidemia, migraine, pain prevention or management, peripheral vascular disease, platelet aggregation, premenstrual syndrome, prostatic disorder,
20 elevated triglycerides, respiratory tract infection, retinopathy, sinusitis, rheumatic disease, impaired wound healing, tinnitus, urinary tract infection and venous insufficiency.

Other phenotypes include, but are not limited to, cardiovascular disorders, nervous system disorders, enhancing
25 memory, hypercholesterolemia, immune system stimulation, anti-inflammatory, antipyretic, analgesic, slowing the aging process, accelerated convalescence, anemia, indigestion, impotence and menstrual disorders.

Preferred phenotypes include, but are not limited to, plant resistance phenotypes (e.g. resistance to herbicides or
30 insect predators), microorganism resistance phenotypes (e.g. resistance to antibiotics), cancer (e.g. breast, prostate),

osteoporosis, obesity, type II diabetes, and prion-related diseases (e.g. bovine spongiform encephalitis, Creutzfeldt-Jakob disease).

5.8. LINKING OLIGONUCLEOTIDES TO SPECIFIC BINDING LIGANDS

5

The present invention embodies a method for the use of identification tags (i.e. specific binding ligands which are recognized by specific receptors) to facilitate the identification and isolation of sequences of interest from a complex mixture. In order to sort unknown sequences specific
10 to a cell or a given phenotype from a mixture of sequences of different origins, it is important to be able to identify sequences from various sources. One method to label each different source of cDNA with a unique identification tag is accomplished by using labeled PCR oligos.

The PCR oligonucleotide primers utilized to generate the
15 raw material used in the VGIDSM assays are labeled with a specific binding ligand. The labeling involves attaching the ligand to the oligonucleotide in a stable manner. In a preferred embodiment, the ligand is attached to the primer via covalent bonding. Methods for attaching the primer to the ligand are well known in the art. Various
20 oligonucleotide labels include biotin, avidin or streptavidin and their derivatives, lectin, carbohydrate, peptide, hapten, or immunological material.

Oligonucleotides may be labeled with a wide variety of labels for use in the various embodiments of the invention. For example, European Patent Publication No. EP 0370 694 A2,
25 entitled, "Diagnostic Kit and Method Using a Solid Phase Capture Means For Detecting Nucleic Acid", by Burdick and Oakes, publication date May 30, 1990, discloses methods of linking labels to oligonucleotides.

In a preferred embodiment, the oligonucleotides are labeled with peptides. Methods of attaching peptides to
30 oligonucleotides are well known to those with ordinary skill in the art, e.g., see, 1) Preparation and characterization of

antisense oligonucleotide-peptide hybrids containing viral fusion peptides. Soukchareun et al., 1995, Bioconjug. Chem. 6(1), 43-53; 2) Preparation of oligonucleotide-peptide conjugates. Tung, et al., 1991, Bioconjug. Chem. 2(6), 464-465; 3) Template-directed ligation of peptides to
5 oligonucleotides. Bruick et al., 1996, Chem. Biol. 3(1), 49-56; 4) Dual-specificity interaction of HIV-1 TAR RNA with Tat peptide-oligonucleotide conjugates. Tung et al., 1995, Bioconjug. Chem. 6(3), 292-295; 5) Synthesis and Enzymatic Stability of Phosphodiester-Linked Peptide-Oligonucleotide Hybrids. Robles et al., 1997, Bioconjug. Chem. 8(6), 785-788
10 ; and 6) Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules. Rajur et al., 1997, Bioconjug. Chem. 8(6), 935-940.

Oligonucleotides linked to various peptides for use in the methods of this invention may be obtained for example, from Cybergene S.A. (11 rue Claude Bernard, 21 nord, 35400,
15 Saint Mallo, France) and Glen Research (22825 Davis Drive, Sterling, Virginia 20164). Further information from Glen Research can be obtained through their web site (www.glenres.com).

One specific method for linking a peptide to an oligonucleotide recommended by Glen Research is as follows
20 (see also, www.glenres.com). A heterobifunctional crosslinking reagent is used to link a synthetic peptide having an N-terminal lysine residue to a 5'-thiol-modified oligonucleotide. Such a crosslinking reagent is N-maleimido-6-aminocaproyl-(2'-nitro, 4'-sulfonic acid) phenyl ester (mal-sac-HNSA). The sodium salt of mal-sac-HNSA is available
25 from Bachem Bioscience. Conveniently, reaction of the mal-sac-HNSA crosslinker with an amino group releases a dianion phenolate (i.e. 1-hydroxy-2-nitro-4-benzene sulfonic acid). This dianion phenolate is also a yellow chromophore. The chromophore feature provides (i) a means for quantifying the extent of completion of the coupling reaction (where greater
30 yellow color intensity corresponds to a more complete coupling reaction), and (ii) an aid in monitoring the extent

of separation of an activated peptide (i.e. a peptide crosslinked to mal-sac-HNSA and ready for contacting with a 5'-thiol-modified oligonucleotide) from free crosslinking reagent during gel filtration.

The specific steps employed when using a mal-sac-HNSA crosslinker may be as follows. First, a peptide is synthesized having an N-terminal lysine. Alternatively, a peptide having an internal lysine may be used since the lysine epsilon amino group is actually more reactive than the lysine alpha amino group. Second, an oligonucleotide is synthesized having a 5'-thiol group using methods known in the art. Third, the peptide is reacted with an excess of mal-sac-HNSA in a sodium phosphate buffer (pH 7.1). Fourth, the peptide-mal-sac conjugate is separated from free crosslinker and the buffer is exchanged to sodium phosphate (pH 6) using a gel filtration column (e.g. NAP-5, Pharmacia, Uppsala, Sweden). Fifth, a thiol-modified oligonucleotide is activated, desalted and buffer-exchanged to sodium phosphate (pH 6) on a gel filtration column. Sixth, the activated peptide is reacted with the thiol-modified oligonucleotide. Finally, the peptide-oligonucleotide conjugate is purified by ion exchange chromatography (e.g. Nucleogen DEAE-500-10 or equivalent). The elution order from the ion exchange column is as follows: free peptide first, peptide-labeled oligonucleotide next, and free oligonucleotide last.

In a preferred embodiment, the peptide labeled oligonucleotides are recognized by specific receptors, such as antibodies, to sort and isolate particular nucleic acids from a complex mixture. Given that a peptide-labeled oligonucleotide primer may be subjected to high temperatures during PCR, in a preferred embodiment, the peptide is sufficiently short (i.e. no more than five amino acids) to resist irreversible denaturation. In addition, the peptides can be made resistant to different classes of proteases by avoiding the inclusion of protease-sensitive peptide links such as those that involve serine and /or threonine. A number of procedures have been used to add a single primary

aliphatic amino group to oligonucleotides. See e.g. Agrawal et al., 1986, Nucleic Acids Res. 14, 6227-6245; Chollet et al., 1985, Nucleic Acids Res. 13, 1529-1541; Wachter et al., 1986, Nucleic Acids Res. 14, 7985-7994; Sproat et al., 1987, Nucleic Acids Res. 15, 6181-6196; Li et al., 1987, Nucleic
5 Acids Res. 15, 5275-5286; and Smith et al., 1985, Nucleic Acids Res. 13, 2439-2502. Various methods may be used to synthesize oligonucleotides containing multiple amino groups attached to the oligonucleotide through a linker arm. Haralambidis et al., 1990, Nucleic Acids Res. 18, 493-499; Haralambidis et al., 1987, Nucleic Acids Res. 15, 4857-4876;
10 Ruth et al., 1985, DNA 4, 93; Ruth, 1984, DNA 3, 123; Draper, 1984, Nucleic Acids Res. 12, 989-1002. Attachment of a ligand such as biotin to the oligonucleotide is described in Kempe et al., 1985, Nucleic Acids Res. 13, 45-57. The use of an alkylating intercalation moiety as an attachment is described in U.S. Patent No. 4,582,789. Other standard
15 peptide coupling methods and derivatized oligonucleotide methods can also be used (see e.g. EPA 0 370 694).

These standard procedures from the above references are incorporated herein by reference in their entireties.

5.9. ANTIBODIES AND DERIVATIVES THEREOF

20 In a preferred embodiment antibodies may be used to specifically recognize one or more peptide-labeled oligonucleotides used to label a plurality of nucleic acid populations (e.g. cDNA libraries). Such antibodies include but are not limited to polyclonal, monoclonal, humanized or chimeric antibodies, single chain antibodies, Fab fragments
25 and F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies may be used as ligands in one of the screening steps in the present invention.

30 Polyclonal antibodies which may be used in the methods of the invention are heterogeneous populations of antibody molecules derived from the sera of immunized animals.

Various procedures well known in the art may be used for the production of polyclonal antibodies to an antigen-of-interest. For example, the production of polyclonal antibodies, various host animals can be immunized by injection with an antigen of interest or derivative thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies which may be used in the methods of the invention are homogeneous populations of antibodies to a particular antigen. A monoclonal antibody (mAb) to an antigen-of-interest can be prepared by using any technique known in the art which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein, 1975, Nature 256, 495-497, and the more recent human B cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4, 72), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAbs of use in this invention may be cultivated *in vitro* or *in vivo*.

The monoclonal antibodies which may be used in the methods of the invention include but are not limited to human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies. Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80,

7308-7312; Kozbor et al., 1983, Immunology Today 4, 72-79; Olsson et al., 1982, Meth. Enzymol. 92, 3-16).

Further, humanized monoclonal antibodies may be used. Briefly, humanized antibodies are antibody molecules from non-human species having one or more complementarily
5 determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. Various techniques have been developed for the production of humanized antibodies (see e.g., Queen, U.S. Patent No. 5,585,089, which is incorporated herein by reference in its entirety). An immunoglobulin light or heavy chain variable
10 region consists of a "framework" region interrupted by three hypervariable regions, referred to as complementarily determining regions (CDRs). The extent of the framework region and CDRs have been precisely defined (see, Kabat et al., 1983, "Sequences of Proteins of Immunological Interest", U.S. Department of Health and Human Services).
15 A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Techniques have been developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81,
20 6851-6855; Neuberger et al., 1984, Nature, 312, 604-608; Takeda et al., 1985, Nature, 314, 452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity.

Alternatively, techniques described for the production
25 of single chain antibodies (U.S. Patent No. 4,946,778; Bird, 1988, Science 242, 423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85, 5879-5883; and Ward et al., 1989, Nature 334, 544-546) can be adapted to produce single chain antibodies against the peptide portion of the peptide-labeled oligonucleotide nucleotides useful in the methods of the
30 invention. Single chain antibodies are formed by linking the

heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246, 1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to the peptide portion of a peptide-labeled oligonucleotide can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" the peptide, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, FASEB J 7(5), 437-444; and Nissinoff, 1991, J. Immunol. 147(8), 2429-2438). For example, antibodies which bind to the peptide and competitively inhibit the binding of peptide to its receptor can be used to generate anti-idiotypes that "mimic" the peptide receptor and, therefore, bind the peptide.

A molecular clone of an antibody to an antigen-of-interest can be prepared by many well known techniques. Recombinant DNA methodology (see e.g., Maniatis et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) may be used to construct nucleic acid sequences which encode a monoclonal antibody molecule, or antigen binding region thereof.

Antibody molecules may be purified by many well known techniques, e.g., immunoabsorption or immunoaffinity chromatography, chromatographic methods such as HPLC (high performance liquid chromatography), or a combination thereof, etc.

The methods of antibody production and use employed herein can, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D., 1988, Antibodies: A

Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), which is incorporated herein by reference in its entirety.

The single-letter amino acid codes which correspond to the three-letter amino acid codes of the Sequence Listing are set forth hereinbelow: A, Ala; R, Arg; N, Asn; D, Asp; B, Asx; C, Cys; Q, Gln; E, Glu; Z, Glx; G, Gly; H, His; I, Ile; L, Leu; K, Lys; M, Met; F, Phe; P, Pro; S, Ser; T, Thr; W, Trp; Y, Tyr; and V, Val.

Suitable antibodies for use with the methods of this invention include the following, available from Affinity Bioreagents, Inc., 79, rue des Morillons, 75015, Paris, France.

- 1) Catalog No. PA 1-047 (affinity-purified rabbit IgG). The corresponding peptide recognized by this antibody is KFSREKKAAT (SEQ ID NO:71).
- 2) Catalog No. PA 1-039 (affinity-purified rabbit immunoglobins). The corresponding peptide recognized by this antibody is DQKRYHEDIFG (SEQ ID NO:72).
- 3) Catalog No. PA 1-036 (purified rabbit IgG). The corresponding peptide recognized by the antibody is DLKEEKDINNNVKKT (SEQ ID NO:73).
- 4) Catalog No. PA 1-014 (purified rabbit antibody). The corresponding peptide recognized by this antibody is CTGEEDTSE (SEQ ID NO: 74).
- 5) Catalog No. PA 3-013 (affinity purified IgG). The corresponding peptide recognized by this antibody is PEETQTQDQPM (SEQ ID NO:75).

- 6) Catalog No. PA 1-815 (rabbit anti-serum). The corresponding peptide recognized by this antibody is QKSDQGVGPGAT (SEQ ID NO:76).
- 5 7) Catalog No. PA 3-034 (rabbit polyclonal serum IgG). The corresponding peptide recognized by this antibody is DIGQSIKKFSKV (SEQ ID NO:77). This polyclonal antibody will also recognize QRADSLSSHL (SEQ ID No:78).

In addition, antibodies for use with the methods of this invention may be obtained from Medical & Biological Laboratories Co., Ltd., 440 Arsenal Street, Watertown, Massachusetts 02171, U.S.A.

These include the following:

- 1) Code No. 561 (Rabbit IgG from anti-serum). The corresponding peptide recognized by this antibody is YPYDVDPDYA (SEQ ID NO:79).
- 15 2) Code No. 562 (Rabbit IgG from anti-serum). The corresponding peptide recognized by this antibody is EQKLISEEDL (SEQ ID NO:80).
- 20 3) Code No. 563 (Rabbit IgG from anti-serum). The corresponding peptide recognized by this antibody is YTDIEMNKL GK (SEQ ID NO:81).

25 5.10. ANTIBODY COLUMNS FOR SORTING NUCLEIC ACIDS

An antibody specific to a given peptide label which is used to identify nucleic acids arising from different sources may be bound to a solid phase support or carrier material to facilitate separation using various techniques well known in the art.

30 Here, the "solid phase support or carrier" can be any support capable of binding an antigen or an antibody. Well-

known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble or insoluble for the purposes of the present invention. The solid phase support or carrier material can have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration can be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface can be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

For example, the solid phase support or carrier material can be beads, polymeric particles, or other materials, so long as the coupled molecule is capable of binding to an antigen or antibody. Such solid phase supports are readily apparent to one of ordinary skill in the art. Particularly useful solid phase support or carrier materials are polymeric beads having an average particle size of from 0.1 to 10 μ meters.

Antibodies against specific peptides can be bound to any of the above described solid phase support or carrier material in different ways. Two of the most preferred attachments are adsorption and covalent attachment.

The methods for making and using the antibody columns employed herein can, for example, be such as those described in Harlow and Lane (Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), which is incorporated herein by reference in its entirety.

Further, examples of suitable antibodies and peptide labels may be found, for example, in U.S. Application No. 09/174,328, entitled "METHODS FOR MANIPULATING COMPLEX

NUCLEIC ACID POPULATIONS USING PEPTIDE-LABELED OLIGONUCLEOTIDES", by Iris and Pourny (Attorney Docket No. 9408-025), filed October 16, 1998, which is incorporated by reference herein in its entirety.

5 5.11. DETECTION OF ANTIBODIES AGAINST PEPTIDE-LABELED OLIGONUCLEOTIDES

Antibodies which recognizes peptide-labeled oligonucleotides may also be detectably labeled using any method known to one skilled in the art. Many such methods are known. For example, one of the ways in which an anti-peptide antibody can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay (EIA), "The Enzyme Linked Immunosorbent Assay (ELISA)" Voller, 1978, Diagnostic Horizons 2, 1-7; Voller et al., 1978, J. Clin. Pathol. 31, 507-520; Butler, 1981, Meth. Enzymol. 73, 482-523; Maggio, 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL,; Ishikawa et al., 1981, Enzyme Immunoassay, Kaku Shoin, Tokyo). The enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

30 Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively

labeling the antibodies or antibody fragments, it is possible to detect peptide portion of the peptide-labeled oligonucleotide through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, 1986, Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, which is incorporated by reference herein). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wavelength, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

The antibody can also be detectably labeled using fluorescence emitting metals such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of

luminescence. Important bioluminescent compounds for purposes of labeling are green fluorescent protein, luciferin, luciferase and aequorin.

6. EXAMPLE: USE OF THE VGIDSM METHOD TO IDENTIFY *hDinP* GENES

6.1. INTRODUCTION

Two human *DinP* (*hDinP*) genes have been identified using the VGIDSM method applied to cell line sources, as described hereinbelow. The VGIDSM approach employed was that described hereinabove for cell line samples (see FIG. 1). The aim of this example was to isolate any human homologue(s) of the bacterial *DinP* gene. In bacteria and yeast, the product of the *DinP* gene (*i.e.* *DinP*) is central to the inducible DNA damage repair pathway known as the "SOS repair system." Although this DNA repair pathway is known to exist in man, inducibility has never been demonstrated. The components of this pathway are known to be directly involved in the appearance of secondary cancers following radiation therapy or chemotherapy in humans. Nevertheless, the human genes encoding the components of the pathway have not been previously identified. The VGIDSM example described below isolated, in less than three weeks, a total of five independent human cDNA clones. The clones were analyzed by DNA sequencing, translation into all six reading frames, and protein database search (BLASTX). Translations of all five clones displayed high amino acid sequence homology to the bacterial *DinP* protein, thereby confirming the identification of human homologues of bacterial *DinP*. It should be well noted that low stringency hybridization of a bacterial *DinP* probe to a human library would not have identified these clones since the nucleic acid sequence homology is too low to permit this type of screen.

6.2. MATERIALS AND METHODS

Cell lines (phenotype selection). For isolation of *hDinP* transcripts by Muts-mediated selective subtraction, two input cell lines differing in their capacity to effect DNA repair were utilized. The phenotype-of-interest (*i.e.* human *DinP* activity) was provided by presumed "high expressor" cells from a defined lymphoblastoid clonal line (lymphoblasts) (*i.e.* cell line #1 in FIG. 1). These cells were harvested at a time corresponding to the apex of their *in vitro* growth curve (*i.e.* 84 hours after initiation of the growth phase). The competitor-cDNA providers (*i.e.* cell line #2 in FIG. 1) were hepatocytes grown in standard medium for 60 hours before harvesting. These two cell lines originated from different sources and therefore have a very low probability of consanguinity (*i.e.* of having a common ancestor). However, the fast growth rate of these cell lines is associated with the possibility of substantial levels of mutation acquisition.

mRNA extraction and cDNA synthesis. These procedures were performed using Gibco-BRL "Trizol" kits (mRNA preparation) and Promega "Universal Riboclone" kits (cDNA synthesis) according to manufacturers' protocols. Synthesized cDNA was size-fractionated by electrophoresis in an agarose gel (0.8%); fragments ranging from 300 to 600 base pairs were excised from the gel. The cDNA was extracted from the gel slices using Promega Gel-Clean kits according to the manufacturer's protocol.

cDNA libraries. A library for each cell line was constructed by blunt-end ligation of the size-selected cDNA into the QuanTox™ Blunt (Quantum Biotechnologies) plasmid vector. Ligation products were transformed into DH5 α competent *E. coli* cells. These cells were grown overnight in ampicillin-containing liquid medium. Cells were next harvested and the insert-containing plasmid vectors were recovered using Qiagen plasmid purification kits.

Amplification of cDNA inserts. The inserts present in the cDNA library obtained from the lymphoblasts were PCR

amplified using oligonucleotide primers specific to the vector's cloning-cassette. The polymerase enzymes used were Pfu DNA polymerase (1.5 U/100 μ l reaction) and the Stoffel fragment of DNA polymerase I (0.5 U/100 μ l reaction). The cycling protocol used was: 97°C, 3 min; 58°C, 5 sec; 70°C, 1 min; then 93°C, 30 sec; 58°C, 5 sec; 70°C, 1 min for 15 cycles. PCR products were purified over Qiagen columns. The purified PCR products were heat-denatured at 98°C for 5 min, incubated at 65°C for 20 min and cooled to room-temperature.

The renatured and cooled PCR products (350 ng in 90 μ l) were equilibrated in an equal volume of "2X reaction buffer" (40 mM Tris-HCl, pH 7.6; 0.02 mM EDTA; 10 mM MgCl₂; 0.2 mM DTT) and exposed for 35 min to MutS adsorbed onto glass beads packed into a 0.5 ml Eppendorf tube perforated by a small hole at the bottom of the tube. During the incubation phase, the Eppendorf tubes were placed in a horizontal position to increase the contact surface area between the beads and reannealed cDNA. The unbound reannealed PCR products left free in solution were recovered in the supernatant following centrifugation to pellet the beads (8000 X g; 30 sec). This MutS-mediated trapping step was repeated twice more with fresh beads; the supernatant recovered at the end of this operation and stored at 4°C until used. This supernatant contains only the transcripts structurally identical among all lymphoblasts in the phenotype-of-interest cell line.

The procedure followed for isolation of transcripts structurally common to all hepatocytes was identical to that described above, except that the primers used for the PCR amplification (corresponding to vector sequences encoding T3 and T7 promoters) were biotinylated at the 5' end. The final supernatant was also stored at 4°C until used.

Isolation of cDNA encoding hDinP. An aliquot of the stored supernatant from hepatocytes was then mixed with an aliquot of the stored supernatant from lymphoblasts in a 3:1 ratio (hepatocyte:lymphoblast). This mixture was denatured, reannealed, and exposed to MutS-coated beads, as above, to
5 remove all mismatched heteroduplexes.

The supernatant from this mixture was next exposed to streptavidin-coated beads (Dynabeads M-180, Dynal, used according to the manufacturer's protocol) in order to trap all non-mismatched homoduplex hybrids formed from one hepatocyte strand and one lymphoblast strand (*i.e.*
10 transcripts structurally identical in hepatocytes and lymphoblasts), as well as all remaining hepatocyte-specific transcripts. This trapping step was performed by incubating the supernatant recovered after the MutS binding reaction (150 μ l) with 150 μ l of dry streptavidin beads.

Following recovery of the streptavidin bead supernatant,
15 the beads were rinsed twice in 1X reaction buffer to recover all unbound material. The washings were recovered by centrifugation, pooled with the streptavidin bead supernatant, and saved at 4°C. The pooled streptavidin bead supernatant, theoretically containing only lymphoblast-specific transcripts structurally identical in all
20 lymphoblast cells, was then desalted and concentrated using Qiaex II DNA purification kits (Qiagen) as per the manufacturer's protocol.

The purified material was blunt-ended by 3' extension (DNA tailing kit, Boehringer-Mannheim), purified over Quiagen columns as above, and cloned into the QuanTox™ Blunt vector
25 as previously described. The twelve recombinant colonies obtained were then individually tested for the presence of inserts by: (i) PCR amplification; and (ii) hybridization at various stringencies with a PCR-generated, labeled fragment of the *E. coli* DinP gene. Under low stringency hybridization conditions (*i.e.* 40°C overnight in 3X SSC, 1X Denhardt's
30 solution, 20 mM sodium phosphate (pH 6.5), 10% dextran sulfate, 100 μ g/ml salmon sperm DNA; 3 washes in 3X SSC and

1% SDS at 40°C for 15 min each), signals from all twelve clones were obtained, but the signals were slightly stronger for the five clones later identified by sequencing and computer analysis to be derived from two *hDinP* genes (see below). By contrast, under medium stringency hybridization conditions (i.e. 50°C overnight in same buffer used for low stringency plus 25% deionized formamide; 3 washes in 2X SSC and 1% SDS at 50°C for 15 min each), weak signals from all twelve clones were obtained without apparent differences in signal intensities. Finally, under high stringency hybridization conditions (i.e. 60°C overnight in the same buffer used for medium stringency conditions; 3 washes in 1X SSC and 1% SDS at 60°C for 15 min each), a complete absence of signal from all twelve clones resulted. These hybridization results suggest that at least five of the twelve clones isolated contain inserts. The results further suggest that one would not isolate any *hDinP* clones by simply screening a human library directly with a labeled fragment of the *E. coli* DinP gene; the hybridization signal in such a library screen would be indistinguishable from background.

Of the twelve clones isolated by the method of the invention, five were sequenced which displayed the slightly stronger signal under high stringency conditions relative to the other seven. These five clones were next used as query sequences in individual BLASTX protein database searches after translation into all six reading frames (FIGs. 5-9). The single-letter amino acid codes appearing in the computer analyses provided by the BLASTX searches (see FIGs. 5-9) which correspond to the three-letter amino acid codes of the Sequence Listing are set forth in Section 5.9 *Supra*.

6.3. RESULTS

This VGIDSM example isolated a total of five overlapping human cDNA inserts (see FIG. 4 for a map of overlapping regions) which appear in the Sequence Listing as SEQ ID NOS:1-5. BLASTX protein database search and a computer analysis was performed on each of the five identified

sequences after translation into all six reading frames (see FIGS. 5-9 for BLASTX results). The results revealed high amino acid sequence homology exclusively with the bacterial DinP protein and its close relatives such as UV protection protein mucB (see FIG. 5A). On the basis of overlapping
5 sequences, these five inserts were assigned to two separate, homologous *hDinP* genes, as described below.

Three of the five overlapping inserts (SEQ ID NOs:1-3) cover about half of the predicted length for a full-length *hDinP* transcript after assembly into a composite sequence (SEQ ID NO:6). The other two inserts (SEQ ID NOs:4-5), which
10 correspond to a cumulative length of 386 bases, also overlap with each other and with the composite sequence of SEQ ID NO:6. However, these two inserts provide evidence for the existence of two *hDinP* genes, as further described below. This result is in agreement with other characterized human DNA repair genes, which are all known to be encoded by
15 multiple genes. That SEQ ID NOs:4-5 represent transcripts derived from different genes encoding isoforms of *hDinP* is suggested by limited internal sequence divergence at positions 237-252 and 274-279.

6.4. DISCUSSION

20 The two novel *hDinP* genes identified above represent a significant advance in our understanding of human genes involved in DNA repair. Moreover, the new genes will be useful in the development of various prognostic tests, diagnostic tests, and therapeutic interventions for treatment of disease, especially cancer. This is true, in part,
25 because DNA repair pathways have been so strongly connected to cancer-causing mechanisms (see e.g. Fishel et al., 1993, Cell 75(5), 1027-1038).

The protein sequences encoded by the five human clones and their corresponding bacterial relatives are set forth in SEQ ID NOs:7-70. The search analyses for the five clones
30 listed in SEQ ID NOs:1-5 are set forth in FIGS. 5-9, respectively. It is noteworthy that all five independent

clones encode a protein homologous to *E. coli* DinP; i.e. mainly hDinP clones (five of twelve) were identified by the VGIDSM method in this experiment. This result dramatically demonstrates the high specificity for gene identification obtainable with the VGIDSM method. This specificity is
5 directly correlated with the well defined input phenotypes employed. Protein translation results for SEQ ID NO:1 (# 1) are listed in SEQ ID NOS:7-24. Protein translation results for SEQ ID NO:2 (Tor-M) are listed in SEQ ID NOS:25-29. Protein translation results for SEQ ID NO:3 (# 3) are listed in SEQ ID NOS:30-41. Protein translation results for SEQ ID
10 NO:4 (*1) are listed in SEQ ID NOS:42-58. Protein translation results for SEQ ID NO:5 (*2) are listed in SEQ ID NOS:59-70.

6.5. APPLICATION OF THE VGIDSM METHOD TO A COMPLEX, MULTISTAGE SYSTEM - MULTIPLEX VGIDSM (VGGTSM)

15 The VGIDSM method may be applied to complex, multistage systems, such as cancer. In cancer, several stages having different phenotypes can coexist, e.g., within a single biopsy specimen, or within primary cell cultures propagated therefrom. When applied to such a system, however, the VGIDSM method requires performance of a large number of assays (i.e.
20 one unlabeled cDNA library and one biotin-labeled cDNA library for pairwise comparison of each stage with all other stages). Multiplex VGIDSM, also known as ValiGene Gene Trapping (VGGTSM), offers an alternative approach for analysis of complex, multistage systems.

VGGTSM does not require performance of a large number of
25 pairwise comparisons. By contrast, the number of assays performed is considerably reduced, thus saving the user time and money. VGGTSM (Multiplex VGIDSM) permits the simultaneous analysis of more than two phenotypes (represented by more than two cDNA libraries) by PCR labeling inserts from each library using primers having a unique label. In a preferred
30 embodiment, the unique label is a peptide label. In another

preferred embodiment, the unique peptide label is recognized by an antibody specific for the label.

In this way, cDNA fragments derived from each of any number of libraries subjected to a Multiplex VGIDSM analysis can be specifically identified and retrieved as desired by the user. Further, such identification and retrieval can be at any point in the Multiplex VGIDSM analysis by virtue of the unique library labels. For example, fragments from any number of cDNA libraries can be mixed, denatured, reannealed, and subjected to one or more rounds of MutS chromatography and/or antibody affinity chromatography, all without losing track of the phenotypic source (i.e. cDNA library) from which any particular fragment-of-interest originated.

In a typical Multiplex VGIDSM assay, reannealing occurs in the presence of high complexity (i.e. labeled fragments from more than two cDNA libraries are mixed, denatured and reannealed). After reannealing, sorting of the various cDNAs is carried out using MutS chromatography and/or antibody affinity chromatography as desired by the user. The labeling scheme permits the user to isolate any desired cDNA fragment for cloning, probe use, or further sorting as desired.

In summary, peptide-labeled oligonucleotide PCR primers are used for differential labeling of cDNA fragments originating from different libraries. The labels allow one to identify sequences common to more than two libraries and to isolate sequences specific to each library through chromatography. Further, the labels allow one to retrieve cDNA fragments-of-interest from a mixture of nucleic acids of different origins. Overall, the Multiplex VGIDSM process allows one to differentially label, sort and isolate expressed nucleotide sequences representing defined phenotypes present in complex mixtures.

6.5.1. EXAMPLE OF A COMPLEX SYSTEM - BREAST CANCER

One example of a complex system which may be subjected to the Multiplex VGIDSM method of the invention is breast cancer. In this example, congenic cell lines obtained from
5 the same individual (HBL 100, HH9, MCF-7 and MCF-7 ras) may be used to represent four different cancer stages (i.e. four different phenotypes), as follows:

- (a) HBL 100 (pre-cancer stage);
- (b) HH9 (pre-metastatic stage, hormone-sensitive);
- (c) MCF-7 (metastatic stage, hormone-dependent); and
- 10 (d) MCF-7 ras (aggressively metastatic stage, hormone-sensitive).

Analysis of this system by VGIDSM, comparing two phenotypes at a time, would require six different experiments. That is, one would compare (a) with (b), (a) with (c), (a) with (d), (b) with (c), (b) with (d), and (c)
15 with (d). Further, in order to gain knowledge of metabolic pathways that might distinguish each stage, and to identify key elements (such as optimal intervention points) within a pathway-of-interest, cell growth of each cancer stage should be analyzed under different conditions. For example, four suitable conditions may be as follows:

- 20 (a) Standard growth conditions (e.g., cell culture medium containing fetal calf serum);
- (b) Non-steroid conditions (e.g. serum-free conditions; or serum-containing conditions where the serum has been treated to remove all steroids);
- (c) Estradiol conditions (e.g. non-steroid conditions
25 where a defined concentration of estradiol has been added back as the only steroid present); and
- (d) Estradiol plus tamoxifen conditions (e.g. estradiol conditions where a defined concentration of tamoxifen has also been added).

For a complete analysis of this system using VGIDSM,
30 where complete is defined as comparing four different

phenotypes to each other under four different conditions, one would perform a total of twenty-four VGIDSM assays.

6.5.2. ANALYSIS OF A COMPLEX SYSTEM USING MULTIPLEX VGIDSM

5 Each pairwise VGIDSM assay just described would provide a readout of the expressed genes distinguishing the two samples being analyzed. Twenty-four such pairwise comparisons could then be further compared among themselves. The efficiency of phenotype comparison in this way is thus hindered by the large number of independent VGIDSM assays that needs to be
10 performed.

An alternative approach is Multiplex VGIDSM. In the above example, HBL 100, HH9, MCF-7 and MCF-7 ras would each be labeled with a different peptide label.

It will be understood that, in the Multiplex VGIDSM process, the labels serve not only to identify the library-
15 of-origin of a particular cDNA insert, but also to provide a means of specific retrieval. Using this approach in the above example, retrieval of cDNA fragments that characterize each cancer stage relative to the others and relative to the applied environmental conditions (i.e. cell culture growth conditions) would require many fewer assays. For example,
20 four assays may be performed in which cDNA fragments from each of the four cell lines are compared (i.e. mixed, denatured, reannealed, and sorted by chromatography on Muts and/or antibody columns) under each of the four growth conditions set forth above. Thus, a full analysis of the system may be performed in just four assays instead of the
25 twenty-four required under the pairwise analysis approach.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed since these embodiments are intended as illustration of several aspects of the invention. Any equivalent embodiments
30 are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to

those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Throughout this application various publications and patents are cited. Their contents are
5 hereby incorporated by reference into the present application in their entireties.

10

15

20

25

30

We claim:

1. A method for identifying one or more genes underlying a defined phenotype comprising the following steps in the order stated:
 - 5 (a) removing mismatched duplex nucleic acid molecules formed from hybridization within each of a plurality of source populations of nucleic acids; and
 - (b) retaining mismatched duplex nucleic acid molecules formed from hybridization among the plurality of
10 source populations,
the retained molecules in step (b) comprising the one or more genes underlying the defined phenotype.
2. The method of Claim 1, wherein the plurality of source populations comprises at least one normalized cDNA
15 library.
3. The method of Claim 1, wherein the plurality of source populations comprises at least one linearized cDNA library.
- 20 4. The method of Claim 1, wherein the plurality of source populations consists of DNA, the DNA of each of the source populations being labeled with a different label, and the hybridization in step (b) is carried out using an excess of labeled DNA from one or more source populations.
- 25 5. The method of Claim 4, wherein the excess of labeled DNA is a three-fold excess.
6. The method of Claim 1, wherein each of the source populations is derived from a cell line.
- 30 7. A method for identifying one or more genes underlying a defined phenotype displayed by a cell or

individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived, comprising:

- (a) hybridizing insert DNA from the first cDNA library with itself;
- 5 (b) hybridizing insert DNA from each library of the plurality of additional cDNA libraries with itself;
- (c) contacting the DNA hybridized in step (a) with a first immobilized mismatch binding protein;
- (d) contacting each separate population of DNAs hybridized in step (b) individually with a second
10 immobilized mismatch binding protein;
- (e) separating unbound DNA from bound DNA contacted in step (c);
- (f) separating unbound DNA from bound DNA contacted individually in step (d);
- 15 (g) labeling each separate population of the unbound DNA separated in step (f) with a distinguishable label capable of binding a partner molecule immobilized on a substrate;
- (h) hybridizing DNA separately labeled in step (g) with unbound DNA separated in step (e);
- 20 (i) contacting DNA hybridized in step (h) with a third immobilized mismatch binding protein;
- (j) separating unbound DNA from bound DNA contacted in step (i);
- (k) contacting unbound DNA separated in step (j) with the partner molecule of each different label; and
- 25 (l) separating unbound DNA from bound DNA contacted in step (k),

which unbound DNA separated in step (l) encodes one or more identified genes underlying the defined phenotype.

8. The method of Claim 7, wherein one or more of the cDNA libraries is normalized.

30

9. The method of Claim 7, wherein one or more of the cDNA libraries is linearized.

10. The method of Claim 7, wherein labeling is carried out by polymerase chain reaction using a 5'-peptide labeled primer.

11. The method of Claim 7, wherein at least one immobilized partner molecule is an antibody.

12. The method of Claim 11, wherein the antibody is an anti-peptide antibody.

13. The method of Claim 7, wherein the hybridization in step (h) is carried out using an excess of labeled DNA.

14. The method of Claim 13, wherein the excess of labeled DNA is a three-fold excess.

15. The method of Claim 7, wherein the first, second, or third immobilized mismatch binding protein is MutS.

16. The method of Claim 1, wherein the defined phenotype is selected from the group consisting of a plant phenotype, a microorganism phenotype, and a pathologic phenotype.

17. The method of Claim 16, wherein the defined phenotype is a pathologic phenotype that is selected from the group consisting of cancer, osteoporosis, obesity, type II diabetes, and a prion-related disease.

18. A method for identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived, comprising:

- (a) amplifying insert DNA from the first cDNA library by polymerase chain reaction;
- (b) amplifying insert DNA from each of the plurality of additional cDNA libraries by polymerase chain reaction;
- 5 (c) hybridizing DNA amplified in step (a) with itself;
- (d) hybridizing each separate population of DNA amplified in step (b) with itself;
- (e) contacting DNA hybridized in step (c) with immobilized MutS;
- 10 (f) contacting each separate population of DNA hybridized in step (d) individually with immobilized MutS;
- (g) separating unbound DNA from bound DNA contacted in step (e);
- (h) separating unbound DNA from bound DNA contacted in step (f);
- 15 (i) labeling unbound DNA separated in step (g) by polymerase chain reaction using unlabeled primers;
- (j) labeling each separate population of unbound DNA separated in step (h) by polymerase chain reaction using at least one primer having a distinguishable 5'-peptide-label capable of binding a partner
- 20 molecule immobilized on a substrate;
- (k) hybridizing DNA labeled in step (i) with DNA labeled in step (j);
- (l) contacting DNA hybridized in step (k) with immobilized MutS;
- (m) separating unbound DNA from bound DNA contacted in
- 25 step (l);
- (n) contacting unbound DNA separated in step (m) with one or more partner molecules capable of binding the distinguishable 5'-peptide-labeled primers; and
- (o) separating unbound DNA from bound DNA contacted in step (n),
- 30 which unbound DNA separated in step (o) encodes one or more identified genes underlying the defined phenotype.

19. A method for identifying one or more alleles underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived, comprising:

- 5 (a) hybridizing insert DNA from the first cDNA library with itself;
- (b) hybridizing insert DNA from each of the plurality of additional cDNA libraries with itself;
- (c) contacting DNA hybridized in step (a) with a first immobilized mismatch binding protein;
- 10 (d) contacting each separate population of DNA hybridized in step (b) individually with a second immobilized mismatch binding protein;
- (e) separating unbound DNA from bound DNA contacted in step (c);
- (f) separating unbound DNA from bound DNA contacted in
15 step (d);
- (g) labeling each separate population of unbound DNA separated in step (f) with a distinguishable label capable of binding a partner molecule immobilized on a substrate;
- (h) hybridizing DNA labeled in step (g) with unbound
20 DNA separated in step (e);
- (i) contacting DNA hybridized in step (h) with a third immobilized mismatch binding protein;
- (j) separating unbound DNA from bound DNA contacted in step (i);
- (k) releasing bound DNA separated in step (j) from the
25 immobilized mismatch binding protein;
- (l) contacting DNA released in step (k) with one or more partner molecules capable of binding the distinct labels;
- (m) denaturing DNA contacted in step (l); and
- 30 (n) separating unbound DNA from bound DNA denatured in step (m), which unbound DNA separated in step (n)

encodes one or more identified alleles underlying the defined phenotype.

20. The method of Claim 18 or Claim 19, wherein at least one cDNA library is normalized.

5

21. The method of Claim 18 or Claim 19, wherein at least one cDNA library is linearized.

22. The method of Claim 19, wherein labeling is carried out by polymerase chain reaction using 5'-peptide labeled primers.

10

23. The method of Claim 19, wherein at least one immobilized partner molecule is an antibody.

24. The method of Claim 23, wherein the antibody is an anti-peptide antibody.

15

25. The method of Claim 19, wherein the hybridization in step (h) is carried out using an excess of labeled DNA.

26. The method of Claim 19, wherein the excess of labeled DNA is a three-fold excess.

20

27. The method of Claim 19, wherein at least one of the immobilized mismatch binding proteins is MutS.

28. A method for identifying one or more alleles underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived, comprising:

25

(a) amplifying insert DNA from the first cDNA library by polymerase chain reaction;

30

- (b) amplifying insert DNA from each of the plurality of additional cDNA libraries by polymerase chain reaction;
- (c) hybridizing DNA amplified in step (a) with itself;
- 5 (d) hybridizing DNA amplified from each library in step (b) with itself;
- (e) contacting DNA hybridized in step (c) with immobilized MutS;
- (f) contacting each population of DNA hybridized in step (d) individually with immobilized MutS;
- 10 (g) separating unbound DNA from bound DNA contacted in step (e);
- (h) separating unbound DNA from bound DNA contacted in step (f);
- (i) amplifying unbound DNA separated in step (g) by polymerase chain reaction using unlabeled primers;
- 15 (j) amplifying and labeling each population of unbound DNA separated in step (h) by polymerase chain reaction using a distinguishable 5'-peptide-labeled primer;
- (k) hybridizing DNA amplified and labeled in step (j) with DNA amplified in step (i);
- 20 (l) contacting DNA hybridized in step (k) with immobilized MutS;
- (m) separating unbound DNA from bound DNA contacted in step (l);
- (n) releasing bound DNA separated in step (m) from immobilized MutS;
- 25 (o) contacting DNA released in step (n) with one or more immobilized antibodies specific for each distinguishable 5'-peptide-labeled primer;
- (p) denaturing DNA contacted in step (o); and
- (q) separating unbound DNA from bound DNA denatured in step (p),

which unbound DNA separated in step (q) encodes one or more
30 identified alleles underlying the defined phenotype.

29. The method of Claim 28, wherein releasing bound DNA from immobilized MutS in step (n) is carried out using ATP or proteinase K.

30. The method of any one of Claims 1, 7, 18, 19 and
5 28, which further comprises using the one or more genes or alleles identified to carry out a prognosis or a diagnosis.

31. The method of claim 30, wherein the one or more genes or alleles identified, or an encoded protein thereof, is a target for drug intervention.

10

32. The method of claim 1, wherein the plurality of source populations is in the range of three to twelve source populations.

33. The method of claim 1, wherein the plurality of
15 source populations is in the range of three to six source populations.

34. The method of claim 1, wherein the plurality of source populations consists of four source populations.

20 35. A method for identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived, comprising:

- 25 (a) hybridizing insert DNA from each cDNA library with itself;
- (b) contacting each separate population of DNA hybridized in step (a) individually with a first immobilized mismatch binding protein;
- (c) separating unbound DNA from bound DNA contacted individually in step (b);
- 30 (d) labeling each separate population of unbound DNA separated in step (c) with a distinguishable label

capable of binding a partner molecule immobilized on a substrate;

- (e) hybridizing DNA separately labeled in step (d);
- (f) contacting DNA hybridized in step (e) with a second immobilized mismatch binding protein; and
- 5 (g) separating unbound DNA from bound DNA contacted in step (f).

36. A method for identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but
10 not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived, comprising:

- (a) amplifying insert DNA from each cDNA library by polymerase chain reaction;
- (b) hybridizing each separate population of DNA amplified in step (a) with itself;
- 15 (c) contacting each separate population of DNA hybridized in step (b) individually with immobilized MutS;
- (d) separating unbound DNA from bound DNA contacted in step (c);
- (e) labeling each separate population of unbound DNA
20 separated in step (d) by polymerase chain reaction using at least one primer having a distinguishable 5'-peptide-label capable of binding a partner molecule immobilized on a substrate;
- (f) hybridizing DNA labeled in step (e);
- (g) contacting DNA hybridized in step (f) with
25 immobilized MutS; and
- (h) separating unbound DNA from bound DNA contacted in step (g).

37. A method for identifying one or more alleles underlying a defined phenotype displayed by a cell or
30 individual from which a first cDNA library is derived, but

not displayed by a cell or individual from which a plurality of additional cDNA libraries is derived, comprising:

- (a) hybridizing insert DNA from each cDNA library with itself;
- 5 (b) contacting each separate population of DNA hybridized in step (a) individually with a first immobilized mismatch binding protein;
- (c) separating unbound DNA from bound DNA contacted in step (b);
- 10 (d) labeling each separate population of unbound DNA separated in step (c) with a distinguishable label capable of binding a partner molecule immobilized on a substrate;
- (e) hybridizing DNA labeled in step (d);
- (f) contacting DNA hybridized in step (e) with a second immobilized mismatch binding protein; and
- 15 (g) separating unbound DNA from bound DNA contacted in step (f).

38. A method for identifying one or more alleles underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a plurality
20 of additional cDNA libraries is derived, comprising:

- (a) amplifying insert DNA from each cDNA library by polymerase chain reaction;
- (b) hybridizing DNA amplified from each library in step (a) with itself;
- 25 (c) contacting DNA from each library hybridized in step (b) individually with a first immobilized mismatch binding protein;
- (d) separating unbound DNA from bound DNA contacted in step (c);
- 30 (e) amplifying and labeling each separate population of unbound DNA separated in step (d) by polymerase chain reaction using at least one primer having a distinguishable 5'-peptide-label;

- (f) hybridizing DNA amplified and labeled in step (e);
- (g) contacting DNA hybridized in step (f) with a second immobilized mismatch binding protein;
- (h) separating unbound DNA from bound DNA contacted in step (g);
- 5 (i) releasing bound DNA separated in step (h); and
- (j) separating DNA released in step (i) into single strands.

39. A method for identifying one or more alleles underlying a defined phenotype comprising the following steps
10 in the order stated:

- (a) removing mismatched duplex nucleic acid molecules formed from hybridization within each of a plurality of source populations of nucleic acids;
- (b) retaining mismatched duplex nucleic acid molecules formed from hybridization among the plurality of
15 source populations; and
- (c) separating mismatched strands retained in step (b), which separated strands comprise one or more alleles underlying the defined phenotype.

40. A method for identifying one or more genes
20 underlying a defined phenotype comprising the following steps in the order stated:

- (a) removing mismatched duplex nucleic acid molecules formed from hybridization within each of two source populations of nucleic acids; and
 - (b) retaining mismatched duplex nucleic acid molecules
25 formed from hybridization between the two source populations,
- the retained molecules in step (b) comprising the one or more genes underlying the defined phenotype.

41. A method for identifying one or more genes
30 underlying a defined phenotype comprising the following steps in the order stated:

- (a) removing mismatched duplex nucleic acid molecules formed from hybridization within a first source population of nucleic acids; and
- (b) retaining mismatched duplex nucleic acid molecules formed from hybridization between the first source population and a second source population of nucleic acids,
- 5 the retained molecules in step (b) comprising the one or more genes underlying the defined phenotype.

42. A method for identifying one or more genes
- 10 underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a second cDNA library is derived, comprising:
- (a) hybridizing insert DNA from the first cDNA library with itself;
- 15 (b) hybridizing insert DNA from the second cDNA library with itself;
- (c) contacting the DNA hybridized in step (a) with a first immobilized mismatch binding protein;
- (d) contacting the DNA hybridized in step (b) with a second immobilized mismatch binding protein;
- 20 (e) separating unbound DNA from bound DNA contacted in step (c);
- (f) separating unbound DNA from bound DNA contacted in step (d);
- (g) labeling unbound DNA separated in step (f) with a label capable of binding a partner molecule
- 25 immobilized on a substrate;
- (h) hybridizing DNA labeled in step (g) with unbound DNA separated in step (e);
- (i) contacting DNA hybridized in step (h) with a third immobilized mismatch binding protein;
- 30 (j) separating unbound DNA from bound DNA contacted in step (i);

- (k) contacting unbound DNA separated in step (j) with the partner molecule immobilized on the substrate capable of binding the label; and
 - (l) separating unbound DNA from bound DNA contacted in step (k),
- 5 which unbound DNA separated in step (l) encodes one or more identified genes underlying the defined phenotype.

43. A method for identifying one or more genes underlying a defined phenotype from organisms having consanguinity comprising:

- 10 (a) hybridizing insert DNA from a first collection of cDNA libraries derived from organisms having the defined phenotype with itself;
- (b) contacting the DNA hybridized in step (a) with a first immobilized mismatch binding protein;
- (c) separating unbound DNA from bound DNA contacted in step (b);
- 15 (d) labeling unbound DNA separated in step (c) with a label capable of binding a partner molecule immobilized on a substrate;
- (e) hybridizing DNA labeled in step (d) with insert DNA from a second collection of cDNA libraries derived from organisms not having the defined phenotype;
- 20 (f) contacting DNA hybridized in step (e) with a second immobilized mismatch binding protein;
- (g) separating unbound DNA from bound DNA contacted in step (f);
- (h) contacting unbound DNA separated in step (g) with the partner molecule immobilized on the substrate capable of binding the label; and
- 25 (i) separating unbound DNA from bound DNA contacted in step (h),

which unbound DNA separated in step (i) encodes one or more identified genes underlying the defined phenotype.

30

44. A method for identifying one or more genes underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a second cDNA library is derived, comprising:

- 5 (a) amplifying insert DNA from the first cDNA library by polymerase chain reaction;
- (b) amplifying insert DNA from the second cDNA library by polymerase chain reaction;
- (c) hybridizing DNA amplified in step (a) with itself;
- (d) hybridizing DNA amplified in step (b) with itself;
- 10 (e) contacting DNA hybridized in step (c) with a first immobilized Muts;
- (f) contacting DNA hybridized in step (d) with a second immobilized Muts;
- (g) separating unbound DNA from bound DNA contacted in step (e);
- 15 (h) separating unbound DNA from bound DNA contacted in step (f);
- (i) amplifying unbound DNA separated in step (g) by polymerase chain reaction using unlabeled primers;
- (j) amplifying and labeling unbound DNA separated in step (h) by polymerase chain reaction using 5'-
- 20 biotinylated primers;
- (k) hybridizing DNA amplified and labeled in step (j) with DNA amplified in step (i);
- (l) contacting DNA hybridized in step (k) with a third immobilized Muts;
- (m) separating unbound DNA from bound DNA contacted in
- 25 step (l);
- (n) contacting unbound DNA separated in step (m) with immobilized streptavidin; and
- (o) separating unbound DNA from bound DNA contacted in step (n),

which unbound DNA separated in step (o) encodes one or more
30 identified genes underlying the defined phenotype.

45. A method for identifying one or more genes underlying a disease phenotype from healthy and affected individuals having consanguinity comprising:

- 5 (a) amplifying insert DNA from a first collection of cDNA libraries derived from affected individuals by polymerase chain reaction;
- (b) hybridizing DNA amplified in step (a) with itself;
- (c) contacting DNA hybridized in step (b) with a first immobilized MutS;
- (d) separating unbound DNA from bound DNA contacted in step (c);
- 10 (e) amplifying and labeling unbound DNA separated in step (d) by polymerase chain reaction using 5'-biotinylated primers;
- (f) amplifying insert DNA from a second collection of cDNA libraries derived from healthy individuals by polymerase chain reaction;
- 15 (g) hybridizing DNA amplified and labeled in step (e) with DNA amplified in step (f);
- (h) contacting DNA hybridized in step (g) with a second immobilized MutS;
- (i) separating unbound DNA from bound DNA contacted in step (h);
- 20 (j) contacting unbound DNA separated in step (i) with immobilized streptavidin; and
- (k) separating unbound DNA from bound DNA contacted in step (j),

which unbound DNA separated in step (k) encodes one or more identified genes underlying the disease phenotype.

25

46. A method for identifying one or more alleles underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a second cDNA library is derived, comprising:

- 30 (a) hybridizing insert DNA from the first cDNA library with itself;

- 5 (b) hybridizing insert DNA from the second cDNA library with itself;
- (c) contacting DNA hybridized in step (a) with a first immobilized mismatch binding protein;
- (d) contacting DNA hybridized in step (b) with a second immobilized mismatch binding protein;
- 10 (e) separating unbound DNA from bound DNA contacted in step (c);
- (f) separating unbound DNA from bound DNA contacted in step (d);
- (g) labeling unbound DNA separated in step (f) with a label capable of binding a partner molecule immobilized on a substrate;
- 15 (h) hybridizing DNA labeled in step (g) with unbound DNA separated in step (e);
- (i) contacting DNA hybridized in step (h) with a third immobilized mismatch binding protein;
- (j) separating unbound DNA from bound DNA contacted in step (i);
- 20 (k) releasing bound DNA separated in step (j) from the third immobilized mismatch binding protein;
- (l) contacting DNA released in step (k) with the partner molecule immobilized on the substrate capable of binding the label;
- (m) denaturing DNA contacted in step (l); and
- (n) separating unbound DNA from bound DNA denatured in step (m),

which unbound DNA separated in step (n) encodes one or more identified alleles underlying the defined phenotype.

25

47. A method for identifying one or more alleles underlying a defined phenotype from organisms having consanguinity comprising:

- 30 (a) hybridizing insert DNA from a first collection of cDNA libraries derived from organisms having the defined phenotype with itself;

- 5 (b) contacting DNA hybridized in step (a) with a first immobilized mismatch binding protein;
- (c) separating unbound DNA from bound DNA contacted in step (b);
- 5 (d) labeling unbound DNA separated in step (c) with a label capable of binding a partner molecule immobilized on a substrate;
- (e) hybridizing DNA labeled in step (d) with insert DNA from a second collection of cDNA libraries derived from organisms not having the defined phenotype;
- 10 (f) contacting DNA hybridized in step (e) with a second immobilized mismatch binding protein;
- (g) separating unbound DNA from bound DNA contacted in step (f);
- (h) releasing bound DNA separated in step (g) from the second immobilized mismatch binding protein;
- 15 (i) contacting DNA released in step (h) with the partner molecule immobilized on the substrate capable of binding the label;
- (j) denaturing DNA contacted in step (i); and
- (k) separating bound DNA from unbound DNA denatured in step (j),
- which bound DNA separated in step (k) encodes one or more
- 20 identified alleles underlying the defined phenotype.

48. A method for identifying one or more alleles underlying a defined phenotype displayed by a cell or individual from which a first cDNA library is derived, but not displayed by a cell or individual from which a second
- 25 cDNA library is derived, comprising:
- (a) amplifying insert DNA from the first cDNA library by polymerase chain reaction;
- (b) amplifying insert DNA from the second cDNA library by polymerase chain reaction;
- 30 (c) hybridizing DNA amplified in step (a) with itself;
- (d) hybridizing DNA amplified in step (b) with itself;

- 5 (e) contacting DNA hybridized in step (c) with a first immobilized MutS;
(f) contacting DNA hybridized in step (d) with a second immobilized MutS;
(g) separating unbound DNA from bound DNA contacted in step (e);
(h) separating unbound DNA from bound DNA contacted in step (f);
(i) amplifying unbound DNA separated in step (g) by polymerase chain reaction using unlabeled primers;
10 (j) amplifying and labeling unbound DNA separated in step (h) by polymerase chain reaction using 5'-biotinylated primers;
(k) hybridizing DNA amplified and labeled in step (j) with DNA amplified in step (i);
(l) contacting DNA hybridized in step (k) with a third immobilized MutS;
15 (m) separating unbound DNA from bound DNA contacted in step (l);
(n) releasing bound DNA separated in step (m) from the third immobilized MutS;
(o) contacting DNA released in step (n) with immobilized streptavidin;
20 (p) denaturing DNA contacted in step (o);
(q) separating unbound DNA from bound DNA denatured in step (p),

which unbound DNA separated in step (q) encodes one or more identified alleles underlying the defined phenotype.

- 25 49. A method for identifying one or more affected alleles underlying a disease phenotype from healthy and affected individuals having consanguinity comprising:
(a) amplifying insert DNA from a first collection of cDNA libraries derived from affected individuals by polymerase chain reaction;
30 (b) hybridizing DNA amplified in step (a) with itself;

- (c) contacting DNA hybridized in step (b) with a first immobilized MutS;
- (d) separating unbound DNA from bound DNA contacted in step (c);
- 5 (e) amplifying and labeling unbound DNA separated in step (d) by polymerase chain reaction using 5'-biotinylated primers;
- (f) amplifying insert DNA from a second collection of cDNA libraries derived from healthy individuals by polymerase chain reaction;
- 10 (g) hybridizing DNA amplified and labeled in step (e) with DNA amplified in step (f);
- (h) contacting DNA hybridized in step (g) with a second immobilized MutS;
- (i) separating unbound DNA from bound DNA contacted in step (h);
- 15 (j) releasing bound DNA separated in step (i) from the second immobilized MutS;
- (k) contacting DNA released in step (j) with immobilized streptavidin;
- (l) denaturing DNA contacted in step (k);
- (m) separating bound DNA from unbound DNA denatured in step (l),
- 20 which bound DNA separated in step (m) encodes one or more identified affected alleles underlying the disease phenotype.

25

30

1/12




FIG. 1




FIG.2

3/12




FIG.3




FIG.4

BLASTX

4/12

Query= #1
(329 letters)

Translating both strands of query sequence in all 6 reading frames

Database: Non-redundant GenBank CDS
translations+PDB+SwissProt+SPupdate+PIR
204,173 sequences; 58,078,033 total letters.

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Probability P(N)	Smallest Sum N
gi 984587 (D38582) DinP [Escherichia coli] ...	-2	118	2.7e-20	2
pir H64239 UV protection protein mucB homolo...	-2	110	4.1e-16	2
gi 1303974 (D84432) YqjW [Bacillus subtilis]	-2	98	1.1e-15	2
gi 1303959 (D84432) YqjH [Bacillus subtilis]	-2	104	1.1e-15	2
sp P34409 YLW6_CAEEL HYPOTHETICAL 59.1 KD PROTEIN F22B...	-2	92	1.4e-14	2

gi|984587 (D38582) DinP [Escherichia coli] gi|1208981 (D83536) unknown
[Escherichia coli]
Length = 351

Minus Strond HSPs:

Score = 118 (54.3 bits), Expect = 2.7e-20, Sum P(2) = 2.7e-20
Identities = 26/64 (40%), Positives = 36/64 (56%), Frame = -2

Query: 193 RGVTTANYVARQLGIHSAMRSAEARRLAPDGI FLTPDFAKYKAISKQIHAVFRTITPKI 14
RGV++TANY AR+ G+ SAM + A+L P L F YK S I +F T+I
Sbjct: 38 RGVISTANYPARKFGVRSAMPTGMALKCPHLTLLPGRFDAYKEASNHIREIFSRYTSRI 97

Query: 13 EAVA 2 (SEQ ID NO: 7)
E ++
Sbjct: 98 EPLS 101 (SEQ ID NO: 8)

SCORE = 100 (46.0 bits), Expect = 2.7e-20, Sum P(2) = 2.7e-20
Identities = 19/29 (65%), Positives = 22/29 (75%), Frame = -2

Query: 307 KFXHVDIDAFYAQVEMRDNPALRHQPLII 221 (SEQ ID NO: 10)
K HVD+D F+A VEMRDNPALR P+ I (SEQ ID NO: 12)
Sbjct: 3 KIIHVDMDCFFAAVEMRDNPALRDIPIAI 31 (SEQ ID NO: 11)

pir||H64239 UV protection protein mucB homolog - Mycoplasma genitalium
(SGC3) gi|1046068 (U39720) UV protection protein [Mycoplasma
genitalium]

FIG. 5A

SUBSTITUTE SHEET (RULE 26)

Length = 411

5/12

Minus Strand HSPs:

Score = 110 (50.6 bits), Expect = $4.1e-16$, Sum P(2) = $4.1e-16$
 Identities = 24/55 (43%), Positives = 32/55 (58%), Frame = -2

Query: 193 RGVTTANYVARQLGIHSAMRSAEARRLAPDGI FLTPDFAKYKAISKQIHAVFRT 29'

R VV+T NYVAR GI S K +A L P+ IF +F Y+ SK+I +V +

Sbjct: 53 RSVVSTCNVARSYGIRSGMSILKALELCPNAIFAHSNFRNYRKHSKRIFSVIES 107

Score = 79 (36.3 bits), Expect = $4.1e-16$, Sum P(2) = $4.1e-16$
 Identities = 15/28 (53%), Positives = 20/28 (71%), Frame = -2

Query: 304 FXHVDIDAFYAQVEMRDNPALRHQPLII 221 (SEQ ID NO: 16)

F + D DAF+A VE +NP L +QPLI+

Sbjct: 20 FLYFDFDAFFASVEELENPELVNQPLIV 47 (SEQ ID NO: 17)

gi|1303974 (D84432) YqjW [Bacillus subtilis]

Length = 412

Minus Strand HSPs:

Score = 98 (45.1 bits), Expect = $1.1e-15$, Sum P(2) = $1.1e-15$
 Identities = 17/34 (50%), Positives = 26/34 (76%), Frame = -2

Query: 295 VDIDAFYAQVEMRDNPALRHQPLIISRDP AETGG 194 (SEQ ID NO: 19)

VD+ +FYA VE +NP L+++P+I+S DP + GG

Sbjct: 10 VDMQSFYASVEKAENPHLKNRPVIVSGDPEKRG 43 (SEQ ID NO: 20)

Score = 88 (40.5 bits), Expect = $1.1e-15$, Sum P(2) = $1.1e-15$
 Identities = 21/60 (35%), Positives = 32/60 (53%), Frame = -2

Query: 190 GVVTTANYVARQLGIHSAMRSAEARRLAPDGI FLTPDFAKYKAISKQIHAVFRTITPKIE 11

GVV A +A+Q G+ +A R EA+ P+ + L P +Y +S QI A+ T +E

Sbjct: 43 GVVLAACPLAKQKGVVNASRLWEAQEKCEAVVLRPRMRYIDVSLQITALEEYTDLVE 102

gi|1303959 (D84432) YqjH [Bacillus subtilis]

Length = 414

Minus Strand HSPs:

Score = 104 (47.8 bits), Expect = $1.1e-15$, Sum P(2) = $1.1e-15$
 Identities = 21/64 (32%), Positives = 37/64 (57%), Frame = -2

Query: 193 RGVTTANYVARQLGIHSAMRSAEARRLAPDGI FLTPDFAKYKAISKQIHAVFRTITPKI 14

+G+V T +Y AR G+ + M +A+R P+ I L P+ F +Y+ S+ + + R T +

Sbjct: 43 KGIVVTCSEARARGVKTTPVWQAKRHCP ELIVLPNFDYRNSSRAMFTILREYTDLV 102

FIG. 5B

6/12

BLASTX

Query= Tor-M
(256 letters)

Translating both strands of query sequence in all 6 reading frames

Database: Non-redundant GenBank CDS
translations+PDB+SwissProt+SPupdate+PIR
221,464 sequences; 63,648,287 total letters.

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Probability P(N)	N
gi 1303959 (D84432) YqjH [Bacillus subtilis]	+1	93	0.00011	1
gi 984587 (D38582) DinP [Escherichia coli]	... +1	90	0.00034	1

gi|1303959 (D84432) YqjH [Bacillus subtilis]
Length = 414

Plus Strand HSPs:

Score = 93 (42.8 bits), Expect = 0.00011, P = 0.00011
Identities = 19/50 (38%), Positives = 28/50 (56%), Frame = +1

Query: 22 IFLTPDFAKYKAISKQIHAVFRTITPKIEPVVIDEAYLDVTANALSGALL 171 (SEQ ID NO: 25)
I L P+ F +Y+ S+ + + R T +EPV IDE Y+D+T S L
Sbjct: 75 IVLPPNFDYRNSSRAMFTILREYTDLVEPVSIDEGYMDMTDTPYSSRAL 124 (SEQ ID NO: 26)

gi|984587 (D38582) DinP [Escherichia coli] gi|1208981 (D83536) unknown
[Escherichia coli] gi|1552799 (U70214) DinP [Escherichia coli]
Length = 351

Plus Strand HSPs:

Score = 90 (41.4 bits), Expect = 0.00034, P = 0.00034
Identities = 18/35 (51%), Positives = 22/35 (62%), Frame = +1

Query: 40 FAKYKAISKQIHAVFRTITPKIEPVVIDEAYLDVT 144 (SEQ ID NO: 27)
F YK S I +F T +IEP+ +DEAYLDVT (SEQ ID NO: 29)
Sbjct: 76 FDAYKEASNHIREIFSRYTSRIEPLSLDEAYLDVT 110 (SEQ ID NO: 28)

FIG. 6

BLASTX

7/12

Query= # 3
(248 letters)

Translating both strands of query sequence in all 6 reading frames

Database: Non-redundant GenBank CDS
translations+PDB+SwissProt+SPupdate+PIR
204,173 sequences; 58,078,033 total letters.

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Probability P(N)	Smallest Sum N
gi 984587 (D38582) DinP [Escherichia coli] ...	+3	128	3.2e-14	2
gi 1303959 (D84432) YqjH [Bacillus subtilis]	+3	121	1.9e-12	2
pir H64239 UV protection protein mucB homolo...	+3	88	6.5e-05	1

gi|984587 (D38582) DinP [Escherichia coli] gi|1208981 (DS83536) unknown
[Escherichia coli]
Length = 351

Plus Strand HSPs:

Score = 128 (58.3 bits), Expect = 3.2e-14, Sum P(2) = 3.2e-14
Identities = 28/69 (40%), Positives = 40/69 (57%), Frame = +3

Query: 39 SGAXLAAQLRHDYKQXRLTSSVGVSYNKLAKLGSXFNKPNGVTVITXENRLXFLXHP 218
S +A ++R I+ + +LT+S GV+ K LAK+ S NKPNG VIT FL P
Sbjct: 118 SATLIAQEIRQTIFNELQLTASAGVAPVKFLAKIASDMNKPNGQFVITPAEVP AFLQTLP 177

Query: 219 ICEFRGVGE 245 (SEQ ID NO: 30)
+ + GVG+
Sbjct: 178 LAKIPGVGK 186 (SEQ ID NO: 31)

Score = 48 (21.8 bits), Expect = 3.2e-14, Sum P(2) = 3.2e-14
Identities = 9/10 (90%), Positives = 10/10 (100%), Frames = +3

Query: 3 DEAYLDVTDN 32 (SEQ ID NO: 33)
DEAYLDVTD+ (SEQ ID NO: 35)
Sbjct: 103 DEAYLDVTDS 112 (SEQ ID NO: 34)

gi|1303959 (D84432) YqjH [Bacillus subtilis]
Length = 414

FIG. 7A

8/12

Plus Strand HSPs:

Score = 121 (55.1 bits), Expect = 1.9e-12, Sum P(2) = 1.9e-12
 Identities = 24/65 (36%), Positives = 38/65 (58%), Frame = +3

Query: 54 AAQLRHDIYQXRLTSSVGVSYNKLLAKLGSXFNKPNGVTVITXENRLXFLXHPIGEFR 233
 A +++ + K+ L SS+G++ NK LAK+ S KP G+T++ L P+GE
 Sbjct: 127 AKEIQSRLQKELLPSIGIAPNKF LAKMASDMKKPLGITILRKQVPDILWPLPVGEMH 186

Query: 234 GVG EK 248 (SEQ ID NO: 36)
 GVG+K

Sbjct: 187 GVGKK 191 (SEQ ID NO: 37)

Score = 43 (19.6 bits), Expect = 1.9e-12, Sum P(2) = 1.9e-12
 Identities = 8/17 (47%), Positives = 10/17 (58%), Frame = +3

Query: 3 DEAYLDVTDNALSGAXL 53 (SEQ ID NO: 38)
 DE Y+D+TD S L
 Sbjct: 108 DEGYMDMTDTPYSSRAL 124 (SEQ ID NO: 39)

pir||H64239 UV protection protein mucB homolog - Mycoplasma genitalium
 (SGC3) gi|1046068 (U39720) UV protection protein [Mycoplasma
 genitalium]
 Length = 411

Plus Strand HSPs:

Score = 88 (40.1 bits), Expect = 6.5e-05, P = 6.5e-05
 Identities = 20/66 (30%), Positives = 39/66 (59%), Frame = +3

Query: 51 LAAQLRHDIYQXRLTSSVGVSYNKLLAKLGSXFNKPNGVTVITXENRLXFLXHPIGE F 230
 +A ++++ +++ R+ S+G+S + L+AK+ S KP G+ + ++ L P I E
 Sbjct: 136 IAKKIKNFVFQNLRIKISIGISDHFLIAKIFSNQAKPFGIKSCSVKDIKKKLWPLPITEI 195

Query: 231 RGVGEK 248 (SEQ ID NO: 40)
 G+GEK

Sbjct: 196 PGIG EK 201 (SEQ ID NO: 41)

sp|P18642|IMPB_SALTY IMPB PROTEIN. pir||JQ0661 impB protein -
 Salmonella typhimurium plasmid TP110 gi|47748 (X53528) impB gene
 product (AA 1-424) [Salmonella typhimurium]
 Length = 424

Plus Strand HSPs:

Score = 49 (22.3 bits), Expect = 0.00024, Sum P(3) = 0.00024
 Identities = 12/37 (32%), Positives = 18/37 (48%), Frame = +3

FIG. 7B

BLASTX

9/12

Query= *1
(388 letters)

Translating both strands of query sequence in all 6 reading frames

Database: Non-redundant GenBank CDS
translations+PDB+SwissProt+SPupdate+PIR
258,816 sequences; 73,256,548 total letters.

Searching.....done

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Probability P(N)	Smallest Sum N
gi 984587 (D38582) DinP [Escherichia coli] ...	+3	115	9.8e-11	2
sp P54545 YQJH_BACSU HYPOTHETICAL 47.0 KD PROTEIN IN G...	+3	108	4.6e-08	2
gi 1706953 (U52110) Dbh [Sulfolobus solfatar...	+3	99	6.0e-06	2
sp P54560 YQJW_BACSU HYPOTHETICAL 45.9 KD PROTEIN IN G...	+3	101	4.3e-05	1
sp P34409 YLW6_CAEEL HYPOTHETICAL 59.1 KD PROTEIN F22B...	+3	82	0.0014	2
gnl PID e290932 (Z83866) unknown [Mycobacterium t...	+3	84	0.0043	2

gi|984587 (D38582) DinP [Escherichia coli] gnl|PID|d1012651 (D3536)
unknown [Escherichia coli] gi|1552799 (U70214) DinP [Escherichia
coli] gi|1786425 (AE000131) hypothetical protein DinP [Escherichia
coli]
Length = 351

Plus Strand HSPs:

Score = 115 (52.9 bits), Expect = 2.9e-10, Sum P(2) = 2.9e-10
Identities = 26/61 (42%), Positives = 34/61 (55%), Frame = +3

Query: 3 QLGHSAMRSAEARRLAPDGI FLTPDFAKYKAISKQIHAVFRTITPKIEAVALDEAYLDV 182
+ G+ SAM + A +L P L F YK S I +F T +IE ++LDEAYLDV
Sbjct: 50 KFGVRSAMPTGMALKLCPHLTLPGRFDAYKEASNHIREIFSRYTSRIEPLSLDEAYLDV 109

Query: 183 T 185 (SEQ ID NO: 42)
T

Sbjct: 110 T 110 (SEQ ID NO: 43)

Score = 47 (21.6 bits), Expect = 9.8e-11, Sum P(2) = 9.8e-11
Identities = 12/41 (29%), Positives = 20/41 (48%), Frame = +2

Query: 218 QLRHDIYIHTRL*FGGCIVYHTISEVGI*FNKPNGVTIVIT 340 (SEQ ID NO: 45)
++R I+ +L G +++ NKPNG VIT
Sbjct: 125 EIRQTIFNELQLTASAGVAPVKFLAKIASDMNKPNGQFVIT 165 (SEQ ID NO: 46)

Score = 47 (21.6 bits), Expect = 2.9e-10, Sum P(2) = 2.9e-10

FIG. 8A

10/12

Identities = 12/38 (31%), Positives = 18/38 (47%), Frome = +3

Query: 198 SGALLAHSYGMTFIYTHDYSSSVGVSYTILLAKLGSDL 311 (SEQ ID NO: 48)

S L+A T ++S GV+ LAK+ SD+

Sbjct: 118 SATLIAQEIRQTIFNELQLTASAGVAPVKFLAKIASDM 155 (SEQ ID NO: 49)

sp|P54545|YQJH_BACSU HYPOTHETICAL 47.0 KD PROTEIN IN GLNQ-ANSR

INTERGENIC REGION gnl|PID|d1013294 (D84432) YqjH [Bocillus subtilis]

Length = 414

Plus Strand HSPs:

Score = 108 (49.7 bits), Expect = 4.6e-08, Sum P(2) = 4.6e-08

Identities = 22/68 (32%), Positives = 38/68 (55%), Frames = +3

Query: 9 GIHSAMRSAEARRLAPDGI FLTPDFAKYKAISKQIHAVFRTITPKIEAVALDEAYLDVTA 188

G+ + M +A+R P+ I L P+F +Y+ S+ + + R T +E V++DE Y+D+T

Sbjct: 57 GVKTTMPVWQAKRHCPELIVLPNFDYRNSSRAMFTILREYTDLVEPVSIDGYMDMTD 116

Query: 189 NALSGALL 212 (SEQ ID NO: 50)

S L

Sbjct: 117 TPYSSRAL 124 (SEQ ID NO: 51)

Score = 42 (19.3 bits), Expect = 4.6e-08, Sum P(2) = 4.6e-08

Identities = 8/18 (44%), Positives = 13/18 (72%), Frame = +3

Query: 258 SSVGVSYTILLAKLGSDL 311 (SEQ ID NO: 52)

SS+G++ LAK+ SD+

Sbjct: 142 SSIGIAPNKFLAKMASDM 159 (SEQ ID NO: 53)

gi|1706953 (U52110) Dbh [Sulfolobus solfataricus]

Length = 354

Plus Strand HSPs:

Score = 99 (45.5 bits), Expect = 6.0e-06, Sum P(2) = 6.0e-06

Identities = 22/61 (36%), Positives = 35/61 (57%), Frames = +3

Query: 3 QLGHSAMRSAEARRLAPDGI FLTPDFAKYKAISKQIHAVFRTITPKIEAVALDEAYLDV 182

+LG+ + M +A ++AP I++ Y+A S +I + KIE ++DEAYLDV

Sbjct: 52 KLGVKAGMPIIKAMQIAPSAIYVPMRKPIYEAFSNRIMLLNKHADKIEVASIDEAYLDV 111

Query: 183 T 185 (SEQ ID NO: 54)

T

Sbjct: 112 T 112 (SEQ ID NO: 55)

Score = 37 (17.0 bits), Expect = 6.0e-06, Sum P(2) = 6.0e-06

Identities = 12/43 (27%), Positives = 20/43 (46%), Frame = +3

Query: 180 VTANALSGALLAHSYGMTFIYTHDYSSSVGVSYTILLAKLGS 308 (SEQ ID NO: 57)

V N +G LA + + +VG+ +LAK+ +D

Sbjct: 115 VEGNFENGIELARKIKQEILEKEKITVTVCVAPNKILAKIID 157 (SEQ ID NO: 58)

FIG. 8B

SUBSTITUTE SHEET (RULE 26)

BLASTX

11/12

Query= *2
(383 letters)

Translating both strands of query sequence in all 6 reading frames

Database: Non-redundant GenBank CDS
translations+PDB+SwissProt+SPupdate+PIR
258,816 sequences; 73,256,548 total letters.

Searching.....done

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Probability P(N)	Smallest Sum N
sp P54545 YQJH_BACSU HYPOTHETICAL 47.0 KD PROTEIN IN G...	+1	83	8.6e-07	2
gi 984587 (D38582) DinP [Escherichia coli] ...	+1	82	1.7e-05	2
sp P54545 YQJH_BACSU HYPOTHETICAL 47.0 KD PROTEIN IN GLNQ-ANSR INTERGENIC REGION gnl PID d1013294 (D84432) YqjH [Bacillus subtilis] Length = 414				

Plus Strand HSPs:

Score = 83 (38.2 bits), Expect = 8.6e-07, Sum P(2) = 8.6e-07
Identities = 16/41 (39%), Positives = 25/41 (60%), Frame = +1

Query: 61 IFLTPDFAKYKAISKQIHAVFRTITPKIEAVVIDEAYLDVT 183 (SEQ ID NO: 69)
I L P+ F +Y+ S+ + + R T +E V IDE Y+D+T
Sbjct: 75 IVLPNFDYRNSSRAMFTILREYTDLVEPVSIDEGYMDMT 115 (SEQ ID NO: 70)

Score = 59 (27.1 bits), Expect = 8.6e-07, Sum P(2) = 8.6e-07
Identities = 11/20 (55%), Positives = 16/20 (80%), Frame = +1

Query: 247 LTSSVGVSYNKLLAKLGSDL 306 (SEQ ID NO: 59)
L SS+G++ NK LAK+ SD+
Sbjct: 140 LPSSIGIAPNKFLAKMASDM 159 (SEQ ID NO: 60)

gi|984587 (D38582) DinP [Escherichia coli] gnl|PID|d1012651 (D83536)
unknown [Escherichia coli] gi|1552799 (U70214) DinP [Escherichia coli]
gi|1786425 (AE000131) hypothetical protein DinP [Escherichia coli]
Length = 351

Plus Strand HSPs:

Score = 82 (37.7 bits), Expect = 1.7e-05, Sum P(2) = 1.7e-05

FIG. 9A

SUBSTITUTE SHEET (RULE 26)

12/12

Identities = 17/35 (48%), Positives = 21/35 (60%), Frame = +1

Query: 79 FAKYKAISKQIHAVFRTITPKIEAVVIDEAYLDVT 183 (SEQ ID NO: 61)
F YK S I +F T +IE + +DEAYLDVT
Sbjct: 76 FDAYKEASNHIREIFSRYTSRIEPLSLDEAYLDVT 110 (SEQ ID NO: 62)

Score = 51 (23.5 bits), Expect = 1.7e-05, Sum P(2) = 1.7e-05
Identifies = 11/20 (55%), Positives = 15/20 (75%), Frame = +1

Query: 247 LTSSVGVSYNKLLAKLGSDL 306 (SEQ ID NO: 64)
LT+S GV+ K LAK+ SD+
Sbjct: 136 LTASAGVAPVKFLAKIASDM 155 (SEQ ID NO: 65)

Score = 40 (18.4 bits), Expect = 0.00079, Sum P(2) = 0.00079
Identities = 8/18 (44%), Positives = 12/18 (66%), Frame = +3

Query: 282 ISEVGI+FNKPNGVTVIT 335 (SEQ ID NO: 66)
+++ NKPNG VIT
Sbjct: 148 LAKIASDMNKPNGQFVIT 165 (SEQ ID NO: 67)

FIG. 9B

SEQUENCE LISTING

<110> Iris, Francois J.-M.

Pourny, Jean-Louis

<120> MULTIPLEX VGID

<130> 9408-024

<140> To be assigned

<141> 1999-01-15

<150> 09/007,905

<151> 1998-01-15

<160> 81

<170> PatentIn Ver. 2.0

<210> 1

<211> 329

<212> DNA

<213> Escherichia coli

<400> 1

```
gggccaccgc ttcaattttt ggcgtaattg tccgaaaaac ggcataaatt tgcttagaaa 60
tggctttata tttggcaaaa tcaggggtca gaaagatccc gtctggcgct aaacgccgcg 120
cttctgcgga tcgcatggcc gaatgaatgc caagttggcg cgcgacatag ttcgccgctc 180
tcaccacccc acgaccccca gtttctgctg gatcacgcga aataattaat ggctggtggc 240
gtaatgccgg attgtcacgc atctcgactt gggcatagaa ggcatacgata tcaacatggn 300
ggaattttac gtgtatcagt tgtcaataa 329
```

<210> 2

<211> 256

<212> DNA

<213> Escherichia coli

<400> 2

```
ccgggcggtt aggcagacgg gatctttctg acccctgatt ttgccaaata taaagccatt 60
tctaagcaaa ttcatgccgt ttttcggaca attacgcaa aaattgagcc ggtggtgatt 120
gatgaggctt acttagatgt gaccgccaat gcgttgtcag gcgcactgct ggccgcacag 180
ttacggcatg acatttatat acacacacga ttactctagt tcggtgggtg tatcgtatac 240
catactatta gcgatg 256
```

<210> 3

<211> 248

<212> DNA

<213> Escherichia coli

<400> 3

```
gggatgagggc ttacttagat gtgaccgaca atgcgttgtc aggcgcaatn ctggccgcac 60
agttacggca tgacatttat aaacaancac gnttaactag ttcgggtgggt gtatcgtata 120
acaaactatt agcgaagttg ggatctgant ttaataagcc aaacgggtgtg acggtgatta 180
cgncggaaaa ccgcctggnt tttttagntc atttnccgat tgggtgaattt cgcgggggtcg 240
gtgagaaaa                                     248
```

<210> 4

<211> 387

<212> DNA

<213> Escherichia coli

<400> 4

```
gccaacttgg cattcattcg gccatgcat ccgcagaagc gcggcgttta gcgccagacg 60
ggatctttct gaccctgat tttgccaaat ataaagccat ttctaagcaa attcatgccg 120
tttttcggac aattacgcca aaaattgaag cgggtggcct tgatgaggct tacttagatg 180
tgaccgccaa tgcgttgta ggcgactgc tggccgcaca gttacggcat gacatttata 240
tacacacacg attactctag ttcgggtgggt gtatcgtata ccatactatt agcgaggttg 300
ggatctgatt taataagcca aacgggtgtga cgggtgattac gcggaaaacc gcctgggtttt 360
ttagtcattt ccgattgggtg aatttcg                                     387
```

<210> 5

<211> 381

<212> DNA

<213> Escherichia coli

<400> 5

```
gccaacttgg cattcattcg gccatgcat ccgaagcgcg gcgtttaggc agcagacggg 60
atctttctga cccctgattt tgccaaatat aaagccattt ctaagcaaat tcatgccgtt 120
tttcggacaa ttacgccaaa aattgaagcg gtggtgattg atgaggctta cttagatgtg 180
accgccaatg cgttgtcagg cgcaatctgg ccgcacagtt acggcatgac atttataaac 240
aacacgtaa ctagttcggg ggggtgatcg tataacaaac tattagcgaa gttgggatct 300
gatttaataa gccaaacggg gtgacgggtg ttacgcggaa aaccgcctgg ttttttagtc 360
atttccgatt ggtgaatttc g                                     381
```

<210> 6

<211> 567

<212> DNA

<213> Escherichia coli

<400> 6

```
ttattgacaa ctgatacacg taaaattccc catgttgata tcgatgcctt ctatgcccaa 60
gtcgagatgc gtgacaatcc ggcattacgc caccagccat taattatttc gcgtgatcca 120
gcagaaactg ggggtcgtgg ggtggtgacg acggcgaaact atgtcgcgcc aacttggcat 180
tcattcggcc atgcgatccg cagaagcgcc gggcgtttag gcagacggga tctttctgac 240
ccctgatttt gccaaatata aagccatttc taagcaaatt catgccgttt ttcggacaat 300
tacgcaaaaa attgagccgg tgggtgattga tgaggcttac ttagatgtga ccgccaatgc 360
```

gttgctcaggc gcactgctgg ccgcacagtt acggcatgac atttataaac aacacgttaa 420
 ctagtccggt ggggtgatcg tataacaaac tattagcgaa gttgggatct gatttaataa 480
 gccaaacggt gtgacgggtga ttacgcggaa aaccgcctgg ttttttagtc atttccgatt 540
 ggtgaatttc gcggggtcgg tgagaaa 567

<210> 7

<211> 63

<212> PRT

<213> Escherichia coli

<400> 7

Arg Gly Val Val Thr Thr Ala Asn Tyr Val Ala Arg Leu Gly Ile His
 1 5 10 15

Ser Ala Met Arg Ser Ala Glu Ala Arg Arg Leu Ala Pro Asp Gly Ile
 20 25 30

Phe Leu Thr Pro Asp Phe Ala Lys Tyr Lys Ala Ile Ser Lys Gln Ile
 35 40 45

His Ala Val Phe Arg Thr Ile Thr Pro Lys Ile Glu Ala Val Ala
 50 55 60

<210> 8

<211> 64

<212> PRT

<213> Escherichia coli

<400> 8

Arg Gly Val Ile Ser Thr Ala Asn Tyr Pro Ala Arg Lys Phe Gly Val
 1 5 10 15

Arg Ser Ala Met Pro Thr Gly Met Ala Leu Lys Leu Cys Pro His Leu
 20 25 30

Thr Leu Leu Pro Gly Arg Phe Asp Ala Tyr Lys Glu Ala Ser Asn His
 35 40 45

Ile Arg Glu Ile Phe Ser Arg Tyr Thr Ser Arg Ile Glu Pro Leu Ser
 50 55 60

<210> 9

<211> 4

<212> PRT

<213> Escherichia coli

<400> 9

Thr Ala Asn Tyr

1

<210> 10

<211> 29

<212> PRT

<213> Escherichia coli

<400> 10

Lys Phe Xaa His Val Asp Ile Asp Ala Phe Tyr Ala Gln Val Glu Met

1

5

10

15

Arg Asp Asn Pro Ala Leu Arg His Gln Pro Leu Ile Ile

20

25

<210> 11

<211> 29

<212> PRT

<213> Escherichia coli

<400> 11

Lys Ile Ile His Val Asp Met Asp Cys Phe Phe Ala Ala Val Glu Met

1

5

10

15

Arg Asp Asn Pro Ala Leu Arg Asp Ile Pro Ile Ala Ile

20

25

<210> 12

<211> 10

<212> PRT

<213> Escherichia coli

<400> 12

Val Glu Met Arg Asp Asn Pro Ala Leu Arg

1

5

10

<210> 13

<211> 55

<212> PRT

<213> Escherichia coli

<400> 13

Arg Gly Val Val Thr Thr Ala Asn Tyr Val Ala Arg Gln Leu Gly Ile
1 5 10 15

His Ser Ala Met Arg Ser Ala Glu Ala Arg Arg Leu Ala Pro Asp Gly
20 25 30

Ile Phe Leu Thr Pro Asp Phe Ala Lys Tyr Lys Ala Ile Ser Lys Gln
35 40 45

Ile His Ala Val Phe Arg Thr
50 55

<210> 14

<211> 55

<212> PRT

<213> Escherichia coli

<400> 14

Arg Ser Val Val Ser Thr Cys Asn Tyr Val Ala Arg Ser Tyr Gly Ile
1 5 10 15

Arg Ser Gly Met Ser Ile Leu Lys Ala Leu Glu Leu Cys Pro Asn Ala
20 25 30

Ile Phe Ala His Ser Asn Phe Arg Asn Tyr Arg Lys His Ser Lys Arg
35 40 45

Ile Phe Ser Val Ile Glu Ser
50 55

<210> 15

<211> 5

<212> PRT

<213> Escherichia coli

<400> 15

Asn Tyr Val Ala Arg
1 5

<210> 16

<211> 28

<212> PRT

<213> Escherichia coli

<400> 16

Phe Xaa His Val Asp Ile Asp Ala Phe Tyr Ala Gln Val Glu Met Arg
1 5 10 15

Asp Asn Pro Ala Leu Arg His Gln Pro Leu Ile Ile
20 25

<210> 17

<211> 28

<212> PRT

<213> Escherichia coli

<400> 17

Phe Leu Tyr Phe Asp Phe Asp Ala Phe Phe Ala Ser Val Glu Glu Leu
1 5 10 15

Glu Asn Pro Glu Leu Val Asn Gln Pro Leu Ile Val
20 25

<210> 18

<211> 4

<212> PRT

<213> Escherichia coli

<400> 18

Gln Pro Leu Ile
1

<210> 19

<211> 34

<212> PRT

<213> Escherichia coli

<400> 19

Val Asp Ile Asp Ala Phe Tyr Ala Gln Val Glu Met Arg Asp Asn Pro
1 5 10 15

Ala Leu Arg His Gln Pro Leu Ile Ile Ser Arg Asp Pro Ala Glu Thr
20 25 30

Gly Gly

<210> 20

<211> 34

<212> PRT

<213> Escherichia coli

<400> 20

Val Asp Met Gln Ser Phe Tyr Ala Ser Val Glu Lys Ala Glu Asn Pro
1 5 10 15

His Leu Lys Asn Arg Pro Val Ile Val Ser Gly Asp Pro Glu Lys Arg
20 25 30

Gly Gly

<210> 21

<211> 59

<212> PRT

<213> Escherichia coli

<400> 21

Gly Val Val Thr Thr Ala Asn Tyr Val Ala Arg Gln Leu Gly Ile His
1 5 10 15

Ser Ala Met Arg Ser Ala Glu Ala Arg Arg Leu Ala Pro Asp Gly Ile
20 25 30

Phe Leu Thr Pro Phe Ala Lys Tyr Lys Ala Ile Ser Lys Gln Ile His
35 40 45

Ala Val Phe Arg Thr Ile Thr Pro Lys Ile Glu
50 55

<210> 22

<211> 60

<212> PRT

<213> Escherichia coli

<400> 22

Gly Val Val Leu Ala Ala Cys Pro Leu Ala Lys Gln Lys Gly Val Val
1 5 10 15

Asn Ala Ser Arg Leu Trp Glu Ala Gln Glu Lys Cys Pro Glu Ala Val
20 25 30

Val Leu Arg Pro Arg Met Gln Arg Tyr Ile Asp Val Ser Leu Gln Ile

35 40 45
Thr Ala Ile Leu Glu Glu Tyr Thr Asp Leu Val Glu
50 55 60

<210> 23
<211> 60
<212> PRT
<213> Escherichia coli

<400> 23
Arg Gly Val Val Thr Thr Ala Asn Tyr Val Ala Arg Gln Leu Gly Ile
1 5 10 15
His Ser Ala Met Arg Ser Ala Glu Ala Arg Arg Leu Ala Pro Asp Gly
20 25 30
Ile Phe Leu Thr Pro Asp Phe Ala Lys Tyr Lys Ala Ile Ser Lys Gln
35 40 45
Ile His Ala Val Phe Arg Thr Ile Thr Pro Lys Ile
50 55 60

<210> 24
<211> 60
<212> PRT
<213> Escherichia coli

<400> 24
Lys Gly Ile Val Val Thr Cys Ser Tyr Glu Ala Arg Ala Arg Gly Val
1 5 10 15
Lys Thr Thr Met Pro Val Trp Gln Ala Lys Arg His Cys Pro Glu Leu
20 25 30
Ile Val Leu Pro Pro Asn Phe Asp Arg Tyr Arg Asn Ser Ser Arg Ala
35 40 45
Met Phe Thr Ile Leu Arg Glu Tyr Thr Asp Leu Val
50 55 60

<210> 25
<211> 35
<212> PRT
<213> Escherichia coli

<400> 25

Ile Phe Leu Tyr Lys Ala Ile Ser Lys Gln Ile His Ala Val Phe Arg
1 5 10 15

Thr Ile Thr Pro Lys Ile Glu Pro Val Val Ile Asp Glu Ala Tyr Leu
20 25 30

Asp Val Thr
35

<210> 26

<211> 50

<212> PRT

<213> Escherichia coli

<400> 26

Ile Val Leu Pro Pro Asn Phe Asp Arg Tyr Arg Asn Ser Ser Arg Ala
1 5 10 15

Met Phe Thr Ile Leu Arg Glu Tyr Thr Asp Leu Val Glu Pro Val Ser
20 25 30

Ile Asp Glu Gly Tyr Met Asp Met Thr Asp Thr Pro Tyr Ser Ser Arg
35 40 45

Ala Leu
50

<210> 27

<211> 35

<212> PRT

<213> Escherichia coli

<400> 27

Phe Ala Lys Tyr Lys Ala Ile Ser Lys Gln Ile His Ala Val Phe Arg
1 5 10 15

Thr Ile Thr Pro Lys Ile Glu Pro Val Val Ile Asp Glu Ala Tyr Leu
20 25 30

Asp Val Thr
35

<210> 28

<211> 35

<212> PRT

<213> Escherichia coli

<400> 28

Phe Asp Ala Tyr Lys Glu Ala Ser Asn His Ile Arg Glu Ile Phe Ser
1 5 10 15

Arg Tyr Thr Ser Arg Ile Glu Pro Leu Ser Leu Asp Glu Ala Tyr Leu
20 25 30

Asp Val Thr
35

<210> 29

<211> 8

<212> PRT

<213> Escherichia coli

<400> 29

Asp Glu Ala Tyr Leu Asp Val Thr
1 5

<210> 30

<211> 69

<212> PRT

<213> Escherichia coli

<400> 30

Ser Gly Ala Xaa Leu Ala Ala Gly Leu Arg His Asp Ile Tyr Lys Gln
1 5 10 15

Xaa Arg Leu Thr Ser Ser Val Gly Val Ser Tyr Asn Lys Leu Leu Ala
20 25 30

Lys Leu Gly Ser Xaa Phe Asn Lys Pro Asn Gly Val Thr Val Ile Thr
35 40 45

Xaa Glu Asn Arg Leu Xaa Phe Leu Xaa His Xaa Pro Ile Gly Glu Phe
50 55 60

Arg Gly Val Gly Glu
65

<210> 31

<211> 69

<212> PRT

<213> Escherichia coli

<400> 31

Ser Ala Thr Leu Ile Ala Gln Glu Ile Arg Gln Thr Ile Phe Asn Glu
1 5 10 15

Leu Gln Leu Thr Ala Ser Ala Gly Val Ala Pro Val Lys Phe Leu Ala
20 25 30

Lys Ile Ala Ser Asp Met Asn Lys Pro Asn Gly Gln Phe Val Ile Thr
35 40 45

Pro Ala Glu Val Pro Ala Phe Leu Gln Thr Leu Pro Leu Ala Lys Ile
50 55 60

Pro Gly Val Gly Lys
65

<210> 32

<211> 5

<212> PRT

<213> Escherichia coli

<400> 32

Asn Lys Pro Asn Gly
1 5

<210> 33

<211> 10

<212> PRT

<213> Escherichia coli

<400> 33

Asp Glu Ala Tyr Leu Asp Val Thr Asp Asn
1 5 10

<210> 34

<211> 10

<212> PRT

<213> Escherichia coli

<400> 34

Asp Glu Ala Tyr Leu Asp Val Thr Asp Ser

1 5 10

<210> 35

<211> 9

<212> PRT

<213> Escherichia coli

<400> 35

Asp Glu Ala Tyr Leu Asp Val Thr Asp

1 5

<210> 36

<211> 65

<212> PRT

<213> Escherichia coli

<400> 36

Ala Ala Gln Leu Arg His Asp Ile Tyr Lys Gln Xaa Arg Leu Thr Ser

1 5 10 15

Ser Val Gly Val Ser Tyr Asn Lys Leu Leu Ala Lys Leu Gly Ser Xaa

20 25 30

Phe Asn Lys Pro Asn Gly Val Thr Val Ile Thr Xaa Glu Asn Arg Ile

35 40 45

Xaa Phe Leu Xaa His Xaa Pro Ile Gly Glu Phe Arg Gly Val Gly Glu

50 55 60

Lys

65

<210> 37

<211> 65

<212> PRT

<213> Escherichia coli

<400> 37

Ala Lys Glu Ile Gln Ser Arg Leu Gln Lys Glu Leu Leu Leu Pro Ser

1 5 10 15

Ser Ile Gly Ile Ala Pro Asn Lys Phe Leu Ala Lys Met Ala Ser Asp

20 25 30

Met Lys Lys Pro Leu Gly Ile Thr Ile Leu Arg Lys Arg Gln Val Pro

13

35

40

45

Asp Ile Leu Trp Pro Leu Pro Val Gly Glu Met His Gly Val Gly Lys
 50 55 60

Lys
 65

<210> 38

<211> 17

<212> PRT

<213> Escherichia coli

<400> 38

Asp Glu Ala Tyr Leu Asp Val Thr Asp Asn Ala Leu Ser Gly Ala Xaa
 1 5 10 15

Leu

<210> 39

<211> 17

<212> PRT

<213> Escherichia coli

<400> 39

Asp Glu Gly Tyr Met Asp Met Thr Asp Thr Pro Tyr Ser Ser Arg Ala
 1 5 10 15

Leu

<210> 40

<211> 66

<212> PRT

<213> Escherichia coli

<400> 40

Leu Ala Ala Gln Leu Arg His Asp Ile Tyr Lys Gln Xaa Arg Leu Thr
 1 5 10 15

Ser Ser Val Gly Val Ser Tyr Asn Lys Leu Leu Ala Lys Leu Gly Ser
 20 25 30

Xaa Phe Asn Lys Pro Asn Gly Val Thr Val Ile Thr Xaa Glu Asn Arg
 13

35 40 45
 Leu Xaa Phe Leu Xaa Glu Xaa Pro Ile Gly Glu Phe Arg Gly Val Gly
 50 55 60

Glu Lys
 65

<210> 41
 <211> 66
 <212> PRT
 <213> Escherichia coli

<400> 41
 Ile Ala Lys Lys Ile Lys Asn Phe Val Phe Gln Asn Leu Arg Ile Lys
 1 5 10 15

Ile Ser Ile Gly Ile Ser Asp His Phe Leu Ile Ala Lys Ile Phe Ser
 20 25 30

Asn Gln Ala Lys Pro Phe Gly Ile Lys Ser Cys Ser Val Lys Asp Ile
 35 40 45

Lys Lys Lys Leu Trp Pro Leu Pro Ile Thr Glu Ile Pro Gly Ile Gly
 50 55 60

Glu Lys
 65

<210> 42
 <211> 61
 <212> PRT
 <213> Escherichia coli

<400> 42
 Gln Leu Gly Ile His Ser Ala Met Arg Ser Ala Glu Ala Arg Arg Leu
 1 5 10 15

Ala Pro Asp Gly Ile Phe Leu Thr Pro Asp Phe Ala Lys Tyr Lys Ala
 20 25 30

Ile Ser Lys Gln Ile His Ala Val Phe Arg Thr Ile Thr Pro Lys Ile
 35 40 45

Glu Ala Val Ala Leu Asp Glu Ala Tyr Leu Asp Val Thr
 50 55 60

<210> 43

<211> 61

<212> PRT

<213> Escherichia coli

<400> 43

Lys Phe Gly Val Arg Ser Ala Met Pro Thr Gly Met Ala Leu Lys Leu
1 5 10 15

Cys Pro His Leu Thr Leu Leu Pro Gly Arg Phe Asp Ala Tyr Lys Glu
20 25 30

Ala Ser Asn His Ile Arg Glu Ile Phe Ser Arg Tyr Thr Ser Arg Ile
35 40 45

Glu Pro Leu Ser Leu Asp Glu Ala Tyr Leu Asp Val Thr
50 55 60

<210> 44

<211> 9

<212> PRT

<213> Escherichia coli

<400> 44

Leu Asp Glu Ala Tyr Leu Asp Val Thr
1 5

<210> 45

<211> 39

<212> PRT

<213> Escherichia coli

<400> 45

Gln Leu Arg His Asp Ile Tyr Ile His Thr Arg Leu Leu Phe Gly Gly
1 5 10 15

Cys Ile Val Tyr His Thr Ile Ser Glu Val Gly Ile Phe Asn Lys Pro
20 25 30

Asn Gly Val Thr Val Ile Thr
35

<210> 46

<211> 41

<212> PRT

<213> Escherichia coli

<400> 46

Glu Ile Arg Gln Thr Ile Phe Asn Glu Leu Gln Leu Thr Ala Ser Ala
1 5 10 15

Gly Val Ala Pro Val Lys Phe Leu Ala Lys Ile Ala Ser Asp Met Asn
20 25 30

Lys Pro Asn Gly Gln Phe Val Ile Thr
35 40

<210> 47

<211> 5

<212> PRT

<213> Escherichia coli

<400> 47

Asn Lys Pro Asn Gly
1 5

<210> 48

<211> 38

<212> PRT

<213> Escherichia coli

<400> 48

Ser Gly Ala Leu Leu Ala His Ser Tyr Gly Met Thr Phe Ile Tyr Thr
1 5 10 15

His Asp Tyr Ser Ser Ser Val Gly Val Ser Tyr Thr Ile Leu Leu Ala
20 25 30

Lys Leu Gly Ser Asp Leu
35

<210> 49

<211> 38

<212> PRT

<213> Escherichia coli

<400> 49

Ser Ala Thr Leu Ile Ala Gln Glu Ile Arg Gln Thr Ile Phe Asn Glu

1 5 10 15
 Leu Gln Leu Thr Ala Ser Ala Gly Val Ala Pro Val Lys Phe Leu Ala
 20 25 30

Lys Ile Ala Ser Asp Met
 35

<210> 50
 <211> 68
 <212> PRT
 <213> Escherichia coli

<400> 50
 Gly Ile His Ser Ala Met Arg Ser Ala Glu Ala Arg Arg Leu Ala Pro
 1 5 10 15

Asp Gly Ile Phe Leu Thr Pro Asp Phe Ala Lys Tyr Lys Ala Ile Ser
 20 25 30

Lys Gln Ile Asx Ala Val Phe Arg Thr Ile Thr Pro Lys Ile Glu Ala
 35 40 45

Val Ala Leu Asp Glu Ala Tyr Leu Asp Val Thr Ala Asn Ala Leu Ser
 50 55 60

Gly Ala Leu Leu
 65

<210> 51
 <211> 68
 <212> PRT
 <213> Escherichia coli

<400> 51
 Gly Val Lys Thr Thr Met Pro Val Trp Gln Ala Lys Arg His Cys Pro
 1 5 10 15

Glu Leu Ile Val Leu Pro Pro Asn Phe Asp Arg Tyr Arg Asn Ser Ser
 20 25 30

Arg Ala Met Phe Thr Ile Leu Arg Glu Tyr Thr Asp Leu Val Glu Pro
 35 40 45

Val Ser Ile Asp Glu Gly Tyr Met Asp Met Thr Asp Thr Pro Tyr Ser
 50 55 60

Ser Arg Ala Leu

65

<210> 52

<211> 18

<212> PRT

<213> Escherichia coli

<400> 52

Ser Ser Val Gly Val Ser Tyr Thr Ile Leu Leu Ala Lys Leu Gly Ser

1

5

10

15

Asp Leu

<210> 53

<211> 18

<212> PRT

<213> Escherichia coli

<400> 53

Ser Ser Ile Gly Ile Ala Pro Asn Lys Phe Leu Ala Lys Met Ala Ser

1

5

10

15

Asp Met

<210> 54

<211> 61

<212> PRT

<213> Escherichia coli

<400> 54

Gln Leu Gly Ile His Ser Ala Met Arg Ser Ala Glu Ala Arg Arg Leu

1

5

10

15

Ala Pro Asp Gly Ile Phe Leu Thr Pro Asp Phe Ala Lys Tyr Lys Ala

20

25

30

Ile Ser Lys Gln Ile His Ala Val Phe Arg Thr Ile Thr Pro Lys Ile

35

40

45

Glu Ala Val Ala Leu Asp Glu Ala Tyr Leu Asp Val Thr

50

55

60

<210> 55

<211> 61

<212> PRT

<213> Escherichia coli

<400> 55

Lys Leu Gly Val Lys Ala Gly Met Pro Ile Ile Lys Ala Met Gln Ile
1 5 10 15

Ala Pro Ser Ala Ile Tyr Val Pro Met Arg Lys Pro Ile Tyr Glu Ala
20 25 30

Phe Ser Asn Arg Ile Met Asn Leu Leu Asn Lys His Ala Asp Lys Ile
35 40 45

Glu Val Ala Ser Ile Asp Glu Ala Tyr Leu Asp Val Thr
50 55 60

<210> 56

<211> 8

<212> PRT

<213> Escherichia coli

<400> 56

Asp Glu Ala Tyr Leu Asp Val Thr
1 5

<210> 57

<211> 43

<212> PRT

<213> Escherichia coli

<400> 57

Val Thr Ala Asn Ala Leu Ser Gly Ala Leu Leu Ala His Ser Tyr Gly
1 5 10 15

Met Thr Phe Ile Tyr Thr His Asp Tyr Ser Ser Ser Val Gly Val Ser
20 25 30

Tyr Thr Ile Leu Leu Ala Lys Leu Gly Ser Asp
35 40

<210> 58

<211> 43

<212> PRT

<213> Escherichia coli

<400> 58

Val Glu Gly Asn Phe Glu Asn Gly Ile Glu Leu Ala Arg Lys Ile Lys
1 5 10 15

Gln Glu Ile Leu Glu Lys Glu Lys Ile Thr Val Thr Val Gly Val Ala
20 25 30

Pro Asn Lys Ile Leu Ala Lys Ile Ile Ala Asp
35 40

<210> 59

<211> 20

<212> PRT

<213> Escherichia coli

<400> 59

Leu Thr Ser Ser Val Gly Val Ser Tyr Asn Lys Leu Leu Ala Lys Leu
1 5 10 15

Gly Ser Asp Leu
20

<210> 60

<211> 20

<212> PRT

<213> Escherichia coli

<400> 60

Leu Pro Ser Ser Ile Gly Ile Ala Pro Asn Lys Phe Leu Ala Lys Met
1 5 10 15

Ala Ser Asp Met
20

<210> 61

<211> 35

<212> PRT

<213> Escherichia coli

<400> 61

Phe Ala Lys Tyr Lys Ala Ile Ser Lys Gln Ile His Ala Val Phe Arg

1 5 10 15
Thr Ile Thr Pro Lys Ile Glu Ala Val Val Ile Asp Glu Ala Tyr Leu
 20 25 30
Asp Val Thr
 35

<210> 62
<211> 35
<212> PRT
<213> Escherichia coli

<400> 62
Phe Asp Ala Tyr Lys Glu Ala Ser Asn His Ile Arg Glu Ile Phe Ser
1 5 10 15
Arg Tyr Thr Ser Arg Ile Glu Pro Leu Ser Ile Asp Glu Ala Tyr Leu
 20 25 30

Asp Val Thr
 35

<210> 63
<211> 8
<212> PRT
<213> Escherichia coli

<400> 63
Asp Glu Ala Tyr Leu Asp Val Thr
1 5

<210> 64
<211> 20
<212> PRT
<213> Escherichia coli

<400> 64
Leu Thr Ser Ser Val Gly Val Ser Tyr Asn Lys Leu Leu Ala Lys Leu
1 5 10 15

Gly Ser Asp Leu
 20

<210> 65

<211> 20

<212> PRT

<213> Escherichia coli

<400> 65

Leu Thr Ala Ser Ala Gly Val Ala Pro Val Lys Phe Leu Ala Lys Ile

1 5 10 15

Ala Ser Asp Met

20

<210> 66

<211> 17

<212> PRT

<213> Escherichia coli

<400> 66

Ile Ser Glu Val Gly Ile Phe Asn Lys Pro Asn Gly Val Thr Val Ile

1 5 10 15

Thr

<210> 67

<211> 18

<212> PRT

<213> Escherichia coli

<400> 67

Leu Ala Lys Ile Ala Ser Asp Met Asn Lys Pro Asn Gly Gln Phe Val

1 5 10 15

Ile Thr

<210> 68

<211> 5

<212> PRT

<213> Escherichia coli

<400> 68

Asn Lys Pro Asn Gly

1 5

<210> 69

<211> 41

<212> PRT

<213> Escherichia coli

<400> 69

Ile Phe Leu Thr Pro Asp Phe Ala Lys Tyr Lys Ala Ile Ser Lys Gln
1 5 10 15

Ile His Ala Val Phe Arg Thr Ile Thr Pro Lys Ile Glu Ala Val Val
20 25 30

Ile Asp Glu Ala Tyr Leu Asp Val Thr
35 40

<210> 70

<211> 41

<212> PRT

<213> Escherichia coli

<400> 70

Ile Val Leu Pro Pro Asn Phe Asp Arg Tyr Arg Asn Ser Ser Arg Ala
1 5 10 15

Met Phe Thr Ile Leu Arg Glu Tyr Thr Asp Leu Val Glu Pro Val Ser
20 25 30

Ile Asp Glu Gly Tyr Met Asp Met Thr
35 40

<210> 71

<211> 11

<212> PRT

<213> Oryctolagus cuniculus

<400> 71

Lys Phe Ser Arg Glu Lys Lys Ala Ala Lys Thr
1 5 10

<210> 72

<211> 11

<212> PRT

<213> Oryctolagus cuniculus

<400> 72

Asp Gln Lys Arg Tyr His Glu Asp Ile Phe Gly

1 5 10

<210> 73

<211> 15

<212> PRT

<213> Oryctolagus cuniculus

<400> 73

Asp Leu Lys Glu Glu Lys Asp Ile Asn Asn Asn Val Lys Lys Thr

1 5 10 15

<210> 74

<211> 9

<212> PRT

<213> Oryctolagus cuniculus

<400> 74

Cys Thr Gly Glu Glu Asp Thr Ser Glu

1 5

<210> 75

<211> 11

<212> PRT

<213> Oryctolagus cuniculus

<400> 75

Pro Glu Glu Thr Gln Thr Gln Asp Gln Pro Met

1 5 10

<210> 76

<211> 13

<212> PRT

<213> Oryctolagus cuniculus

<400> 76

Gln Lys Ser Asp Gln Gly Val Glu Gly Pro Gly Ala Thr

1 5 10

<210> 77

<211> 12

<212> PRT

<213> Oryctolagus cuniculus

<400> 77

Asp Ile Gly Gln Ser Ile Lys Lys Phe Ser Lys Val

1 5 10

<210> 78

<211> 10

<212> PRT

<213> Oryctolagus cuniculus

<400> 78

Gln Arg Ala Asp Ser Leu Ser Ser His Leu

1 5 10

<210> 79

<211> 9

<212> PRT

<213> Oryctolagus cuniculus

<400> 79

Tyr Pro Tyr Asp Val Pro Asp Tyr Ala

1 5

<210> 80

<211> 10

<212> PRT

<213> Oryctolagus cuniculus

<400> 80

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu

1 5 10

<210> 81

<211> 11

<212> PRT

<213> Oryctolagus cuniculus

<400> 81

Tyr Thr Asp Ile Glu Met Asn Lys Leu Gly Lys

1 5 10

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/01037

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 22457 A (MASSACHUSETTS INST TECHNOLOGY) 11 November 1993 see the whole document ---	1-49
Y	WO 95 12689 A (GENE CHECK INC ;WAGNER ROBERT E JR (US)) 11 May 1995 see the whole document ---	1-49
Y	WO 93 02216 A (UPSTATE BIOTECH INC) 4 February 1993 see the whole document ---	1-49
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 June 1999

Date of mailing of the international search report

17/06/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hagenmaier, S

INTERNATIONAL SEARCH REPORT

Int .lional Application No.

PCT/US 99/01037

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>LAVERY D J ET AL: "SELECTIVE AMPLIFICATION VIA BIOTIN- AND RESTRICTION-MEDIATED ENRICHMENT (SABRE), A NOVEL SELECTIVE AMPLIFICATION PROCEDURE FOR DETECTION OF DIFFERENTIALLY EXPRESSED mRNAs"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, 6 June 1997, pages 6831-6836, XP002039837 see the whole document</p> <p style="text-align: center;">---</p>	1-49
Y	<p>WO 97 43443 A (BOEHRINGER MANNHEIM GMBH ;SCHIBLER UELI (CH); LAVERY DANIEL (CH)) 20 November 1997 see the whole document</p> <p style="text-align: center;">---</p>	1-49
A	<p>BELLANNÉ-CHANTELOT ET AL.: "SEARCH FOR DNA SEQUENCE VARIATIONS USING A MutS-BASED TECHNOLOGY"</p> <p>MUTATION RESEARCH GENOMICS, vol. 382, 1997, pages 35-43, XP002104859 see the whole document</p> <p style="text-align: center;">---</p>	
A	<p>HSU I -C ET AL: "DETECTION OF DNA POINT MUTATIONS WITH DNA MISMATCH REPAIR ENZYMES"</p> <p>CARCINOGENESIS, vol. 15, no. 8, 1 August 1994, pages 1657-1662, XP000571680 see the whole document</p> <p style="text-align: center;">---</p>	
A	<p>LISITSYN N ET AL: "CLONING THE DIFFERENCES BETWEEN TWO COMPLEX GENOMES"</p> <p>SCIENCE, vol. 259, 12 February 1993, pages 946-951, XP000601302 see the whole document</p> <p style="text-align: center;">---</p>	
A	<p>ZENG J ET AL: "DIFFERENTIAL CDNA CLONING BY ENZYMATIC DEGRADING SUBTRACTION (EDS)"</p> <p>NUCLEIC ACIDS RESEARCH, vol. 22, no. 21, 1 January 1994, pages 4381-4385, XP002039836 see the whole document</p> <p style="text-align: center;">-----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/01037

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9322457 A	11-11-1993	US 5750335 A	12-05-1998
WO 9512689 A	11-05-1995	AU 700959 B	14-01-1999
		AU 1050895 A	23-05-1995
		AU 9607698 A	04-02-1999
		CA 2175222 A	11-05-1995
		EP 0733126 A	25-09-1996
		JP 9504699 T	13-05-1997
WO 9302216 A	04-02-1993	AT 151114 T	15-04-1997
		AU 664381 B	16-11-1995
		AU 2415992 A	23-02-1993
		CA 2113716 A	04-02-1993
		DE 69218776 D	07-05-1997
		DE 69218776 T	27-11-1997
		EP 0596028 A	11-05-1994
		IL 102550 A	18-03-1997
		JP 7500493 T	19-01-1995
WO 9743443 A	20-11-1997	EP 0839214 A	06-05-1998

THIS PAGE BLANK (USPTO)